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Chapter 1: Applications of biofunctional water-soluble 
polyisocyanopeptides 
 
Water-soluble polyisocyanopeptides are semi-flexible polymers that can form 
hydrogels under certain conditions. Their unique properties make these polymers 
attractive for a large number of biological applications, ranging from drug delivery and 
diagnostics to tissue engineering and regenerative medicine. This chapter provides a 
general overview of this new class of polymers. Following a description of the 
synthesis and characteristics of polyisocyanides and polyisocyanopeptides, the new 
subclass of water-soluble polyisocyanopeptides is introduced. This chapter focuses 
on the synthesis as well as on the unique properties of these interesting molecules. It 
further introduces possible strategies for the biofunctionalization of these polymers in 
the context of potential applications. 
 
1.1. History of polyisocyanides and polyisocyanopeptides  
Polyisocyanides are prepared by the polymerization of isocyanides (Scheme 
1.1a). Isocyanides were already discovered in the 1860s1,2, but only explored further 
after Ugi introduced an easy synthesis of isocyanides in 1958.3 The driving force for 
polymerization is the conversion of the divalent carbon atom of the isocyanide 
monomer into a tetravalent carbon atom in the polymer, resulting in a heat of 
polymerization of about 81 kJ/mol.4 Upon polymerization, a polymer backbone fully 
consisting of carbon-carbon bonds is formed where every carbon atom in the main 
chain bears a substituent (Scheme 1.1a). Neighbouring substituents feel steric 
hindrance, forcing the polymer backbone to adopt a helical conformation.5 
The ability of isocyanides to polymerize was known for a long time. A first 
catalysed polymerization reaction was only developed by Millich in the 1970s, 
however, using acid-coated glass as the catalyst.6 Another and more frequently used 
method for the preparation of polyisocyanides is the polymerization with transition 
metal complexes7–9, in particular with Ni(II) salts.10–12 Using these catalysts, 
polymerization proceeds via the “merry-go-round” mechanism and yields a helical 
structure with four monomers per turn (41 helix) (Scheme 1.1b). 13,14 In this 
mechanism, the starting point is the formation of a tetrakis isocyanide Ni(II) complex, 
which can be activated by the addition of a nucleophile, most typically an amine or an 
alcohol (Scheme 1.1b, step 1).  
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The nucleophile first coordinates to the nickel centre and subsequently reacts 
with one of the isocyanide ligands to form a carbene-like ligand (Scheme 1.1b, step 
2), which then attacks a neighbouring isocyanide ligand (Scheme 1.1b, step 3). A 
new monomer from the solution then coordinates to the vacant position of the 
activated nickel species, facilitating a polymerization reaction that proceeds in the 
direction of the initial attack (Scheme 1.1b, step 4). As a consequence of this 
mechanism, one particular helical sense is formed per polymer chain. For an achiral 
initiator, equal amounts of right- and left-handed helices are formed. In contrast, one 
helical sense is preferred over the other when a chiral initiator or monomer is 
used.15,16 When sufficiently bulky groups are introduced into the side chains, the 
polymer is locked in a certain conformation and the helical sense of each polymer is 
preserved.10 If the side chains are not bulky enough, however, the polymer is more 
dynamic and conformational changes are possible.17,18 
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Scheme 1.1. Polyisocyanide structure and polymerization mechanism. a) The polymerization of 
isocyanides into polyisocyanides. b) Proposed “merry-go-round” mechanism for the nickel catalysed 
polymerization of isocyanides. Adapted from reference 14.   
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Scheme 1.2. Polyisocyanopeptide stabilized by a hydrogen-bonding network between the side chains. 
The side chains can either be a di- or a tripeptide (n=1 or n=2).  
 
The helical structure can also be preserved when using side chains that are 
able to form hydrogen bonds so that a stabilizing hydrogen-bonding network is 
formed along the polymer. This strategy has been elegantly implemented by 
Cornelissen et al. who synthesized polyisocyanides with di- or tripeptide-
functionalized side chains, so-called polyisocyanopeptides (Scheme 1.2).19–22 Using 
these peptide side chains, hydrogen bonding occurs between the amide bonds of 
parallel side chains, i.e. between side chains n and n+419. The distance between the 
participating amide bonds was estimated to be 0.46 nm and an overall β-sheet-like 
packing of the side chains was found along the polymer backbone.19 As a result of 
this interaction, very long (from 100 nm to several micrometres) and rigid polymers 
were formed. These polyisocyanopeptides possess persistence lengths up to 
76 nm,23 making these polymers very suitable candidates for ordering electroactive 
and optically-active (chromophoric) groups in array-like structures.24,25 Two 
fundamentally different strategies have been used to introduce these active groups 
into the polymer. The first strategy is based on the synthesis of ‘active’ 
isocyanopeptide monomers that are subsequently polymerized. Over the years many 
different monomers have been synthesized that carry active groups, such as 
thiophenes, porphyrins, and perylenes.26–31 
Although the synthesis of these compounds is feasible, a second strategy 
using a post-modification approach was developed to functionalize 
polyisocyanopeptides with active groups. To be able to chemically modify an already 
polymerized scaffold,32 monomers carrying an acetylene functional group were 
developed. After polymerization, the acetylene-containing polymers were reacted 
with azide-functionalized compounds in an azide-alkyne cycloaddition (‘click’) 
reaction.32 This post-modification approach has allowed for the synthesis of a large 
number of different functional polymers, e.g. carrying perylenes and phthalocyanines 
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as active groups. But also oligo (ethylene glycol) groups have been coupled to the 
polymer with the goal of increasing its water solubility.33,34 
 
1.2 Water-soluble polyisocyanopeptides 
Polyisocyanopeptides have shown great potential as a scaffold in organic 
solvents. More recent research has focused on the synthesis of water-soluble 
derivatives to extend this potential to biological applications. In a first attempt, 
Schwartz et al. co-polymerized an azide-bearing isocyanopeptide monomer IAA-N3 
with D-isocyanoalanyl-L-alanine methyl ester IAA-OMe (Scheme 1.3a).35 Upon 
saponification (hydrolysis of the methyl ester), this polymer became soluble in water, 
resulting from the large number of newly generated carboxylic acid groups. 
Subsequently, the azide groups were used in a post-modification step, using a 
copper-catalysed azide–alkyne cycloaddition reaction (CuAAC).36 The obtained 
polymer was characterized with circular dichroism (CD) spectroscopy to determine its 
secondary structure. Comparing the polymer before and after saponification, showed 
very similar secondary structure characteristics, however, the signal intensity was 
slightly lower after ester hydrolysis. This was attributed to the long hydrolysis process 
that may partly unfold a small portion of the helix.  
 
 
Scheme 1.3. Post-modification strategies to obtain water-soluble polyisocyanopeptides. a) Azide-
functionalized monomers are polymerized with methyl ester-containing monomers, yielding a 
statistical distribution of functional monomers in the polymer backbone. Saponification of the methyl 
ester results in a water-soluble polymer. b) Acetylene-functionalized polyisocyanopeptides able to 
react with azides in a copper catalyzed azide-alkyne cycloaddition reaction. 
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To obtain a non-ionic, water-soluble polyisocyanopeptide analogue, acetylene-
bearing homo-polymers were reacted with azide-functionalized oligo ethylene glycol 
chains (Scheme 1.3b). 34 Although the resulting polymer was water-soluble, a change 
in the CD spectrum was observed for the post-modified polymer. Again this may be a 
result of partial unfolding. Alternatively, the polymer may remain in a folded, helical 
state characterized by a different side chain arrangement. 
In addition to the post-modification approach using oligo ethylene glycol 
chains, also the possibility of polymerizing oligo ethylene glycol-containing 
isocyanopeptide monomers was investigated.37 The size of the oligo ethylene glycol 
chain was varied from m=2 to m=4 (PIAA-OEG2-OMe, PIAA-OEG3-OMe and PIAA-
OEG4-OMe) (Figure 1.1a). Polymers could be synthesized from all three monomers 
and an extensive structure determination was carried out for these polymers. CD 
spectroscopy showed very different spectra for these polymers when compared to 
polyisocyanopeptides that lack the oligo ethylene glycol tail. Without the tail, a strong 
cotton effect centred around λ = 310 nm was found. In contrast, the CD spectrum of 
PIAA-OEG2,3,4-OMe showed two peaks: a positive peak at λ = 272 nm and a smaller 
negative peak at λ = 360 nm.37 To confirm that the helical backbone of the polymer 
was not disrupted, the CD measurements were complemented with IR 
measurements. Focussing on the N-H stretches of the amide bond in the hydrogen-
bonding peptide side chains, it was shown that the oligo ethylene glycol-containing 
polymers possess a slightly less defined hydrogen-bonding network. The altered CD 
spectra may be directly attributed to this effect while the polymer still follows the 
classical 41 structure. 
In the next step, the water solubility of PIAA-OEG2,3,4-OMe was examined. 
Whereas PIAA-OEG2-OMe did not dissolve in water, a good water solubility was 
observed for the polymers PIAA-OEG3,4-OMe. Non-linear poly ethylene glycol (PEG) 
analogues, such as the newly synthesized polymers, frequently show a thermo-
responsive behaviour in aqueous solution. This is directly related to the properties of 
the PEG side chains, which dehydrate upon heating. This dehydration may decrease 
the water solubility of the polymer, leading to precipitation above a certain 
temperature. This temperature, the so-called lower critical solution temperature 
(LCST), can be determined when testing polymer solubility over a range of 
temperatures. Both polymers PIAA-OEG3-OMe and PIAA-OEG4-OMe showed a 
phase transition with LCST values of ~20-25 °C (n=3) and ~42-50 °C (n=4).37 The 
different LCSTs can be explained with the fact that the longer oligo ethylene glycol 
chains in the PIAA-OEG4-OMe polymer interact with a larger number of water 
molecules so that more energy is required to dehydrate the polymer. 
The most interesting result of this experiment was that these polymers did not 
precipitate above the LCST, but were trapped in a gel state instead. Remarkably, 
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these hydrogels formed at very low concentrations, as low as 0.006 (wt.%).38 To 
understand the gelation mechanism and the mechanical properties of this hydrogel, it
was characterized with a number of different techniques.38 Atomic force microscopy 
and cryo-scanning electron microscopy revealed a bundled structure of the hydrogel
(Figure 1.1b). This bundling behaviour is a direct result of the LCST behaviour. Upon 
heating, the entropic desolvation of the oligo ethylene glycol tails increases the 
hydrophobicity of the side chains. These more hydrophobic chains increasingly 
interact with each other (instead of water), bundle up and remain kinetically trapped 
in a network state. Surprisingly, the bundle dimensions were independent of polymer 
concentration. Higher concentrations of polymer only resulted in a higher number of 
bundles and, consequently, a denser bundle network. This makes the polymer 
concentration an effective parameter to tune the pore size of the gel.  
Figure 1.1. Water-soluble polyisocyanopeptides. a) Molecular structure of oligo ethylene glycol-
functionalized polyisocyanopeptides. b) Bundled structure of the polyisocyanopeptide hydrogel as 
measured with atomic force microscopy. The size of the image is 1x1 µm2 (reproduced with 
permission from reference 38). c) Rheology measurements of G’ (storage modulus) and G” (loss 
modulus) for PIAA-OEG3-OMe and PIAA-OEG4-OMe (reproduced with permission from reference 
38). d) Stress-stiffening of polyisocyanopeptide hydrogels, as indicated by the differential modulus K’. 
For comparison also the synthetic hydrogel polyacrylamide is shown along with hydrogels formed from 
natural biopolymers (reproduced with permission from reference 42).
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Using rheology, the mechanical properties of the hydrogels were investigated. 
In general, the two main parameters extracted from these measurements are the G’ 
(storage modulus) and G’’ (loss modulus), where G’ gives insight into the elastic 
properties and G’’ reflects the viscous properties of a material. The temperature 
where the value of G’ crosses G’’ is defined as the precise gel point of a hydrogel. 
For PIAA-OEG3-OMe and PIAA-OEG4-OMe gel points of 20 °C and 42 °C were 
found, respectively (Figure 1.1c), matching the previously determined LCST values. 
The mechanical properties of these gels are characterized by an unexpected stress-
stiffening behaviour, which is usually only observed for natural hydrogels formed from 
biological polymers, such as actin, collagen and intermediate filaments.39,40 This non-
linear stress-stiffening behaviour describes the increased resistance of these 
biopolymer gels to a mechanical deformation.40  
This mechanism, which protects biological materials from mechanical damage, 
is rarely observed for synthetic hydrogels. The surprising result that 
polyisocyanopeptide hydrogels exhibit this behaviour38,41,42 can be explained when 
considering the helical nature of polyisocyanopeptides and the stiffness of the 
polymer chains in water. The persistence length Lp of individual PIAA-OEG3-OMe 
and PIAA-OEG4-OMe polymers is on the order of 5-10 nm.38,43 This Lp is ~1/10th of 
the polymer length, making these polymers semi-flexible. During bundling, the Lp 
increases quadratically with the number of polymers per bundle, leading to very stiff 
bundles.38 As a consequence, the LP value of the bundles (460 nm) is of a similar 
value as the pore size of the hydrogel (110 nm). 
For biopolymer networks it has been shown theoretically and experimentally 
that this relationship between pore size and Lp is sufficient to explain their stress-
stiffening behaviour. Polyisocyanopeptides consequently form hydrogels with a 
similar network structure as biopolymer hydrogels. More interestingly, even the stress 
range where the non-linear properties become dominant is very similar to that of 
biopolymers (Figure 1.1d). More recently, the influence of polymer length, polymer 
concentration and the addition of salts has been investigated and it has been shown 
that these are all good parameters to tune the mechanical properties of the 
hydrogels.41,44 
Their long helical structure and their ability to form hydrogels that closely 
mimic natural filaments make these water-soluble polyisocyanopeptides very 
interesting candidates for a range of biomedical applications. At the physiologically 
relevant temperature of 37 °C, PIAA-OEG3-OMe forms a hydrogel whereas PIAA-
OEG4-OMe does not. This opens up a number of fundamentally different applications 
for these two structurally similar, thermo-responsive polymers. Hydrogels consisting 
of PIAA-OEG3-OMe could be suitable as wound dressing materials, cell growth 
matrixes or even in tissue engineering. On the other hand, freely soluble PIAA-
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OEG4-OMe polymers are ideal fibre-like, multivalent scaffolds for drug delivery or 
other in vivo applications that utilize polymer-drug conjugates. For all these 
applications, the polyisocyanopeptide polymers have to be decorated with bioactive 
compounds such as peptides, proteins, antibodies or drugs. In the next sections, 
possible applications of polyisocyanopeptides as functional hydrogels or in vivo 
multivalent therapeutic scaffolds are introduced and the required biofunctionalization 
strategies are addressed. 
 
1.3. Polyisocyanopeptides as multivalent scaffolds 
Many biological processes start with the binding of a multivalent ligand to a 
cell receptor. A prototype example of such a multivalent interaction is the binding of a 
virus to the cell surface. Another well-studied example is the interaction of cells with 
their extracellular matrix via multicomponent focal adhesion complexes. Also the 
communication between different cells of the immune system requires the formation 
of well-defined multivalent interactions, e.g. between T cells and dendritic cells. To 
trigger and influence all these processes artificially, scaffolds have been developed to 
mimic the multivalent interaction in a ‘natural way’. Synthetic polymers are one 
possible scaffold to obtain a multivalent ligand-functionalized structure. The research 
described in this thesis aims to develop a polyisocyanopeptide-based, multivalent 
structure that is able to activate T cells and to test the potential of this artificial 
multivalent scaffold in immunotherapeutic applications. 
Immunotherapy has become one of the prime treatments for cancer. The idea 
behind this therapy is to redirect the immune system in such a way that it can 
recognize dangerous cancer cells and destroy them. One of the key players in the 
immune system is the dendritic cell (DC), which is a natural antigen-presenting cell 
(APC). DCs encounter and take up antigens, process the antigenic component 
intracellularly and present small parts of it on their surface. Other cells of the immune 
system, primarily T cells, recognize these antigen fragments and become activated. 
When exposed to cancer specific antigens DCs will consequently display the 
corresponding cancer-related antigen fragments and the immune system will become 
activated against the cancer cells. Several studies have highlighted the potential of in 
vivo administered or ex vivo loaded DCs in cancer treatment.45,46 The clinical use of 
DCs remains limited, however, as this treatment is very costly and laborious. Cells 
have to be harvested and processed for every individual patient.47,48 To overcome 
these limitations, artificial antigen-presenting cells (aAPCs) have been developed. 
Synthetic variants are much cheaper and easier to make so that an “off-the-shelf” 
approach can potentially be implemented.49 
Over the years, many aAPC scaffolds have been investigated, varying in 
shape, size and presented ligands (Figure 1.2).50 When looking at the natural 
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multivalent DC - T cell interaction, the requirements for aAPC design can be 
established. The initial contact between DCs and T cells involves the multivalent 
binding of the T cell receptor (TCR) to the antigen fragments, displayed on the DC 
surface via the major histocompatibility complex (MHC). Adhesion molecules 
stabilize this interaction further. It has been shown that binding first occurs in small 
micro-domains. Later, these micro-domains cluster together into the so-called 
immune synapse (IS).51,52 Thus, activation of T cells by DCs requires a multivalent 
interaction between many different binding partners, which are mobile on the cell 
membrane allowing the required spatial rearrangements to occur.
  
Figure 1.2. Design principles of artificial antigen-presenting cells. Shown are examples using either 
solid particle, liposomal or rigid carbon nanotube scaffolds.
The first generation of aAPCs was based on solid microbead-like scaffolds 
that were functionalized with T cell-stimulating molecules (Figure 1.2).53 Although 
these beads were able to form multiple interactions with a T cell, they represent a 
rigid scaffold lacking the possibility for ligand and receptor rearrangement. This 
limitation can be overcome when using liposomal aAPCs. Their fluidic membrane 
allows the receptors to cluster more efficiently (Figure 1.2).54 In general, however, the 
use of micrometre-sized spherical structures is not favourable. Only a small number 
of aAPC-bound ligands are involved during the activation, as the contact area 
between the surface of the aAPC and the T cell is small. To overcome this limitation, 
structures with higher aspect ratios such as rod-shaped carbon nanotubes and 
filomicelles could be used (Figure 1.2).55,56 Carbon nanotubes are extremely rigid, 
however, and filomicelles have a large size of 6-7 µm. The ideal scaffold would 
combine a high aspect ratio with the ability to form multiple interactions and the 
flexibility to rearrange the bound ligands or receptors. Water-soluble 
polyisocyanopeptides with tetra ethylene glycol side chains (PIAA-OEG4-OMe) are 
ideal candidates as they fulfil all these requirements. They are semi-flexible (Lp in the 
order of 10 nm43) and long filamentous structures (hundreds of nanometres) that are 
easily functionalized with different ligands through post-modification reactions. 
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Chapters 2, 3 and 4 focus on this topic, describing biofunctionalization strategies 
developed for coupling T cell interacting ligands to PIAA-OEG4-OMe polymers. 
These chapters further describe a number of approaches to optimize the multivalent 
interaction and to increase the specificity of the T cell response. 
 
1.4. Polyisocyanopeptide hydrogels 
A hydrogel is a natural or synthetic polymeric material that is able to absorb a 
high content of water. Prominent natural examples of hydrogels are the cytoskeleton 
(actin, microtubules and intermediate filaments) and the extra cellular matrix (ECM; 
collagen and fibrin) that are composed of protein-based biopolymers. But also 
carbohydrate-based structures are able to form hydrogels, such as hyaluronic acid, 
alginate and carrageenan. Over the years, hydrogels have gained increasing 
attention for a large number of biomedical applications. For example, they are used 
as coating for contact lenses and as hygiene products and wound dressing 
materials.57,58 Considering the function of their natural counterparts, they have further 
found application as 2D and 3D ECM mimics. Lastly, stimuli-responsive hydrogels 
have been developed for drug delivery applications.  
The applications of synthetic ECM mimics range from fundamental studies 
aimed at investigating the physical nature of the cell-matrix interaction to applications 
in tissue engineering and regenerative medicine.59,60 Many studies have indicated 
that the mechanical properties of an ECM mimicking hydrogel influence the 
behaviour of cells, e.g. determining cell size and shape as well as migration and 
differentiation. For example, Engler et al. have shown that human mesenchymal 
stem cells cultured on soft (0.1-1 kPa) and stiff (8-18 kPa) polyacrylamide gels 
(collagen I coated to facilitate cell adhesion), committed into softer neuronal tissue or 
stiffer muscle tissue, respectively.61 So far, many of these studies have been 
conducted on 2D substrates. These 2D cell culture systems are easy to handle, but 
do not always resemble the complexity of the ECM in three dimensions.59 
Furthermore, the ECM consists of natural filaments that show stress-stiffening 
behaviour. Although synthetic hydrogels allow for a great deal of control, they lack 
this unusual mechanical response. On the other hand, hydrogels made from 
biopolymers are stress-stiffening. For natural hydrogels it is impossible, however, to 
decouple their mechanical (e.g. stiffness) and their biochemical properties (e.g. 
ligand density). This makes it very difficult to assess the influence of these different 
parameters on cellular behaviour. The ideal ECM combines the mechanical 
properties of natural hydrogels with the same level of control that is available when 
designing synthetic hydrogels. 
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Water-soluble polyisocyanopeptides with tri ethylene glycol side chains (PIAA-
OEG3-OMe) have the potential to fulfil all these requirements. The synthetic hydrogel 
formed from PIAA-OEG3-OMe polymers possesses stress-stiffening behaviour and 
its mechanical properties are easily tuned. To allow for cell adhesion to occur, the 
hydrogel can be functionalized with cell-adhesive ligands that are able to bind to 
integrin receptors on the cell surface. A common integrin ligand for cell adhesion is 
the RGD peptide.62,63 This small peptide is able to bind to many types of integrins, 
thus providing a general anchor point for cells. When functional monomers are built 
into the polymer, the RGD ligand can easily be attached to the polymer via post-
modification. Chapter 5 introduces the synthesis and application of this synthetic 
stress-stiffening hydrogel as a 3D ECM mimic for stem cell differentiation. 
Stimuli-responsive polymer hydrogels are an interesting class of smart 
materials with an increasing number of possible applications. With their ability to 
adapt to a changing environment, they play an important role in novel drug delivery 
systems, diagnostics and as sensing materials.64 These smart materials respond to 
changes in temperature, pH, electrical or magnetic fields or to chemical signals. One 
prominent class of stimuli-responsive hydrogels is based on polymeric DNA-hybrid 
materials.65 DNA allows for a great deal of control as the nucleotide sequences can 
be fully controlled and designed by the user. Furthermore, DNA sequences can be 
developed in such a way that they respond to various external stimuli, like pH, 
temperature or the addition of complementary DNA. As mentioned in the previous 
section, these DNA-containing hydrogels lack the ability to stress-stiffen and fail to 
closely mimic typical natural hydrogel materials. Water-soluble polyisocyanopeptides 
decorated with DNA molecules are a potential DNA-responsive stress-stiffening 
hydrogel scaffold. Chapter 6 aims at the development of such a DNA-responsive, 
stress-stiffening hydrogel based on PIAA-OEG3-OMe that may find application in 
drug delivery and sensing. 
 
1.5. Aim and outline of this thesis 
To fully use the favourable properties of water-soluble polyisocyanopeptides 
for the above-mentioned applications, the polymers have to be functionalized with 
biomolecules such as antibodies, proteins, peptides or DNA oligonucleotides. As the 
required bioconjugation reactions are usually carried out in aqueous buffer systems, 
a post-modification approach is required. For this purpose, all polyisocyanopeptide 
polymers need to be equipped with a functional group during synthesis that can then 
be used for coupling the biomolecule in a second step. It is one goal of this thesis to 
develop water-soluble, azide-functionalized polyisocyanopeptides that can then be 
“clicked” with acetylene-functionalized biomolecules. An azide group is chosen as a 
functional handle on the polymer as a number of azide-containing polymers were 
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already shown to be functional in other applications. Instead of coupling a terminal 
alkyne in a CuAAC reaction, a strain-promoted azide-alkyne cycloaddition (SPAAC) 
reaction has been selected, as this reaction does not require a catalyst. More 
specifically, the strained alkynes bicyclononyne (BCN) and azadibenzocyclooctyne 
(DBCO) are used for bioconjugation (Figure 1.3).66–68 The second, and more 
important goal of this thesis is to test the potential of these newly synthesized 
bioconjugates and hydrogels in the previously described applications. 
 
Figure 1.3. Functionalization of water-soluble polyisocyanopeptides with biomolecules using a post-
modification approach. The polymer carries a statistical ratio of azide-functionalized monomers that 
can be reacted with strained alkyne modified biomolecules in a strain-promoted azide-alkyne 
cycloaddition reaction. 
 
After this introductory chapter, this thesis continues with a description of the 
synthesis of the proposed azide-containing polyisocyanopeptide polymers and the 
biofunctionalization of the PIAA-OEG4-OMe scaffold with T cell activating antibodies. 
These bioconjugates are tested for their ability to stimulate T cells and compared to 
spherical particles carrying the same antibody (Chapter 2). Chapter 3 describes the 
effect of polymer length and antibody spacing on T cell activation. It further highlights 
the T cell stimulating effect of the antibody-functionalized polyisocyanopeptide at 
different points in time, comparing early and late markers of T cell activation. Chapter 
4 introduces a strategy to functionalize the scaffold with a second antibody that 
shapes the specificity of the T cell response. 
In chapter 5, azide-functionalized PIAA-OEG3-OMe polymers are used as a 
scaffold to synthesize bioactive hydrogels for cell culture applications. The hydrogel 
is functionalized with integrin-binding GRGDS peptides and the impact of stress-
stiffening on stem cell differentiation is investigated. In chapter 6, the 
N
O
H
N
O
OC
O
m
n
N
O
H
N
O
OC
O
3
n
N3
st
at
DBCO
BCN
HH
O
R
N O
R
R= Biomolecule
Processed on: 10-10-2016
505747-L-bw-Hammink
Chapter 1 
!
!
! 14 
polyisocyanopeptide is functionalized with DNA oligonucleotides. These short DNA 
molecules are subsequently hybridized with a complementary sequence that allows 
for the formation of specific DNA cross-links. In this way, a stimuli-responsive, 
dynamic and tuneable hydrogel is obtained whose mechanical properties can be 
controlled by the addition of specific DNA sequences. 
The synthesis of many of the described polymer bioconjugates requires 
extensive and difficult purification steps. Based on the experience gained in the 
previous chapters, a new affinity-based purification method is introduced. This new 
method facilitates an easier, faster and better purification of the bioconjugates 
(chapter 7). 
This thesis finishes with a discussion of the knowledge obtained from the 
tested biofunctionalized scaffolds and highlights future directions for the design and 
application of this interesting class of polymers (chapter 8).  
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Towards Novel Synthetic Dendritic 
Cells for Immunotherapy 
Parts of this chapter have been published: 
Therapeutic nanoworms: towards novel synthetic dendritic cells for immunotherapy.
Mandal, S.; Eksteen-Akeroyd, Z. H.; Jacobs, M. J.; Hammink, R.; Koepf, M.; 
Lambeck, A. J. a.; van Hest, J. C. M.; Wilson, C. J.; Blank, K.; Figdor, C. G.; Rowan, 
A. E. Chem. Sci. 2013, 4 (11), 4168–4174.
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Chapter 2: Towards Novel Synthetic Dendritic Cells for 
Immunotherapy 
 
2.1 Introduction 
The innate immune system is the body’s first line of defence against 
invaders like pathogens and cancerous cells. Among the various cell types of 
the innate immune system, dendritic cells (DCs), also known as “professional” 
antigen-presenting cells (APCs) are of prime importance.1 The knowledge 
about DCs has increased tremendously in the last 30 years2 and their 
applicability for cancer immunotherapy has been investigated. Ex-vivo 
generated DCs, when loaded with tumour lysates, tumour antigen-derived 
peptides or whole tumour proteins, have demonstrated enhanced anti-cancer 
immune responses.3 Clinical studies have shown the potential of DCs as an 
autologous vaccine for cancer immunotherapy.4,5 In spite of their potency, the 
application of ex-vivo DCs is so far limited by their availability. Growth of ex-
vivo DCs is both labour and resource intensive. The requirement to generate 
a tailor made vaccine for every patient6,7 means that ex-vivo DCs are not 
economically sustainable. The aforementioned inefficiencies in the production 
of ex-vivo DC’s has inspired investigators to design artificial antigen-
presenting cells (aAPCs) as alternatives. 
Extensive studies on DC/T cell interactions in vitro have shown that the 
activation of T cells proceeds via a pre-clustering of MHC-peptide complexes 
in microdomains. These microdomains subsequently cluster into the so-called 
‘immune synapse’ (IS).8,9 Similar to many extracellular biological recognition 
processes, T cell activation consequently requires the simultaneous 
multivalent interaction of a number of receptors to initiate clustering. Molecular 
constructs that are able to mimic this simultaneous multivalent binding have a 
higher efficacy by increasing the avidity.10–12 Further, activation does not only 
involve one type of receptor but multiple receptors instead that interact with 
different activation inducing molecules (i.e. MHC/peptides, co-stimulatory 
adhesion molecules, etc.). 
The first generation of aAPCs, microbead-based DCs, have shown a 
marked advantage in expanding specific T cells under laboratory conditions 
compared to free MHC peptide complexes. Their efficacy for long-term T cell 
expansion has been limited, however.13 Unlike aAPCs, natural APCs have the 
ability to conform to the cell surface topography and allow the dynamic 
movement of receptor-ligand complexes to form the IS that ultimately causes 
T cell activation. Most likely the rigid sphere morphology of these microbead 
Processed on: 10-10-2016
505747-L-bw-Hammink
Towards Novel Synthetic Dendritic Cells for Immunotherapy!
!
! 21 
based aAPCs hinders the efficient formation of multivalent interactions with 
the T cells.14,15 These aAPCs lack the plasma membrane fluidity of natural 
APCs that allows for the dynamic movement of these complexes to the IS 
site.16 Soft spherical aAPCs, such as liposomes,17 have overcome the 
membrane fluidity constraint enhancing T cell activation over and above that 
observed for the rigid sphere models, suggesting that the IS can form more 
efficiently if a dynamic movement of both binding partners can take place 
(Figure 2.1). 
 
Figure 2.1. Schematic diagram illustrating different systems for T cell activation. 
Besides an efficient formation of the IS, also the number of receptor-
ligand interactions involved in IS formation is known to play an important role 
in T cell activation. The number of interactions is dictated by the size and the 
morphology of the particle. In general, for rigid spherical particles the number 
of ligands available to participate in the required simultaneous interaction is 
limited by its topology.17–19 Second-generation immunotherapeutic delivery 
vehicles have, therefore, explored extended aspect ratio topologies such as 
filamentous or rod-like particles. These extended aspect ratio structures have 
utilized either copolymer filomicelles20 or decorated carbon nanotubes 
(CNTs).21 Both filomicelles and CNTs have demonstrated a higher activity 
compared to their spherical counterparts.21,22 This marked increase in efficacy 
is most likely a result of the larger surface-to-volume ratio that allows a more 
effective loading. If the micelle area is held constant for a given mass of co-
polymer their effective loading is increased by 50 % compared to the 
corresponding sphere.20 Besides the increased effective loading that may aid 
in enhancing multivalent binding, filamentous or rod-like particles also show 
longer circulation times in the body that might play an additional 
advantageous role in T cell activation.20  
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The design criteria for an ideal synthetic dendritic cell (sDC) should 
incorporate the described knowledge gained from aAPCs and commonly used 
therapeutic delivery vehicles. It should combine the above characteristics of a 
high aspect ratio, a flexible architecture and multiple interactions to achieve 
highly efficient T cell activation. The sDCs should further possess an 
extended half-life and a low systemic toxicity.23–25  
Here, a fundamentally new design of sDCs is proposed that has the 
potential to fulfil all of the above criteria. The strategy to building these novel 
delivery vehicles is based on a new class of rod-like, semi-stiff and water-
soluble polymers derived from oligo ethylene oxide-substituted 
polyisocyanopeptides.26,27 Polyisocyanopeptides consist of a helical 
polyisocyanide backbone. This backbone carries peptide-functionalized side 
chains that are attached to every carbon stabilizing the helix through 
hydrogen bonding.28–30 These polymers can be up to 2 µm long and exhibit a 
well-defined stereoregularity31 as well as a controlled stiffness that can be 
tuned between persistence lengths (LP) of 5 nm to 200 nm.27,32 Since in 
principle every individual monomer can be substituted with a functional unit, a 
versatile synthon for the design of multivalent filamentous sDCs is easily 
obtained (Figure 2.2). 
 
 
Figure 2.2. Stages of sDC binding and T cell activation. a) the mobility of the sDC assists in 
locating the T cell; b) sDC docks onto the T cell; c) attachment to multiple recognition sites; d) 
sDC contracting/clustering at the recognition sites, IS formation. 
This design is based on the following hypothesis: First, the semi-stiff 
polyisocyanopeptide decorated with effector molecules docks on T cells 
(Figure 2.2a/b). The semi-stiffness of the polyisocyanopeptide will then allow 
all effector molecules on the sDC to bind to neighbouring receptors on the 
same cell (Figure 2.2c). This is not possible for a rigid spherical bead or a 
flexible random-coil polymer, where multivalent interactions require 
entropically non-favourable, extended polymer conformations.10,12 
Subsequently, using a semi-stiff polymer, these receptor sites will be able to 
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cluster with a concomitant contraction of the polymer backbone to form the IS 
while retaining the activated state (Figure 2.2d). To test the design strategy, 
sDCs were functionalized with anti-CD3 antibodies (αCD3-sDC) that are 
known to cause T cell activation and the efficacy of these sDCs was 
compared with microbead based aAPCs (αCD3-PLGA) and free αCD3 
antibodies. 
 
2.2 Results and Discussion 
 
2.2.1 Synthesis and Characterization of the αCD3-sDCs 
Synthetic dendritic cells (sDCs) carrying T cell stimulating αCD3 antibodies 
have been synthesized from semi-stiff polyisocyanopeptides. To obtain these 
sDCs, an azide-containing polyisocyanopeptide was synthesized in the first 
step (see experimental section for synthesis details). This was achieved by 
co-polymerizing a mixture of an azide-functionalized monomer and a 
methoxy-functionalized monomer using a 1:100 molar ratio resulting in a 
random copolymer (Scheme 2.1). 
 
Scheme 2.1. Synthetic scheme to obtain Streptavidin (SAv)-functionalized 
polyisocyanopeptides. a) random co-polymerization of the azide (1) and the methoxy (2) 
monomers to obtain the azide-functionalized polymer (3), i) Ni(Cl2O4)2 • 6 H2O, toluene; b) 
coupling of BCN-NHS (4) to SAv, ii) 4 days at 4 ˚C in 10 mM borate buffer pH 8.5; c) 
synthesis of the SAv-polymer bioconjugate (6), iii) 4 days at 4 ˚C in 10 mM borate buffer pH 
8.5. 
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The obtained polymers have a degree of polymerization DP = 1633 
and a length between 150 nm and 200 nm (Table 2.1). The statistical spacing 
between azide groups is 10 nm. These azide groups were subsequently used 
to couple BCN-functionalized streptavidin (SAv) to the polymer backbone 
using a strain-promoted azide alkyne cycloaddition (SPAAC) reaction.33 
 
 
Figure 2.3. AFM analysis of SAv-functionalized polyisocyanopeptides. a) representative AFM 
image clearly showing the SAv molecules (bright dots) attached to the polymer; b) number of 
SAv molecules per polymer. 
The obtained SAv-functionalized polymer contains on average one SAv 
molecule every 40-50 nm (Figure 2.3), as determined with AFM. sDCs were 
obtained by adding biotinylated αCD3 antibodies yielding αCD3-sDC. When 
preparing the αCD3-sDC, the ratio of αCD3 to SAv on the polymer was 
adjusted such that on average every SAv was bound to one αCD3 antibody 
(Figure A2.1.6). Consequently, an average polymer with a length of 150-200 
nm contains between 3 and 5 αCD3 antibodies. 
 
2.2.2 Cell viability measurements 
Before testing the efficacy of these novel sDCs on peripheral blood 
lymphocytes (PBLs), cell viability studies were carried out to study their 
biocompatibility. PBLs exposed to αCD3-sDC or free αCD3 at different 
concentrations exhibited no significant decrease in cell viability (MTT assay; 
Figure 2.4a). At higher αCD3 concentrations even an increase in the number 
of cells was observed, which can be explained by induction of T cell 
proliferation by the αCD3 antibodies (vide infra). Even after prolonged 
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incubation times, cell viability remained constant between 90-100 % even up 
to 72 hours (Trypan Blue assay; Figure 2.4b). 
 
Figure 2.4. Viability of PBLs exposed to αCD3-sDC. a) MTT assay showing cell viability as a 
function of αCD3 concentration (incubation time 24 h) b) Trypan Blue assay showing cell 
viability as a function of incubation time (αCD3 concentration of 200 ng/mL for both αCD3-
sDC and free αCD3). The results represent the mean ± s.e.m. (n = 3). 
 
2.2.3 T cell activation 
In subsequent experiments, the capacity of αCD3-sDC to activate T 
cells was determined in comparison to free αCD3 antibodies, streptavidin-
bound αCD3 (αCD3-SAv) and the corresponding isotype control (mIgG2a-
sDC). After clustering of CD3 on the T cells, intracellular signalling results in 
direct activation as demonstrated by expression of the early T cell activation 
marker CD69.34 Activated T cells further show enhanced secretion of IFNγ as 
a late activation event35 and eventual T cell proliferation is observed.36  
At saturating concentrations (>50 ng/mL), CD69 expression was at its 
maximum, for both the αCD3-sDC and the controls including free αCD3 and 
αCD3-SAv (Figure 2.5a). At low concentrations (1-20 ng/mL), however, the 
αCD3-sDCs were ~2.5 fold more effective in inducing T cell activation when 
compared to the αCD3 and αCD3-SAv controls. Similarly, the αCD3-sDC 
activated T cells released 2-3 fold higher amounts of IFNγ than the tested 
controls (Figure 2.5b). Taken together, these findings and the additional 
controls shown in Figure A2.1.7 indicate that αCD3-sDC induces a more 
robust T cell activation when compared to T cells exposed to free αCD3 or 
αCD3-SAv. 
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Figure 2.5. T cell activation profile upon treatment at different concentrations and after 
different time points. a) percentage of T cells showing CD69 expression and b) IFNγ release 
at different αCD3 concentrations (incubation time 24 h); c) percentage of T cells showing 
CD69 expression after different incubation times (αCD3 concentration 5 ng/mL); d) T cell 
proliferation estimated using a CFSE assay (αCD3 concentration 50 ng/mL). The values were 
normalized against the untreated control. Each value represents the mean ± s.e.m. (n = 4). 
The asterisks (*) indicate the statistical significance (*, **, *** p ≤ 0.05, 0.01, 0.001) of αCD3-
sDC compared to αCD3. 
To substantiate the above findings, T cell activation was followed over 
time at a low effective treatment concentration (5 ng/mL αCD3 for both αCD3-
sDC and free αCD3). The αCD3-sDC treated T cells were activated at 
significantly earlier time points (Figure 2.5c). Over prolonged exposure, T cell 
activation increased up to ~35 %. In comparison, T cell activation following 
treatment with free αCD3 shows a delay in T cell activation (10 hours vs. 
7 hours for αCD3-sDC) and a lower percentage of activated T cells (only ~10-
15 %). Finally, the ability of αCD3-sDC to induce T cell proliferation was 
tested (50 ng/mL αCD3 for both αCD3-sDC and free αCD3). In line with the 
above results, a 2-3 fold higher number of proliferated T cells was detected 
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when the T cells were treated with αCD3-sDC (Figure 2.5d). Treatment with 
αCD3-sDC leads to a constant increase in the proliferation rate until 72 h of 
treatment. The observed decrease in the number of T cells at 96 h is likely 
resulting from nutrient depletion in the growth medium at high cell 
concentrations. 
To investigate the importance of the structural architecture of the novel 
sDCs, their efficacy was compared to spherical αCD3-PLGA particles (1.8 µm 
diameter, see experimental section). The worm-like αCD3-sDCs were ~7 fold 
more efficient in stimulating T cell activation (CD69 expression) when 
compared to αCD3-PLGA particles, even at concentrations as low as 1 ng/mL 
(Figure 2.6a). Also the production of IFNγ was ~3 fold higher when compared 
to αCD3-PLGA particles (Figure 2.6b). Together these observations indicate 
that the αCD3-sDCs do not only activate T cells significantly better at lower 
concentrations. They also induce the highest IFNγ production when compared 
with solid particle based DCs. 
 
 
Figure 2.6. Comparison of αCD3-sDC with spherical αCD3-PLGA. a) percentage of T cells 
showing CD69 expression and b) IFNγ release at different αCD3 concentrations (incubation 
time 24 h); The results represent the mean ± s.e.m. (n = 3). The asterisks (*, **, *** p ≤ 0.05, 
0.01, 0.001) indicate the statistical significance of αCD3-sDC compared to αCD3. 
This difference in efficacy cannot be explained with the number of 
receptor-ligand interactions that can form when using αCD3-sDCs (~3-5 
interactions) or αCD3-PLGA particles (~1-10 interactions; see appendix 2.2). 
This similar number of possible interactions for both geometries clearly 
suggests that it is not the density of αCD3 but the ability of polymer-based 
sDCs to flexibly adjust to the spacing of receptors and to dynamically form the 
immune synapse that leads to the superior activity of the sDCs. In other 
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words, multiple static interactions are not sufficient. It has been postulated 
that a more dynamic anisotropic interaction between the binding partners is 
required to induce and enhance T cell activation.37,38 Unlike the static shape 
of the hard sphere model, the controlled stiffness of the αCD3-sDC filament 
has the capacity to ‘concertina’ in response to the receptor clustering events 
associated with the formation of the immune synapse (Figure 2.2). 
2.2.4 Localization of αCD3-sDC on the cell surface 
To investigate the molecular process in more detail and to understand 
how the sDCs interact with T cells, binding studies were performed with 
fluorescently labelled αCD3-sDCs. The PBLs were incubated with different 
concentrations of either fluorescein labelled αCD3-sDCs (FαCD3-sDC) or free 
αCD3 (FαCD3) for 24 hours (see experimental section). Subsequently, the 
number of fluorescent cells was determined using a laser scanning confocal 
microscope (Figures 2.7 and A.2.1.9). 
 
 
Figure 2.7. αCD3-sDC binding and location on the cell. a) percentage of PBLs showing 
bound FαCD3 or FαCD3-sDC after 24 hours of treatment. The result shows the mean ± 
s.e.m. (n = 3). The significance of αCD3-sDC compared to αCD3 is indicated by the asterisks 
(*** p≤ 0.001). b) orthographic projection of one PBL illustrating αCD3-sDC clustering/binding 
(yellow; co-localization of red and green fluorescence). The fluorescence image is merged 
with a DIC image. The series shows optical cross sections over the y-coordinate (x- and z-
coordinate constant), demonstrating the αCD3-sDC distribution on the cell. 
At high concentrations (50 and 100 ng/mL) the relative number of T 
cells that show binding of FαCD3-sDC on their surface was comparable to the 
percentage of cells that have been treated with free FαCD3. In the low 
concentration range (≤20 ng/mL), however, a higher fraction of PBLs carrying 
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FαCD3-sDC was observed when compared to the cells treated with free 
FαCD3. This result clearly explains the higher efficacy of the αCD3-sDCs in 
the low concentration range (Figure 2.7a). Besides more efficient binding, 3D 
images taken after 24 hours further reveal that FαCD3-sDC remained co-
localized on the membrane indicating that no receptor internalization has 
been taking place (Figure 2.7b). 
Summarizing the above results, this new class of semi-stiff and 
filamentous polymers serves as an ideal scaffold for functionalization with 
antibodies to allow for multiple, simultaneous receptor interactions. These 
novel sDCs do not only activate T cells at significantly lower concentrations 
than free antibodies and their rigid sphere-like PLGA counterparts but also 
induce a faster T cell response. Docking of the first antibody to the T cell 
increases the effective molarity of αCD3 at the cell surface thereby increasing 
the probability for the remaining antibodies to bind (Figure 2.2b). It is known 
that T cell stimulation by αCD3 in solution causes internalization of the CD3 
leading to termination of the T cell response.39 The experiments with 
fluorescently labelled FαCD3-sDC have indicated that FαCD3-sDC remains 
bound on the T cell surface even after 24 h of treatment. The semi-stiff, 
filamentous morphology of the αCD3-sDCs consequently does not only lead 
to a significantly higher and earlier (CD69 expression) but also to a more 
sustained T cell response compared to the free antibody and the spherical 
geometry. This result is supported by the expression of the late stage 
activation marker INFγ and the associated higher T cell proliferation rates. 
These findings have important consequences for the therapeutic use of αCD3 
antibodies, which show in vivo toxicity at high concentrations.40 As our αCD3-
sDCs show T cell activation at lower concentrations compared to free αCD3 
antibodies, this new design can help to overcome these toxicity problems and 
widen the therapeutic window of αCD3 antibodies. 
Despite their clearly proven potential as DC mimic, a number of open 
questions remain. The stiffness of the polymer combined with the density of 
effector molecules appears to be the crucial parameter for efficient T cell 
activation. Antibody-functionalized polyisocyanopeptides are an ideal scaffold 
to investigate the importance of these parameters in a systematic way. Both 
the density of effector molecules as well as the polymer stiffness can be easily 
tuned for this new class of functional polymers. Experiments to study the role 
of effector molecule spacing and polymer length are described in chapter 3. 
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2.3 Conclusions 
In this chapter it was demonstrated that multivalency in combination 
with a controlled semi-stiffness are key parameters for designing potentially 
therapeutically active vehicles that closely mimic natural DCs. Using a novel 
sDC design, a more efficient as well as more sustained T cell response was 
observed. This enhanced activity clearly validates the final stage of the 
proposed binding mechanism (Figure 2.2d) that requires the sDC to respond 
to the processes occurring on the T cell surface during formation of the 
immune synapse. Having shown the potency of the sDCs, the next goal is a 
more detailed investigation of the sDC induced T cell activation mechanism. 
This will ultimately allow for increasing their efficacy even further. To develop 
the presented sDC system for clinical applications against cancer, the αCD3 
antibodies will be replaced with MHC-peptide complexes and co-stimulatory 
molecules, necessary for highly efficient T cell activation. Cytokines can be 
coupled in addition to further shape the T cell response. Ultimately, after 
characterization of their in vivo behaviour, sDCs have the potential to become 
a highly efficient and cost-effective nanovaccine for cancer immunotherapy. 
Besides cancer immunotherapy, the semi-stiff polyisocyanopeptides scaffold 
might be used for other applications where multivalent binding is essential. 
Multivalency, for example, plays an important role in drug targeting. 
Functionalization of the scaffold with effector molecules as well as targeting 
and imaging moieties can potentially lead to a more efficient accumulation 
and detection of the therapeutic agent at the desired site of action opening up 
a far bigger range of possible therapeutic and diagnostic applications. 
 
2.4 Experimental section 
Materials 
Unless otherwise stated, all chemicals were obtained from Sigma Aldrich (Zwijndrecht, The 
Netherlands) and used without further purification. Toluene was distilled over sodium. 
Dichloromethane was distilled over phosphorous pentoxide. Column chromatography was 
performed using silica gel (0.060-0.200 mm) provided by Baker (Deventer, The Netherlands). 
Thin layer chromatography (TLC) analyses were carried out on silica 60 F254 coated glass 
obtained from Merck Millipore (Schiphol-Rijk, The Netherlands). The compounds were 
visualized using Ninhydrin or basic aqueous KMnO4 solutions. 1H NMR and 13C NMR spectra 
were recorded on a Bruker AC-300 MHz instrument (Delft, The Netherlands) operating at 300 
MHz and 75 MHz, respectively. J values are given in Hz and chemical shifts are reported in 
ppm. Me4Si was used as the internal standard. FT-infrared spectra of the compounds were 
measured using a Thermo Nicolet IR300 FT-IR spectrometer (Thermo Fisher Scientific, 
Breda, The Netherlands) equipped with a Harrick ATR unit. UV/VIS measurements were 
done using a Varian Cary 50 spectrometer (Agilent Technologies, Amstelveen, The 
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Netherlands). For mass spectrometry a LCQ Advantage MAX instrument (Thermo Fisher 
Scientific) was used. 
 
Monomer synthesis 
Synthesis of the azide-functionalized isocyanide monomer (1) 
The synthesis of (R)-2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl 2-((S)-2-isocyano 
propanamido)propanoate (1) was performed as shown in scheme S1 and is described below. 
Tetraethylene glycol was tosylated to yield S1. Compound S1 was then coupled to Boc-(L)-
alanine via a carbodiimide coupling using N,N'-dicyclohexylcarbodiimide (DCC) in the 
presence of 0.1 mol equivalents of 4-dimethylaminopyridine (DMAP) resulting in S2. The Boc 
group was removed using a HCl saturated ethyl acetate solution. Deprotection was monitored 
by TLC (SiO2, 10 % MeOH/CH2Cl2). The deprotected ethylene glycol-functionalized amino 
acid was treated with N,N-Diisopropylethylamine (DIPEA) before being coupled to Boc-(D)-
alanine via a DCC coupling in the presence of N-Hydroxybenzotriazole (HOBt) yielding S3. 
Again, the Boc protecting group of S3 was removed using a HCl saturated ethyl acetate 
solution. Formamide S4 was obtained by refluxing with 4 eq of sodium formate using ethyl 
formate as the solvent. Nucleophilic substitution of the tosyl-group with sodium azide resulted 
in S5. Finally, compound S5 was dehydrated using diphosgene to obtain the isocyanide 1. 
 
 
 
Scheme S1. Synthetic route towards the azide-functionalized monomer (1) 
 
Synthesis of 2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl 4-methylbenzene sulfonate (S1) 
Tetraethylene glycol (28.5 mL, 164.3 mmol) was dissolved in 50 mL pyridine. The solution 
was subsequently cooled to 0° C while stirring. Argon was bubbled through the solution for 
15 minutes. Tosylchloride (21.93 g, 115 mmol) was added portion wise to the stirring solution. 
The mixture was further stirred at room temperature for 12 hours. The reaction mixture was 
diluted with 50 mL of 10 % citric acid. The mixture was extracted three times into 250 mL of 
chloroform. The combined organic layers were dried over anhydrous Na2SO4, filtered and 
evaporated under vacuum. The resulting yellow oil was purified using column 
chromatography (SiO2, 0.060 - 0.200 mm; ethyl acetate as eluent) to yield S1 as a pale yellow 
oil (11.69 g, 33.6 mmol, 29 %); Rf = 0.4 (ethyl acetate). FT-IR (cm-1, ATR) 3442 (O-H), 2870 
(C-H), 1597 (N-H), 1453 (C-H), 1352 (S=O), 1175 (S=O), 1096 (C-O); 1H NMR δH(300 MHz; 
CDCl3; Me4Si) 7.80 (dd, J = 7.81 Hz, 2H, -CHAr-), 7.33 (d, J = 7.35 Hz, 2H, -CHAr-S), 4.17 (m, 
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2H, O-CH2-CH2-), 3.65 (m, 16H, -CH2-), 2.45 (s, 3H, -CH3); 13C NMR δC(75 MHz; CDCl3; 
Me4Si) 21.16 (1C, CCH3), 61.0 (1C, COH), 68.13(1C, COS), 69.0 (1C, OCH2), 70.0, 70.1, 
70.1, 70.2 (4C, OCH2), 70.8, 72.0 (2C, OCH2), 127.5 (2C, CHCCH), 129.5 (2C, CHCCH), 
139.7 (1C, CCH3), 144.5 (1C, CHCS). 
 
Synthesis of (R)-2-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)ethyl 2-((tert-
butoxycarbonyl)amino)propanoate (S2) 
Compound S1 (5.23 g, 15.01 mmol), N-Boc-(L)-alanine (2.86 g, 15.01 mmol) and DMAP 
(0.198 g, 1.65 mmol) were dissolved in 25 mL of freshly distilled CH2Cl2 and cooled to 0° C 
while stirring. DCC (3.12 g, 15.01 mmol) was added portion wise. The mixture turned yellow 
and was stirred for 1 h at 0° C followed by stirring for 3 h at room temperature. The 
precipitated dicyclohexyl urea was removed by filtration and washed with ethyl acetate (3 x 
20 mL). The organic layer was concentrated under vacuum. The crude product was purified 
using column chromatography (SiO2, 0.060 - 0.200 mm; 1 % MeOH/CH2Cl2 as eluent) to yield 
S2 as a light orange oil (5.49 g, 11.4 mmol, 76 %); Rf = 0.4 (10 % MeOH/CH2Cl2). FT-IR 
(cm-1, ATR) 2924 (C-H), 1745 (C=O ester), 1712 (C=O amide), 1597 (N-H), 1452 (C-H), 1352 
(S=O), 1173 (S=O), 1120 (C-O); 1H NMR δH(300 MHz; CDCl3; Me4Si) 7.79 (d, J = 8.4 Hz, 2H, 
-CHAr-), 7.33 (d, J = 8.1 Hz, 2H, -CHAr-), 5.02 (s, 1H, -NH-), 4.28 (m, 3H, -CH(CH3)-, 
COOCH2-), 4.15 (m, 2H, O-CH2-CH2-), 3.69 (m, 14H, O-CH2-CH2-), 2.44 (s, 3H, -CH3), 1.44 
(s, 9H, -OC(CH3)3), 1.37 (d, J = 7.2 Hz, 3H, -CH(CH3)-); 13C NMR δC(75 MHz; CDCl3; Me4Si) 
18.8 (1C, CHCH3), 21.7 (1C, CCH3), 28.4 (3C, C(CH3)3), 49.4 (1C, O(C=O)CHNH), 64.5 (1C, 
Boc-OCH2), 68.9 (2C, OCH2), 69.4 (1C, OCH2), 70.7 (4C, OCH2), 80.3 (1C, C(CH3)3), 128.2 
(2C, CHCCH), 130.0 (2C, CHCCH), 145.0 (1C, CCH3), 155.4 (1C, CHCS), 173.6 (1C, 
CH(C=O)NH), 176.7 (1C, CH(C=O)O); MS (ESI) m/z [M+Na]+ calcd 542.2; found 542.2. 
 
Synthesis of (R)-2-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)ethyl 2-((S)-2-((tert-
butoxycarbonyl)amino)propanamido)propanoate (S3) 
Compound S2 (5.94 g, 11.4 mmol) was dissolved in 60 mL of HCl saturated ethyl acetate and 
stirred for 2 h at room temperature. The solvent was evaporated under vacuum and the 
excess of HCl was removed by adding 30 mL of CH2Cl2 and 1 mL of n-BuOH followed by 
evaporation. The residual n-BuOH was removed via azeotropic distillation with 3x 30 mL 
CH2Cl2. The resulting HCl salt of S2, N-Boc-(D)-alanine (2.14 g, 11.4 mmol) and N-
hydroxybenzotriazole monohydrate (HOBt; 1.74 g, 11.4 mmol) were dissolved in 40 mL 
freshly distilled CH2Cl2. DIPEA (2 mL, 11.4 mmol) was added drop wise and the mixture was 
stirred at room temperature until everything was dissolved. The solution was cooled to 0 °C 
and DCC (2.35 g, 11.4 mmol) was added portion wise. A white precipitate was formed and 
the mixture was stirred for 1 h at 0° C followed by 3 h of stirring at room temperature. The 
precipitate was filtered off, washed with ethyl acetate (3x 30 mL) and the solvent was 
evaporated under vacuum. The crude product was purified using column chromatography 
(SiO2, 0.060 - 0.200 mm; 2 % MeOH/CH2Cl2 as eluent) to yield S3 as a pale yellow oil 
(3.37 g, 5.7 mmol, 52 %); Rf = 0.3 (10 % MeOH/CH2Cl2). FT-IR (cm-1, ATR) 2876 (C-H), 1740 
(C=O ester), 1718 (C=O amide), 1667 (N-H), 1522 (N-H), 1452 (C-H), 1365 (S=O), 1161 
(S=O), 1105 (C-O); 1H NMR δH(300 MHz; CDCl3; Me4Si) 7.80 (d, J = 8.4, 2H, -CHAr- C-S), 
7.36 (d, J = 8.1, 2H, -CHAr-), 6.91 (s, 1H, -NH), 5.00 (s, 1H, -NH), 4.58 (m, 1H, -NHCH(CH3)-), 
4.28 (m, 2H, -COOCH2-), 4.14 (m, 2H, O-CH2-CH2-), 3.61 (m, 
12H, -C(O)OCH2CH2O(CH2CH2O)3-), 2.45 (s, 3H, -CH3), 1.45 (s, 9H, -OC(CH3)3), 1.40 (d, J = 
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7.2, 3H, -CH(CH3)-), 1.35 (d, J = 7.2, 3H, -CH(CH3)-); 13C NMR δC(75 MHz; CDCl3; Me4Si) 
18.2 (2C, CHCH3), 21.7 (1C, CCH3), 28.4 (3C, C(CH3)3), 47.2 (1C, NCH), 50.0 (1C, NCH), 
64.5 (1C, Boc-OCH2), 68.7 (2C, OCH2), 69.3 (1C, OCH2), 70.6 (4C, OCH2), 80.2 (1C, 
C(CH3)3), 128.0 (2C, CHCCH), 129.9 (2C, CHCCH), 133.1 (1C CCH3), 144.9 (1C, CHCS), 
172.7 (2C, C=O); MS (ESI) m/z [M+Na]+ calcd 613.2; found 613.1. 
 
Synthesis of (R)-2-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)ethyl 2-((S)-2-
formamidopropanamido)propanoate (S4) 
Compound S3 (1.70 g, 2.85 mmol) was deprotected following the same procedure as 
described for compound S2 and used without further purification. The crude product was 
dissolved in 25 mL ethyl formate. Sodium formate (0.97 g, 14.25 mmol) was added and the 
mixture was heated for 8 hours at 66 °C. The mixture was cooled to room temperature and 
the solid was filtered off. The solvent was evaporated under vacuum. The crude product was 
purified using column chromatography (SiO2, 0.060 - 0.200 mm; 4 % MeOH/CH2Cl2 as eluent) 
to yield S4 as a light yellow oil (0.79 g, 1.52 mmol, 54 %); Rf = 0.3 (10 % MeOH/CH2Cl2). FT-
IR (cm-1, ATR) 2873 (C-H), 1738 (C=O), 1653 (N-H), 1532 (N-H), 1452 (C-H), 1352 (S=O), 
1174 (S=O), 1097 (C-O); 1H NMR δH(300 MHz; CDCl3; Me4Si) 8.18 (s, 1H, HC(O)NH-), 7.79 
(d, J = 8.4, 2H, -CHAr- C-S), 7.35 (d, J = 8.7, 2H, -CHAr-), 6.78 (s, 1H, -NH), 6.55 (s, 1H, -NH), 
4.55 (m, 2H, -NHCH(CH3)-), 4.30 (m, 2H, -COOCH2-), 4.13 (m, 2H, O-CH2-CH2-), 3.61 (m, 
12H, -(CH2CH2O)3-), 2.44 (s, 3H, -CH3), 1.42 (m, 6H, -CH(CH3)-); 13C NMR δC(75 MHz; 
CDCl3; Me4Si) 17.9 (1C, CHCH3), 18.2 (1C, CHCH3), 21.7 (1C, CCH3), 47.2 (1C, 
O(C=O)HNCH), 48.1 (1C, HNHC(C=O)), 64.5 (1C, OCH2), 68.7 (2C, OCH2), 69.3 (1C, 
OCH2), 70.6 (4C, OCH2), 128.0 (2C, CHCCH), 129.9 (2C, CHCCH), 133.1 (1C, CCH3), 144.9 
(1C, CHCCH), 161.0 (1C, H(C=O)NH)), 172.6 (1C, CH(C=O)NH), 173.2 (1C, CH(C=O)O); 
MS (ESI) m/z [M+Na]+ calcd 541.2; found 541.2. 
 
Synthesis of (R)-2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl 2-((S)-2-formamido 
propanamido)propanoate (S5) 
Compound S4 (0.550 g, 1.06 mmol) was dissolved in 40 mL of absolute EtOH. Sodium azide 
(0.38 g, 5.9 mmol) was added and the mixture was refluxed overnight. Once cooled to room 
temperature, the solids were removed by filtration and the filtrate was dried under vacuum. 
The crude product was purified using column chromatography (SiO2, 0.060 - 0.200 mm; 4 % 
MeOH/CH2Cl2 as eluent) to yield S5 a pale orange oil (0.32 g, 0.82 mmol, 78 %); Rf = 0.4 
(10 % MeOH/CH2Cl2).  FT-IR (cm-1, ATR) 3309 (N-H), 2875 (C-H), 2105 (N3), 1737 (C=O), 
1651 (N-H), 1529 (N-H), 1453 (C-H), 1133 (C-O); 1H NMR δH(300 MHz; CDCl3; Me4Si) 8.20 
(s, 1H, HC(O)NH-), 6.84 (s, 1H, -NH), 6.60 (s, 1H, -NH), 4.60 (m, 2H, NHCH(CH3)), 4.26 (m, 
2H, -C(O)OCH2-), 3.68 (m, 12H, -(CH2CH2O)3-), 3.40 (m, 2H, N3CH2-), 1.42 (m, 6H, -
CH(CH3)-); 13C NMR δC(75 MHz ; CDCl3; Me4Si) 17.9 (1C, CH3), 18.2 (1C, CH3), 47.4 (1C, 
CH2N3), 48.4 (1C, H(C=O)HNCH), 50.7 (1C, HNC(CH3)C=O), 69.0 (1C, CH2CH2O), 70.1 (1C, 
OCH2CH2), 70.6 (2C, OCH2), 70.7 (2C, OCH2), 161.4 (1C, H(C=O)NH), 172.7 (1C, 
CH(C=O)NH), 172.9 (1C, CH(C=O)O); MS (ESI) m/z [M+Na]+ calcd 412.2; found 412.2. 
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Synthesis of (R)-2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl 2-((S)-2-
isocyanopropanamido)propanoate (1) 
Compound S5 (221 mg, 0.57 mmol) and N-methylmorpholine (NMM; 0.24 mL, 2.27 mmol) 
were dissolved in 150 mL freshly distilled CH2Cl2 and cooled down to -40 °C (dry acetone 
bath) under an argon atmosphere. A solution of diphosgene (0.048 mL, 0.398 mmol) in 10 mL 
of freshly distilled CH2Cl2 was added drop wise under argon over 1 h. While adding 
diphosgene, the mixture was stirred and kept strictly at -40° C. Once the mixture began to 
turn yellow, the reaction was rapidly quenched with an excess of sodium bicarbonate (5 g). 
The quenched mixture was stirred for 5 minutes at -40 °C. The reaction mixture was passed 
over a short silica column plug (SiO2, 0.060 - 0.200 mm). The plug was packed with CH2Cl2 
but the desired compound was eluted with CH2Cl2/acetonitrile (3:1) to yield 1 as a pale yellow 
oil (48.1 mg, 0.48 mmol, 27 %); Rf = 0.5 (10 % MeOH/CH2Cl2). FT-IR (cm-1, ATR) 3318 (N-H), 
2875 (C-H), 2142 (C≡N), 2105 (N3), 1744 (C=O), 1540 (N-H), 1453 (C-H), 1123 (C-O); 1H 
NMR δH(300 MHz; CDCl3; Me4Si) 7.00 (bd, 1H, -NH-), 4.59 (m, 1H, -NHCH(CH3)C(O)O-), 
4.32 (m, 3H, (-C(O)OCH2CH2O-), -C≡NCH(CH3)C(O)NH-), 3.67 (m, 12H, -(OCH2CH2)3), 3.39 
(m, 2H, N3CH2-), 1.65 (d, J = 7.2, 3H, C≡NCH(CH3)C(O)-), 1.48 (d, J = 7.2, 3H, 
C≡NCH(CH3)C(O)-); 13C NMR δC(75 MHz; CDCl3; Me4Si) 170.69 (1C, CH(CH3)C(O)OCH2), 
165.72 (1C, CH(CH3)C(O)NH), 70.69, 70.65, 70.61, 70.56, 70.02, 68.81 (1 C, CH2CH2O), 
50.66 (1C, CH2N3), 48.56 (C≡NCH), 19.66, 18.04 (1C, CH(CH3)CO); MS (ESI) m/z [M+Na]+ 
(C15H25N5O6Na), calcd 394.17; found 394.1. 
 
Synthesis of the methoxy-functionalized isocyanide monomer (2) 
The synthesis of (S)-2,5,8,11-tetraoxatridecan-13-yl 2-((R)-2-isocyanopropanamido) 
propanoate (2) was performed as shown in scheme S2 and has been reported previously.26,27  
Tetraethylene glycol monomethyl ether was coupled to Boc-(L)-alanine to obtain S6 via DCC 
coupling in the presence of 0.1 mol equivalents of DMAP. S6 was deprotected using a HCl 
saturated ethyl acetate solution. After deprotection, S6 was coupled to Boc-(D)-alanine via a 
DCC coupling in the presence of HOBt. The product S7 was again deprotected using a HCl 
saturated ethyl acetate solution until no more starting material could be observed by TLC 
analysis (SiO2, 5 % MeOH/CH2Cl2). The deprotected amine was formylated with sodium 
formate to obtain formamide S8. After purification, S8 was dehydrated with diphosgene to 
obtain the isocyanide 2. 
 
 
 
 
 
Scheme S2. Synthetic route towards the methoxy-functionalized monomer (2) 
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Synthesis of (R)-2,5,8,11-tetraoxatridecan-13-yl 2-((tert-butoxycarbonyl)amino) propanoate 
(S6) 
Tetraethylene glycol monomethylether (5.01 g, 24.1 mmol), N-Boc-(L)-alanine (4.47 g, 
23.6 mmol) and DMAP (0.37 g, 3.0 mmol) were dissolved in 30 mL of freshly distilled CH2Cl2 
and cooled to 0 °C while stirring. DCC (4.96 g, 24.0 mmol) was added and the mixture turned 
yellow gradually. It was stirred for 1 h at 0 °C and allowed to heat up to room temperature for 
another 3 h. The precipitate was filtered off, washed with ethyl acetate (3 x 20 mL) and the 
filtrate was dried under vacuum. The crude product was purified using column 
chromatography (SiO2, 0.060 - 0.200 mm; 1 % MeOH/CH2Cl2 as eluent) to yield S6 as an 
orange oil (7.24 g, 19.08 mmol, 80.7 %); Rf = 0.8 (CH2Cl2). FT-IR (cm-1, ATR): 3344 (N-H), 
2878 (C-H), 1757 (C=O ester), 1712 (C=O protecting group), 1520 (N-H), 1453 (C-H), 1165 
(C-O); 1H NMR δH(300 MHz; CDCl3; Me4Si) 5.08 (s, 1H, -NH-), 4.29 (m, 3H, -CH(CH3)-, 
COOCH2-), 3.65 (m, 14H, -CH2-), 3.38 (s, 3H, -OCH3), 1.43 (d, J = 1.39 Hz, 9H, -C(CH3)-), 
1.37 (s, 3H, -CH(CH3)-). 
 
Synthesis of (R)-2,5,8,11-tetraoxatridecan-13-yl 2-((S)-2-((tert-butoxycarbonyl) 
amino)propanamido)propanoate (S7) 
Compound S7 was synthesized according to the same procedure as compound S3. The 
crude product was purified using column chromatography (SiO2, 0.060 - 0.200 mm; 
2 % MeOH/CH2Cl2 as eluent) to yield S7 as a slightly yellow oil (4.43 g, 9.5 mmol, 63 %); Rf = 
0.5 (10 % MeOH/CH2Cl2). FT-IR (cm-1, ATR) 3317 (N-H), 2876 (C-H), 1739 (C=O ester), 
1671 (N-H), 1517 (N-H), 1452 (C-H), 1163 (C-O); 1H NMR δH(300 MHz; CDCl3; Me4Si) 6.80 
(s, 1H, -NHCH-), 5.11 (bs, 1H, -NHCH), 4.60 (q, J = 8.56 Hz, 1H, -NHCH(CH3)-), 4.28 (m, 3H, 
-C(O)OCH2CH2O-, -CH(CH3)COO-), 3.73-3.64 (m, 14H, -C(O)OCH2CH2O(CH2CH2O)3-), 3.39 
(s, 1H, -OCH3), 1.46 (s, 9H, -OC(CH3)3), 1.43 (d, J = 1.40 Hz, 3H, -NHCH(CH3)-), 1.36 (d, J = 
1.33 Hz,3H, -NHCH(CH3)-). 
 
Synthesis of (S)-2,5,8,11-tetraoxatridecan-13-yl 2-((R)-2-formamidopropan amido)propanoate 
(S8) 
Compound S8 was synthesized according to the same procedure as described for compound 
S4. The crude product was purified using column chromatography (SiO2, 0.060 - 0.200 mm; 
4 % MeOH/CH2Cl2 as eluent) to yield S8 as a colorless oil (1.74 g, 4.6 mmol, 69 %); Rf = 0.4 
(10 % MeOH/CH2Cl2). FT-IR (cm-1, ATR) 3297 (N-H), 2875(C-H), 1739 (C=O ester), 1653 (N-
H), 1529(N-H), 1452 (C-H), 1101 (C-O); 1H NMR δH(300 MHz; CDCl3; Me4Si) 8.21 (s, 
1H, -C(O)NH-), 6.96 (bd, J=7.5Hz, 1H, -NHCH-), 6.79 (bd, J=7.5Hz, 1H, -NHCH-), 4.58 (m, 
2H, NHCH(CH3)), 4.31 (m, 2H, -C(O)OCH2-), 3.67-3.56 (m, 
14H, -C(O)OCH2CH2O(CH2CH2O)3-), 3.39 (s, 3H, -OCH3), 1.43 (m, 6H, -NHCH(CH3)-
, -NHCH(CH3)-). 
 
Synthesis of (S)-2,5,8,11-tetraoxatridecan-13-yl 2-((R)-2-isocyanopropanamido) propanoate 
(2) 
Compound 2 was synthesized according to the same procedure as compound 1. The crude 
product was purified using column chromatography (SiO2, 0.060 - 0.200 mm; 
CH2Cl2/acetonitrile 3:1 as eluent) to yield 2 as a colorless oil (174 mg, 0.48 mmol, 63 %); Rf = 
0.4 (10 % MeOH/CH2Cl2). FT-IR (cm-1, ATR) 3250 (N-H, amide), 2875 (C-H), 2140 (C≡N, 
isocyanide), 1741 (C=O, ester), 1682 (C=O, amide), 1100 (C-O, ether); 1H NMR δH(300 MHz; 
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CDCl3; Me4Si) 6.99 (bd, 1H, -NH-), 4.58 (m, 1H, -NHCH(CH3)C(O)O-), 4.32 (m, 
2H, -C(O)OCH2CH2O-), 4.25 (m, 1H, C≡NCH(CH3)C(O)NH-), 3.73-3.53 (m, 
14H, -OCH2CH2(OCH2CH2)3OCH3), 3.37 (s, 3H, -OCH3), 1.64 (d, J = 7.2 Hz, 3H, 
C≡NCH(CH3)C(O)-), 1.49 (d, J = 7.2 Hz, 3H, -NHCH(CH3)C(O)O-); 13C NMR δC(75 MHz; 
CDCl3; Me4Si) 171.98 (-CH(CH3)C(O)OCH2-), 165.73 (-CH(CH3)C(O)NH-), 160.9 (C≡N-), 
71.92 (-CH2CCH), 70.60, 70.60, 70.60, 70.51, 70.51, 68.8, 65.55 (-OCH2CH2O)3-), 64.72 
(-C(O)OCH2-), 59.00 (-OCH3), 48.58 (C≡NCH(CH3)CONH-), 48.58 (-NHCH(CH3)C(O)O-), 
19.66 (C≡NCH(CH3)CONH-), 18.02 (NHCH(CH3)C(O)O-); MS (ESI) m/z [M+Na]+
(C18H39N2O7Na), calcd 383.1; found 383.2.
Polymer synthesis (3)
Compound 1 (3.1 mg, 8.310-3 mmol) and compound 2 (300 mg, 8.310-1 mmol) were 
dissolved in 30 mL of distilled toluene yielding a ratio of azide-functionalized monomers (1) to 
methoxy-functionalized monomers (2) of 1:100. The catalyst stock solution was prepared 
separately by dissolving Ni(Cl2O4)2•6 H2O (30.7 mg, 8.410-2 mmol) in 10 mL of absolute 
ethanol and 90 mL of toluene. From the catalyst stock solution 8.310-5 mmol was added to 
the reaction mixture. The mixture was stirred for 3 days at room temperature (RT). The 
reaction was followed by IR until all isocyanide was consumed (peak at 2142 cm-1). The 
polymer (compound 3) was isolated via precipitation into diisopropylether. This precipitation 
cycle was repeated thrice to obtain 299.6 mg, 78 % yield.
Polymer characterization
The molecular weight Mw of the resulting polymer was determined from both viscosity and 
size exclusion chromatography (SEC) measurements. In addition, the polymer length was 
determined using atomic force microscopy (AFM). The corresponding experiments are 
described in detail below. The results are summarized in table 2.1.
Table 2.1. Summary of molecular weight Mw and polymer length l
molecular weight Mw (kg/mol) apparent polymer length l (nm)
viscosity 421 123
a
Mw SEC 588 172a
AFM 677b 197
aThe apparent polymer length l was calculated from the measured molecular weight: 
bThe molecular weight Mw was calculated from the experimentally determined polymer length: 
Viscosity measurements
The intrinsic viscosity of polymer 3 was obtained from measurements with an Ubbelohde 
viscometer (Schott Instruments, Mainz, Germany). A stock solution (4 mg/mL) of polymer 3
was prepared in acetonitrile. From this stock solution, 4 mL of the following concentrations 
were prepared: 0.6; 0.5; 0.4; 0.3; 0.2 and 0.1 mg/mL. The solutions were loaded into a 
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viscometry tube (nr. 1053431; Schott Instruments). The tube was placed into the water bath 
(25 ˚C) and allowed to equilibrate for 15 min before the measurement. The flow speed for 
each sample was measured four times and used to determine the kinematic viscosity ν. From 
this data, the reduced viscosity ηred and the inherent viscosity ηinh were calculated41 and 
plotted against the polymer concentration. The intrinsic viscosity [η] represents the limiting 
value of ηred or ηinh at infinite dilution of the polymer, i.e. . From extrapolation of 
ηred to c = 0, an intrinsic viscosity [η] = 9.64 dLg-1 was obtained (Figure A2.1.1). Based on 
[η], a molecular weight of 421 kg/mol was determined using the Mark-Houwink equation
. The constants K = 1.410-9 dLmolag-(1+a) and a = 1.75 for a rigid 
polyisocyanide have been reported previously.42 The average polymer length was calculated 
to be 123 nm (Table 2.1).
Size exclusion chromatography
Polymer 3 was further analyzed by size exclusion chromatography (SEC) to determine its 
hydrodynamic radius. The SEC system was equipped with a Waters 1515 Isocratic HPLC 
pump, a Waters 2414 refractive index detector, a Waters 2707 autosampler, a PSS PFG 
guard column followed by 2 PFG-linear-XL (7 µm, 8*300 mm) columns in series. The system 
was run at 40 °C. Hexafluoroisopropanol (HFIP, Biosolve) with potassium trifluoroacetate 
(3 g/L) was used as eluent at a flow rate of 0.8 mL/min. The molecular weights were 
calculated against poly(methyl methacrylate) standards (Mp = 580 Da up to Mp = 7.1·106 Da; 
Agilent). The measurement yielded a molecular weight of 588 kg/mol and the average 
polymer length was calculated to be 172 nm (Figure A2.1.2 and Table 2.1).
AFM measurements
The polymer sample was diluted in 1 mM sodium acetate buffer pH 4.5 to obtain a 
concentration between 0.5 µg/mL and 5 µg/mL. The samples were drop casted onto freshly 
cleaved and polylysine coated mica and incubated for 10 minutes. The remaining liquid was 
removed and the sample was dried in a stream of N2. AFM images were recorded in tapping 
mode in air using a Nanoscope IV instrument (Bruker) and NSG-10 tapping mode tips (NT-
MDT, Limerick, Ireland). The polymer length was determined by hand using the program 
ImageJ43 (Figure A2.1.3 and Table 2.1).
Synthesis and characterization of the SAv-polymer bioconjugate (6)
Functionalization of Streptavidin with BCN-NHS (5)
Streptavidin (SAv) was obtained from Thermo Fisher Scientific (Etten-Leur, The Netherlands) 
and 2,5-dioxopyrrolidin-1-yl 1-(bicyclo[6.1.0]non-4-yn-9-yl)-3,14-dioxo-2,7,10-trioxa-4,13-
diazaoctadecan-18-oate (BCN-NHS; compound 4) was obtained from Synaffix (Nijmegen, 
The Netherlands). SAv (34.5 mg, 5.210-4 mmol) was dissolved in 7 mL of borate buffer 
(10 mM, pH 8.5) and BCN-NHS (1.7 mg, 3.110-3 mmol) was added to the SAv solution. The 
mixture was kept at 4 ˚C for four days. BCN-functionalized SAv (compound 5) was purified by 
gel filtration (PD 10 column, GE Healthcare) followed by ultrafiltration (Amicon Ultra-4, 
10 kDA; Merck Millipore). The final yield of 5 was determined by measuring absorption at 
280 nm. Using an extinction coefficient of ε = 167280 mol-1 cm-1, the yield was determined to 
be 26.1 mg, 76 %. The conjugate was further characterized using MALDI-ToF to obtain the 
labelling ratio. MALDI-ToF was performed using a Bruker Biflex III MALDI-ToF spectrometer. 
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SAv and SAv-BCN samples were prepared using α-Cyano-4-hydroxycinnamic acid as the 
matrix. The mass obtained for SAv (monomer) was determined to be 13280 Da [M+ H+]. This 
served as a reference for 5. Compound 5 shows both the peak of the non-functionalized 
monomer of 13280 Da [M+ H+] as well as the mass of 5 carrying one BCN-group coupled to 
the SAv monomer: 13783 Da [M+ 2K+] (Figure A2.1.4). No peak corresponding to a doubly 
labelled monomer was visible. Consequently, the degree of functionalization is between 0 and 
4 BCN-groups for the SAv tetramer. 
 
Synthesis of the SAv-polymer conjugate (6) 
Polymer 3 in 10 mL of 10 mM borate buffer (10 mg, 2.710-5 mmol) was mixed with SAv-BCN 
(26 mg, 3.910-7 mmol) in 4 mL of 10 mM borate buffer. The mixture was incubated at 4 ˚C for 
four days to obtain polymer 6. Polymer 6 was purified by dialysis against water at 4 ˚C for 2 
days using a membrane with cut-off of 100 kDa. 
 
Characterization of the SAv-polymer conjugate (6) 
Circular dichroism measurements 
To ensure that the bioconjugation does not affect the structure of the poly(isocyanopeptide) 
polymer, circular dichroism spectra were recorded for both polymer 3 and polymer 6. The 
measurements were performed at 20 °C at a concentration of 1 mg/mL in 50 mM borate 
buffer pH 8.5 using a Jasco J-810 CD spectrometer (de Meern, The Netherlands). Both 
polymers showed identical spectra (Figure A2.1.5) clearly indicating that the coupling of SAv 
does not influence the secondary structure of the SAv-polymer conjugate. 
 
AFM measurements 
The SAv loading of 6 was determined with AFM using the same procedure as for polymer 3. 
The results of this analysis are shown in Figure 2.3. 
 
Synthesis and characterization of αCD3-sDCs 
To obtain the αCD3-sDCs, the αCD3 antibodies were first biotinylated with EZ-Link Sulfo-
NHS-LC-Biotin (Thermo Fisher Scientific) to allow for binding to SAv on polymer 6. Before 
preparing the αCD3-sDCs, the molecular ratio of αCD3:SAv bound to the sDCs was 
optimized using a biotinylated AlexaFluor488-labelled αCD3 antibody. Using the fluorescently 
labelled antibody, it was possible to determine the αCD3 concentration while measuring the 
total protein concentration in the same sample. First, the SAv concentration on polymer 6 was 
determined using a BCA micro assay (Thermo Fisher Scientific). Then polymer 6 was mixed 
with the AlexaFluor488-labelled and biotinylated αCD3 antibody using 4:1, 6:1 and 8:1 molar 
ratios of αCD3:SAv. The mixture was left at 4 °C for 24 h. After removing the free αCD3 by 
ultrafiltration (Nanosep Omega, cut-off of 300 kDa, PALL Life Sciences, Zaventem, Belgium) 
the total protein concentration was again determined using the BCA assay. In addition, the 
fluorescence originating from the AlexaFluor488-labelled antibody was determined from a 
fluorescence measurement in a microplate reader (Cytofluor II, PerSeptive Biosystems, 
Framingham, MA, USA). The αCD3 concentration was calculated from a standard curve of 
AlexaFluor488-labelled αCD3. Subtracting the Alexa488-αCD3 concentration from the total 
protein concentration, the SAv concentration as well as the αCD3:SAv ratio was determined. 
For a 4:1 mixing ratio of αCD3:SAv approximately one αCD antibody was bound per SAv 
molecule (Figure A2.1.6). To prepare the sDCs for the T cell experiments, a 4:1 mixing ratio 
Processed on: 10-10-2016
505747-L-bw-Hammink
Towards Novel Synthetic Dendritic Cells for Immunotherapy!
!
! 39 
was used following exactly the same protocol as used in the preliminary experiment 
described above. Assuming that the ratio of bound αCD3:SAv will be identical, the 
concentration of αCD3 could now be determined from the total protein concentration without 
the need for fluorescently labelling the αCD3 antibody. For the T cell experiments, all the 
treatment concentrations were based on the concentration of αCD3 present on the sDC 
backbone, on the microbead system or as free αCD3. 
 
Cell preparation and cell culture 
Peripheral Blood Lymphocytes (PBLs) were isolated from the buffy-coat obtained from a 
healthy volunteer via Ficoll density gradient centrifugation (Lucron Bioproducts, Sint Martens-
Latem, Belgium). The PBLs and OKT3 hybridoma cells were always maintained in RPMI-
1640 medium (Life Technologies, Bleiswijk, The Netherlands) containing 10 % Fetal Bovine 
Serum (FBS) (Greiner Bio-One B.V., Alphen a/d Rijn, The Netherlands), 1 % glutamine 
(Lonza, Breda, The Netherlands) and 1x Antibiotic-Antimycotic (Life Technologies). For the 
αCD3 production, OKT3 hybridoma cells (at confluence) were transferred into Protein Free 
Hybridoma Medium (PFHM-II, Life Technologies). These cells were cultured for 3-4 days in 
PFHM-II before purifying the αCD3 monoclonal antibodies using HiTrap™ Protein G HP 
Columns (GE Healthcare). 
 
Cell viability measurements 
MTT assay 
The cytotoxic effect of the αCD3-sDCs was determined using a standard MTT assay.44 PBLs 
(105 cells/well) were treated with αCD3-sDC, αCD3 or left untreated (control) for 24 h using 
different concentrations (5, 50, 500 ng/mL) of the respective molecules. After washing twice, 
the cells were incubated with MTT (5 mg/mL; Sigma Aldrich) for 2 h. The medium was then 
replaced with 100 µl of DMSO. After solubilization, the microplates were read at 550 nm using 
a microplate reader (iMark, Bio-Rad, Veenendaal, The Netherlands). The results were 
derived from three independent experiments (with three replicates per experiment). 
 
Trypan Blue assay 
In addition, the cell viability was estimated over time. Viable and non-viable cells were 
counted after αCD3-sDC treatment using the hemacytometer method by means of a Trypan 
Blue assay.45 The percentage of viable cells was determined upon exposure to αCD3-sDC, 
αCD3, and untreated (control) in a concentration of 200 ng/mL and incubation times of 0, 24 
and 72 h. The percentage of viable cells was calculated according to the formula: 100 x 
(number of viable cells in treated samples/total number of cell counted). The results were 
obtained from three independent experiments (with three replicates per experiment). 
 
T cell activation 
Flow cytometry (CD69 expression) 
The estimation of activated T cells (CD69+ T cells) upon αCD3-sDC treatment was 
determined using Fluorescence Activated Cell Scanning (FACS). Briefly, PBLs (105/well) 
were treated with the respective molecules for 24 h at different concentrations (0.005, 0.01, 1, 
5, 10, 50, 100 ng/mL). In addition to these concentration dependent experiments, also time 
dependent T cell activation studies were performed. The T cells were treated with αCD3-sDC 
and αCD3 using a concentration of 5 ng/mL and incubation times of 2, 4, 6, 8, 10, 24, 28 and 
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30 h. The treated cells were washed with PBS containing 10 % BSA (PBA; Sigma Aldrich). 
Subsequently, the cells were incubated with Fluorescein-labelled mouse anti-human CD69 
mAb (activated T cell marker, BD Biosciences, Breda, The Netherlands) and APC-labelled 
mouse anti-human CD4/8 mAb (T cell marker, BD Biosciences). After washing twice with 
PBA, FACS analysis was performed using a CyAn™ ADP Analyzer instrument (Beckman 
Coulter, Woerden, The Netherlands). The results were analyzed using Flow-Jo ver. 9.2 
software (Tree Star Inc., Ashland, OR, USA). The above experiment was repeated four 
independent times (with three replicates per experiment). 
 
Enzyme-linked immunosorbent assay (ELISA; IFNγ secretion) 
The level of secreted IFNγ was determined in the culture supernatants using a standard 
sandwich ELISA method. After coating overnight at 4 °C with mouse anti-human IFNγ 
antibody (Thermo Fisher Scientific), the 96-well microplates (Nunc Immunomodules; Thermo 
Fisher Scientific) were washed with PBS/Tween (0.05 %) and blocked with PBS-1 % BSA. 
Subsequently, the IFNγ standards (Thermo Fisher Scientific) and the supernatants were 
added into the wells and incubated for 1 hour at room temperature. Following washing with 
PBA for three times, the presence of IFNγ was detected using a biotinylated mouse anti-
human IFNγ antibody (Thermo Fisher Scientific) and a streptavidin-horseradish peroxidase 
(HRP) conjugate (Life Technologies). HRP activity was detected using tetramethyl benzidine 
(TMB; Sigma Aldrich). The absorption was measured at 450 nm using an iMark Microplate 
Reader (Bio-Rad). The experiments were conducted for four independent times. 
 
Summary of all controls for CD69 expression and IFNγ secretion 
The level of CD69 expression as well as the concentration of the secreted IFNγ was 
determined for αCD3-sDC and for the following controls: non-biotinylated, free αCD3 
antibodies (αCD3); biotinylated αCD3 bound to streptavidin (αCD3-SAv); biotinylated αCD3 
bound to streptavidin-functionalized PLGA particles (αCD3-PLGA); non-biotinylated αCD3 
mixed with polymer 6 (polymer 6 + αCD3); polymer 6 alone (polymer 6); polymer 3 alone 
(polymer 3); streptavidin alone (SAv); non-biotinylated, free mouse anti-human IgG2a 
antibodies as αCD3 isotype control (mIgG2a); biotinylated mIgG2a antibodies bound to polymer 
6 (mIgG2a-sDC). The results of all treatment conditions are summarized in Figure A2.1.7. 
 
CFSE assay 
T cell proliferation induced by αCD3-sDC was assessed using a CFSE assay.46 PBLs (105) 
were pre-labelled with 5 µM CFSE (Life Technologies). Free CFSE was quenched with FBS. 
αCD3-sDC and αCD3 was added to the CFSE-labelled PBLs (105/well) at a concentration of 
5 ng/mL. Treated cells were incubated overnight along with untreated control cells. After 
incubation times of 0, 24, 48, 72 and 96 h, the treated cells were used for FACS analysis. T 
cells were identified based on labelling with a mouse APC-labelled anti-human CD4/8 
antibody. T cell proliferation was assessed from determining the CFSE staining intensity. The 
results were interpreted by considering the % decrease in fluorescence intensity as a 
corresponding % increase in T cell proliferation. The % difference in T cell proliferation 
(%∆PF) was determined by normalizing the treated value against the untreated (control) 
value. Cyton software was utilized to analyze the number of cells proliferated per generation 
(Figure A2.1.8).47 The results were derived from four independent experiments (with three 
replicates per experiment). 
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Statistical analysis
Two-way ANOVA and Bonferroni post-tests were performed for a pair wise comparison 
between the variables using Graphpad Prism 5 software (San Diego, CA, USA). The 
statistical significance is defined as p < 0.05. The asterisk ‘*’, ‘**’, ‘***’ represents p values 
<0.05, <0.01 and <0.001
Confocal imaging
The binding of αCD3-sDC on the T cell surface was analyzed by confocal imaging using 
sDCs carrying a fluorescein-labelled αCD3 antibody (FαCD3-sDC). PBLs (105/well) were 
treated for 24 h with FαCD3-sDC and FαCD3 (F-Fluorescein, λex = 488 nm, λem = 520 nm) at 
different concentrations (5, 10, 20, 30, 50, 200 ng/mL). Further, these cells were labelled with 
the membrane dye PKH26 (λex = 551 nm, λem = 567 nm; Sigma Aldrich) following the 
manufacturer’s protocol. These labelled PBLs were fixed in 4 % paraformaldehyde. The fixed 
cells were quenched with glycine (0.1 mM) in PBS. The cover slips were mounted onto 
microscope slides (Thermo Fisher Scientific) using MOWIOL (Merck Millipore). The slides 
were imaged using a Confocal Laser Scanning Microscope (Olympus FV1000) equipped with 
a 63x oil immersion objective. The cells that show bound FαCD3-sDC were counted manually 
and compared to the number of FαCD3-sDC-free cells (Figure A2.1.9) using the program 
ImageJ. All the experiments were repeated three independent times using PBLs from three 
different healthy donors.
Comparison of aCD3-sDC efficacy with aCD3-PLGA particles
Synthesis of αCD3-PLGA particles
A particle-based DC system was prepared using PLGA particles as described previously48
with the following modifications. To attach the αCD3 antibody to PLGA via the SAv-biotin 
interaction, SAv was covalently coupled to the PLGA particles (PLGA-SAv). In brief, protected 
sulfhydryl groups were introduced into SAv using N-Succinimidyl S-Acetylthiopropionate 
(SATP; Thermo Scientific) and deprotected with hydroxylamine hydrochloride (Thermo 
Scientific) using the manufacturer’s protocol. Thereafter, the free thiol-groups on the SAv 
were reacted with the maleimide group of the DSPE-PEG-maleimide (MW = 2000 g/mol) that 
is present on the PLGA surface. After washing with PBS, the biotinylated αCD3 antibody was 
bound to PLGA-SAv to obtain αCD3-PLGA.
Characterization of αCD3-PLGA particles
The size and concentration of the SAv-PLGA and αCD3-PLGA were determined using 
Transmission Electron Microscopy (TEM; JEOL TEM 1010, Nieuw-Vennep, The Netherlands) 
(Figures A2.1.10a and A2.1.10b) and Differential Interference Contrast (DIC; Figure A2.1.10c) 
using a confocal microscope (FluoView FV1000, Olympus, Zoeterwoude, The Netherlands).
To obtain the particle concentration, the particle suspension was imaged using a Bürker 
chamber. The suspension was imaged under semi-dry conditions on the Bürker chamber grid 
to ensure that all particles had settled on the grid surface. The number of particles on the 
square grid was counted using the program ImageJ. For the αCD3-PLGA particles, the 
concentration was calculated to be particles per mL. To estimate the amount of 
αCD3 bound per αCD3-PLGA particle, a biotinlyated and AlexaFluor488-labelled αCD3 
antibody was used in the same way as described for the αCD3-sDCs described above. This 
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experiment yielded an amount of 3795 αCD3 antibodies per PLGA particle. For the T cell 
experiments, where no fluorescently labelled antibody was used, it has been assumed that 
the amount of bound αCD3 will be the same for identical experimental conditions. 
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2.5 Appendix 2.1: Supplementary figures  
 
 
 
 
Figure A2.1.1. Ostwald viscosity measurement. The intrinsic viscosity was determined 
experimentally from both the reduced viscosity and the inherent viscosity for different 
concentrations of the polymer in acetonitrile. The value for the intrinsic viscosity 
[η] = 9.64 dLg-1 was obtained from extrapolation to c = 0 g/dL. 
 
 
  
Figure A2.1.2. Size exclusion chromatography. a) Compound 3 eluted at 18.5 min. b) This 
corresponds to a weighted average molecular weight Mw of 588 kg/mol (PMMA standards) 
and a PDI of 2.6. 
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Figure A2.1.3. Measurement of the polymer length with AFM. The mean value is 197 nm (n = 
198). 
 
 
 
Figure A2.1.4. MALDI-ToF analysis. a) SAv before addition of BCN-NHS; b) BCN-
functionalized SAv. 
 
 
 
 
Figure A2.1.5. Circular dichroism spectra. a) polymer 3; b) SAv-polymer conjugate 6.  
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Figure A2.1.6. Loading of polymer 6 with αCD3 antibodies. Different ratios of biotinylated, 
AlexaFluor488-labelled αCD3 were added to polymer 6 (αCD3:SAv ratio = 4:1, 6:1 and 
8:1). For a ratio of 4:1, an average number of 0.93 αCD3 molecules was obtained per SAv 
molecule. For 6:1 and 8:1, a final ratio of 2.69 and 3.37 αCD molecules were bound per 
SAv molecule, respectively. Mean values and standard deviations were determined from 8 
experiments (n = 8). 
 
 
 
Figure A2.1.7. T cell activation profile based on the early activation marker CD69. a) and late 
activation marker IFNγ. b) Each value represents the mean ± s.e.m. of three independent 
donors. 
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Figure A2.1.8. T cell proliferation determined with a CFSE assay. The graph represents the 
increase in the number of T cells per generation after treatment with αCD3-sDC and soluble 
αCD3, respectively. In the case of the αCD3-sDC treatment, the cell proliferation rate 
increases to a maximum in the first generation. This proliferation rate was maintained over 
the following generations (for the complete time period analyzed). When treating the T cells 
with soluble αCD3, the cell number only gradually increases per generation. 
 
 
 
Figure A2.1.9. Overview images illustrating co-localization (yellow) of a) Fluorescein-labelled 
αCD3 (FαCD3, green) loaded onto polymer 6 (FαCD3-sDCs) and b) free FαCD3 on the PBL 
membrane (stained with the membrane specific dye PKH26, red). 
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Figure A2.1.10. Characterization of αCD3-PLGA particles. a) Particle size obtained from 
TEM. The result represents mean ± s.e.m. (n = 300 particles). b) representative TEM image 
of αCD3-PLGA. c) representative DIC image of αCD3-PLGA. 
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2.6 Appendix 2.2: Estimation of the contact area and the number of 
possible interactions 
Based on the measurement of 3795 αCD3 antibodies per PLGA particle, the surface density 
of αCD3 antibodies on the PLGA particles can be calculated. The average number of 3795 
αCD3 molecules per PLGA particle corresponds to 1 αCD3 antibody within 2688 nm2 and an 
average distance between antibodies of roughly 50 nm. Based on these values, the number 
of possible interactions with the cell surface can be obtained. Before this number can be 
calculated, the contact area of the PLGA particle with the cell has to be determined first. The 
calculation of the contact area is based on Hertz theory (Figure A2.2.1):49
Figure A2.2.1. Geometry of the particle membrane interaction; with R - particle radius, d -
indentation depth, a - radius of the contact area.
The contact area A is described by (1)
with 
To obtain the contact area, first the force F that the particle exerts on the cell surface and the 
corresponding indentation depth d are calculated:
The indentation depth d and the Force F are related by the following equations:
(2)
and
(3)
with the combined elastic modulus (4)
To model the natural “bouncing” of the sphere into the cell membrane in an aqueous 
environment, the corresponding force is first modelled as a function of gravity. A radius of 
R = 0.9 µM has been determined for the SAv-PLGA particles (Figure A2.1.10). These 
particles have a density that is 1.2x larger than the density of water. Using equation (5)50 the 
maximum speed va that a PLGA particle can reach in an aqueous environment can be 
calculated:
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(5)
with ∆Dr - difference in density, g – gravitational acceleration, η – viscosity of water
For the PLGA particles the value for the maximum speed is:
The corresponding force can then be calculated for low Reynolds number (Re << 1):
(6)
where f depends on the particle radius R and the viscosity of the environment η via
(7)
In this way the force exerted by the particle on a cell can be estimated as
!for!
Cells are known to have a Young’s Modulus of ≈ 400 Pa – 2500 Pa,51 which is much smaller 
than that of PLGA particles. Therefore, E* can be simplified as:
(8)
Using equations (1) – (8), a PLGA particle consequently indents a cell by . The 
corresponding contact area between the cell and the PLGA particle is 
meaning that the PLGA particle interacts with the cell over a distance of roughly 25 nm. 
Without the 20 nm PEG spacers used for antibody attachment maximally 1 or 2 antibodies 
could interact with the cell at the same time. Considering the flexible spacers, up to 10 
antibodies are able to interact with the cell simultaneously. Based on these results it can be 
concluded that multivalent interactions can also take place when using αCD3-PLGA particles. 
More importantly, the total number of antibodies able to interact with the cell and the spacing 
between them is nearly the same for both the αCD3-PLGA particles and the αCD3-sDCs 
(approx. 50 nm in both cases).
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Chapter 3: Controlling T cell activation with synthetic Dendritic 
Cells using the multivalency effect 
 
3.1 Introduction 
One important goal of cancer immunotherapy is the replacement of costly 
dendritic cells (DCs) vaccines, which have to be generated for every individual 
patient, with synthetic variants.1 These synthetic variants, called artificial antigen 
presenting cells (aAPCs), are designed to prime T cells against cancer specific 
antigens. These aAPCs can be produced in a straightforward manner from synthetic 
building blocks, opening up the possibility for standardized “off-the-shelf” protocols2 
and circumventing elaborate and expensive personalized medicine. Different aAPC 
designs have been synthesized over the last years with scaffolds varying from 
polymer beads,3,4 carbon nanotubes,5 liposomes6 and many others.7 In general, the 
design of aAPCs is inspired by the natural DC and its interaction with the T cell. DC 
binding to T cells involves three main signals that are all required to fully activate the 
T cell: antigen-loaded major histocompatibility complexes (MHC) of the DC bind to 
specific T cell receptors (TCR; signal 1). At the same time, co-stimulatory molecules 
on the DC surface interact with their T cell binding partners (signal 2). In addition to 
these receptor interactions, also soluble factors (cytokines) are involved in T cell 
activation (signal 3). In the first stage of activation, signal 1 and 2 interactions are 
arranged in microclusters (around 20-300 TCRs per cluster).8–10! These nanometre-
sized contact areas between both cells are stabilized by a number of different 
adhesion molecules. After the initial stimulation, triggered microclusters move 
towards the so-called supramolecular adhesion complex (SMAC) where receptors 
and adhesion molecules are rearranged to form a ‘bulls eye’ pattern of micrometre 
size.11 This process clearly involves the dynamic multivalent binding of many 
(different) binding partners. 
Multivalent interactions generally form at the interface between two objects 
that carry multiple, complementary functionalities.12,13 The simultaneous interaction 
between these functionalities enhances the binding strength (avidity), sometimes by 
several orders of magnitude compared to the affinity of the monovalent interaction.14 
This enhancement mainly originates from an increase in the effective concentration 
of the binding partners. Once the first ligand is bound, the ‘search volume’ is reduced 
and the following binding events occur with a higher probability.15 In chapter 2 of this 
thesis a new multivalent aAPC design for activating T cells was introduced: synthetic 
Dendritic Cells (sDCs).16,17 In this design, anti-CD3 antibodies (αCD3), which are 
known to trigger the TCR (signal 1), were bound to a semi-flexible and linear 
polyisocyanopeptide scaffold with a length of ~200 nm. Using these novel sDCs, T 
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cell activation occurred at much lower doses of antibody compared to unbound 
αCD3. 
In this chapter a series of experiments was designed with the goal of 
investigating the importance of multivalent binding in more detail. A library of αCD3-
sDCs, containing sDCs with different polymer lengths and αCD3 densities, was 
synthesized and the influence of these parameters on T cell activation was 
investigated. Incubating T cells with these different αCD3-sDCs, it is shown that an 
increase in polymer length or effector molecule density boosts both early (Ca2+-
signalling) and late (interferon γ release) stages of T cell activation and that this 
effect goes beyond a simple avidity increase. A positive effect on T cell signalling is 
further demonstrated after removal of the αCD3-sDCs. T cell activation is sustained 
for extended periods of time (days), as confirmed by prolonged Ca2+-signalling, 
expression of the early activation marker CD69 and the release of interferon γ (IFNγ). 
 
3.2 Results and discussion 
 
3.2.1 Synthesis of αCD3-sDCs 
All polymer-αCD3 conjugates (i.e. the αCD3-sDCs) were synthesized 
according to the method described in chapter 2 (Figure 3.1).16,17 The sDC scaffold is 
based on a water-soluble polyisocyanopeptide co-polymer bearing non-functional 
methoxy and functional azide groups. The corresponding methoxy and azide 
isocyanide monomers were polymerized using a nickel catalyst to obtain azide-
functionalized polyisocyanopeptide polymers. The azide groups were subsequently 
utilized in a strain-promoted azide-alkyne cycloaddition (SPAAC) reaction with 
bicyclononyne-functionalised streptavidin (BCN-SAv).18 The SAv molecules allow for 
the binding of biotinylated αCD3 antibodies to yield the αCD3-sDCs (Figure 3.1a). In 
all experiments, the ratio between SAv and αCD3 was tuned to be 1:1 (see 
experimental section 3.4 for synthetic details). 
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Figure 3.1. Schematic overview of the sDC library. a) Experimental design for sDC synthesis. b) 
Overview of the sDCs used in this study (P1-P3) showing the corresponding polymer lengths and 
αCD3 densities.
3.2.2 Influence of αCD3-sDC length on T cell activation
Polyisocyanopeptides of different length were synthesized using a different 
catalyst-to-monomer ratio during the polymerisation reaction (Table 3.1). Two
polymers of different average lengths (P1’ = 175 nm and P2’ = 350 nm; 
azide:methoxy = 1:100) were synthesized using this strategy (Figures. A3.1.1 and 
A3.1.2; Table 3.1). The density of SAv per polymer chain was determined using 
atomic force microscopy (AFM imaging; Figures A3.1.1 and A3.1.3; Table 3.1). The 
P1-SAv and P2-SAv conjugates possess an average density of 1 SAv molecule per 
110 nm and 120 nm, respectively. As the synthetic protocol was optimized such that
one αCD3 antibody is bound per SAv molecule (chapter 2), it can be assumed that 
these values also represent the densities of αCD3 antibodies on the αCD3-sDC 
conjugates P1 and P2 (Figure 3.1b). This means that P1 carries 1-2 αCD3 antibodies
per polymer, whereas the total number of αCD3 antibodies on P2 is ~3. 
Table 3.1. Characteristics of the polymers used in this study.
P1 and P2 were compared to unbound αCD3 in a single-cell Ca2+-signalling 
experiment (Figure 3.2a). Ca2+-release from the endoplasmic reticulum is one of the 
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earliest activation events when triggering T cells at the TCR level. The subsequent 
complex interplay between Ca2+-release from the endoplasmic reticulum and calcium 
influx across the plasma membrane via Ca2+-release activated Ca2+ (CRAC) 
channels leads to oscillations of cytoplasmic calcium.19 These calcium oscillations, 
which have a direct influence on T cell gene expression, were monitored using 
peripheral blood lymphocytes (PBLs) loaded with the Ca2+-sensitive fluorescent dye 
FURA-2 (for experimental details see Table 3.2, Figure A3.1.4) 20 Determination of 
the number of Ca2+-signalling cells during the first hour of treatment with P1, P2 or 
αCD3 revealed that both the two αCD3-sDCs and unbound αCD3 caused a marked 
increase in the number of Ca2+-signalling cells when using concentrations of 5 and 
50 ng/ml. At 0.5 ng/ml this effect was only seen for P2 and not for P1 or unbound 
αCD3. 
 
Figure 3.2. T cell activation using sDCs of different length and αCD3 density. a) Fraction of activated 
T cells as determined from single-cell Ca2+-signalling measurements performed within the first hour of 
stimulation with P1, P2 and unbound αCD3. b) Relative increase in the concentration of IFNγ secreted 
by T cells treated with P1, P2 and unbound αCD3 for 16 hours. Untreated PBLs were used as a 
reference. c) Fraction of activated T cells as determined from single-cell Ca2+-signalling 
measurements performed within the first hour of stimulation with P3a, P3b, P3c and unbound αCD3 
for 1 hour. d) Relative increase in the concentration of IFNγ secreted by T cells treated with P3a, P3b, 
P3c and unbound αCD3 for 16 hours. Untreated PBLs were used as a reference. For a)-c) the data 
represents the mean ± SEM of 3 independent experiments performed with T cells from different 
donors. For d) the data represents the mean ± SEM of 2 independent experiments performed with T 
cells from different donors. 
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To probe the effect of the two αCD3-sDCs on a late and more robust event in 
T cell activation, PBLs were stimulated for 16 hours with P1, P2 and αCD3 and the 
release of IFNγ was measured. Both αCD3-sDCs stimulated the production of IFNγ 
over a range of concentrations from 0.05 to 100 ng/ml (Figure 3.2b). At all 
concentrations tested, the effect of P2 was most pronounced. Considering that P1 
and P2 possess the same αCD3 density, these results suggest that polymer length is 
a crucial design parameter. It increases the total number of αCD3 molecules per 
αCD3-sDC, thereby causing the stronger T cell stimulating effect. 
 
3.2.3 Influence of αCD3 density on T cell activation 
The previous experiment has shown that a density of one αCD3 antibody in 
110-120 nm combined with a polymer length of maximally 350 nm (P2) leads to a 
small but clearly detectable increase in T cell activation. To investigate the 
multivalency effect over a larger dynamic range, it was therefore decided to increase 
both the polymer length and the αCD3 density. Increasing the number of azide 
functional groups (azide:methoxy = 1:70), polymer P3’ with an average length of 400-
450 nm was synthesized (Figures A3.1.1 and A3.1.2, Table 3.1). This polymer was 
then functionalized with a different number of SAv molecules per polymer, using a 
different ratio of BCN-SAv:azide in the coupling reaction (0.5, 1 and 5 equivalents of 
BCN-SAv). Using AFM imaging, the average SAv density on these polymer 
conjugates was determined to be 1 SAv molecule in every 130 nm (P3a-SAv, 0.5 
eq.), 85 nm (P3b-SAv, 1 eq.) and 40 nm (P3c-SAv, 5 eq.) (Figure 3.1b, Figures 
A3.1.1 and A3.1.3, Table 3.1). Again, it was assumed that these values correspond 
to the density of αCD3 antibodies so that the αCD3-sDCs carry an average of 3-4 
(P3a-SAv), 5 (P3b-SAv) or 10-11 (P3c-SAv) antibodies per polymer. 
The single-cell Ca2+ signalling assay shows a marked increase already at the 
lowest tested concentration of P3c (0.005 ng/ml; Figure 3.2c). In sharp contrast, P3a 
and P3b displayed the same dose-dependency as unbound αCD3. Also for these 
αCD3-sDCs a more clear difference was observed in the IFNγ release assay. All 
three αCD3-sDCs cause significantly higher IFNγ secretion than unbound αCD3 
(Figure 3.2d). Most importantly, a positive correlation was observed between αCD3 
density and IFNγ release over the full range of tested concentrations (0.05-50 ng/ml). 
At the highest αCD3 concentration of 50 ng/ml, P3a, P3b and P3c induced a 2.4-, 
3.5- and 6.1-fold increase of secreted IFNγ compared to unbound αCD3, 
respectively. Clearly in addition to polymer length, αCD3 density is an important 
determinant for T cell activation by αCD3-sDCs. 
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3.2.4 Quantification of the multivalent enhancement factor 
The above results show that both polymer length and αCD3 density are crucial 
design parameters for sDCs. Together, these parameters determine the number of 
interactions that can form between the polymer and the T cell. To quantify the 
enhancement of the multivalent binding strength, dose-response curves were 
established for both unbound αCD3 and the best performing αCD3-sDC (P3c). The 
dose-response curves provide the basis for determining the EC50 values and allow 
for calculating an enhancement factor for the multivalent interaction. To construct 
these dose-response curves, single-cell Ca2+-signalling experiments were performed 
over an extended range of αCD3 concentrations (0.001-100 ng/ml). Even though T 
cell activation was more difficult to quantify in the Ca2+-signalling experiment, this 
readout parameter was chosen as it corresponds to a very early activation event. It 
can be assumed that an early readout parameter is more relevant for quantifying the 
multivalent binding strength than downstream parameters as signal amplification may 
have taken place. 
 
 
 
Figure 3.3. Dose-response curves for T cells treated with P3c and unbound αCD3 as determined from 
single-cell Ca2+-signalling experiments. EC50 values were determined using a four-parameter fit. The 
multivalent enhancement factor is calculated by dividing the EC50 of unbound αCD3 by the EC50 of 
P3c. The data represents the mean ± SEM of 3 independent experiments performed with T cells from 
different donors. 
 
When PBLs were treated with P3c, the first effect on the number of Ca2+-
signalling cells was detected at a ~200-300 fold lower concentration as observed with 
unbound αCD3 (Figure 3.3), which is in line with the results presented in chapter 2.16 
EC50 values were determined from a four-parameter fit to the dose-response curves. 
For unbound αCD3 an EC50 value of 16 ng/ml was found, whereas an EC50 value of 
0.24 ng/ml was obtained for the multivalent P3c. This yields an enhancement factor 
of ~67 for the multivalent system (Figure 3.3).21 This remarkable enhancement 
clearly indicates that multivalency is one of the key parameters responsible for the 
increased potency of αCD3-sDCs. It is worth noting that the slope of the dose-
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response curve does usually contain additional information, e.g. about positive or 
negative cooperativity. The sDC polymers are heterogeneous, however, when 
considering both their length and the αCD3 density. It is therefore highly likely that 
the more gradual response to increasing the concentration of P3c is a direct result of 
this heterogeneity. 
Assuming that the enhancement factor purely characterizes the avidity 
increase of the multivalent interaction, the question remains if enhanced binding of 
the αCD3-sDC is the only parameter that determines T cell activation or if T cell 
signalling is also affected. The polymer linkage between several αCD3 antibodies 
efficiently directs these polymer-coupled αCD3 antibodies to the same microcluster 
even if the overall αCD3 concentration is very low. Considering the sequence of 
events occurring during T cell activation, this may directly lower the threshold for T 
cell activation. A first indication for this can be obtained when re-considering the 
results obtained for the αCD3-sDCs P3a, P3b and P3c (Figure 3.2c, d) that all bind in 
a multivalent fashion. During all experiments the data was normalized to the αCD3 
concentration so that the polymer concentration (i.e. the αCD3-sDC concentration) 
varies between the different samples. When normalizing the data with respect to the 
polymer concentration, it becomes evident that a 1000-fold lower concentration of 
P3c is sufficient to obtain the same effect as with P3a (Figure A3.1.7). This value is a 
lot larger than the multivalent enhancement factor determined above and suggests 
that the co-localization of αCD3 in a small area on the cell surface is a key factor that 
determines T cell activation. Interestingly, a total number of ~10 αCD3 antibodies 
distributed over an area of several tens of nanometres matches with the predicted 
size of TCR nanodomains that are pre-formed on the T cell surface.22,23 It may 
therefore be speculated that αCD3-sDCs form a highly specific, multivalent 
interaction with these nanodomains and that T cell fate is already determined at this 
very early stage of activation. 
 
3.2.5 Long-term effect of αCD3-sDC binding on T cell signalling 
To investigate the effect of the αCD3-sDCs on T cell signalling in more detail, 
a new series of experiments was designed to obtain information about sustained T 
cell activation. Instead of measuring T cell activation in the continuous presence of 
the αCD3-sDCs or unbound antibodies, excess stimulant was washed off after 1 hour 
of treatment and T cell activation was analysed at several time points after removal of 
the stimulant. This allowed for determining the long-term effect of the initial 
stimulation, as no free stimulant was available for binding to the T cells after the 
medium was replaced. To quantify the effect, again single-cell Ca2+-signalling 
experiments were performed and the secretion of IFNγ was determined. In addition, 
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the expression of the surface activation marker CD69 was measured, which is 
another indicator of early T cell activation. 
 
 
Figure 3.4. Analysis of sustained T cell activation. a) Long-term Ca2+-signalling when treating PBLs 
with 12.5 ng/ml P3c or αCD3 for 1 hour. The first measurement (0 h) was performed directly on the 
microscope during incubation with the stimulant. The other time points represent the total time of the 
experiment (i.e. 1 hour incubation with the stimulant + incubation time after removal of the stimulant). 
For all experiments the data represents the mean ± SEM of 3 independent experiments performed 
with T cells from different donors. b) Fraction of T cells expressing CD69 after treatment with P3c or 
αCD3 for 8 hours. For P3c a concentration of 1 and 50 ng/ml was used. For αCD3 a concentration of 
50 ng/ml was used. The first measurement was performed directly before the stimulant has been 
removed (8 hours). The other time points represent the total time of the experiment. For all 
experiments the data represents the mean ± SEM of 3 independent experiments performed with T 
cells from different donors. c) Concentration of secreted IFNγ after treating PBLs with 5 ng/ml P3c or 
αCD3 for 16 hours. The first measurement was performed directly before the stimulant has been 
removed (16 hours). The other time points represent the total time of the experiment. For all 
experiments the data represents the mean ± SEM of 3 independent experiments performed with T 
cells from different donors.  
 
For the Ca2+-signalling measurements, PBLs were treated with unbound αCD3 
or P3c (12.5 ng/ml) for 1 hour. The stimulant was then removed, fresh medium was 
added and the cells were incubated without stimulant for 15 or 23 hours. The fraction 
of Ca2+-signalling cells was determined at the respective time points (16 and 24 h 
time points after the initial addition of the stimulant; see Figure A3.1.5 for a detailed 
timeline) and compared to a reference sample that was imaged while adding the 
stimulant (0 h, Figure A3.1.5). This reference measurement, performed exactly as 
described above, confirms the results presented in Figure 3.1c (80% of signalling 
cells for both αCD3 and P3c in Figure 3.4a). In samples treated with unbound αCD3 
the fraction of Ca2+-signalling T cells was significantly reduced at both post-
stimulation time points. In sharp contrast, the vast majority of P3c-treated T cells 
remained active after removal of the stimulant. Even at 24 h hours after the initial 
stimulation with P3c, the fraction of Ca2+-signalling T cells was still ~75%, indicating 
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that the multivalent sDC causes a sustained stimulation of the intracellular pathways 
involved in Ca2+-responses. Negative controls involving an isotope control (mIgG2a 
antibody), polymers with SAv but no αCD3 and non-treated cells did not show high 
amounts of activated T cells before and after removal of the stimulant (Figure 
A3.1.6). 
To support the results from the single-cell Ca2+-signalling experiments, FACS 
analysis was performed to determine the expression of the surface marker CD69. 
PBLs were treated with 1 and 50 ng/ml of unbound αCD3 or P3c for 8 hours before 
placing the cells in fresh medium. At the time of removal of the stimulant, higher 
numbers of CD69 expressing T cells were observed than when the PBLs were 
treated with unbound αCD3 (Figure 3.4b, Figures A3.1.8 and A3.19). Considering the 
multivalent enhancement factor of 67, one would expect a similar level of activation 
for PBLs treated with either 50 ng/ml of unbound or with 1 ng/ml of P3c. When 
comparing this initial time point, already a large difference is observed for these two 
treatment conditions. The P3c treated sample contains a significantly higher amount 
of CD69 expressing cells that remains fairly constant until 96 hours of measurement 
time. In contrast, the population of CD69+ T cells stimulated with unbound αCD3 
decreased rapidly from its initial value (Figure 3.4b). 
To further confirm that T cells were showing sustained and robust activation 
for an extended period of time, IFNγ release assays were performed. PBLs were 
treated with 5 ng/ml P3c or unbound αCD3 for 16 hours, after which the cells where 
washed and new medium was added. The supernatant was tested for IFNγ directly 
before the removal of the stimulant (16 hours) and a high concentration of IFNγ was 
determined for both treatment conditions as expected. At all subsequent time points 
(24, 48, 72, 96 and 120 hours after the initial stimulation, a clear difference was seen 
between PBLs treated with P3c or unbound αCD3 (Figure 3.4c). PBLs treated with 
unbound αCD3 do not seem to produce new IFNγ and a decrease in the IFNγ level is 
seen over time. In contrast, PBLs stimulated with P3c produced new IFNγ. Until the 
96 hour time point an approximately constant level of IFNγ was maintained, after 
which a decrease of the IFNγ concentration was observed. Taken together, these 
results show that sDCs stimulate T cells over much longer periods of time compared 
to unbound αCD3 and this effect is observed for both early and late T cell activation 
markers.  
 
3.3 Conclusion 
In summary, this chapter shows that polymer length and effector molecule 
density are key design parameters in the development of sDCs. These parameters 
have a direct effect on the valency of the sDC and, consequently, on the effective 
concentration required for T cell activation. In addition to this enhancement of the 
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binding strength, robust and sustained T cell activation was observed that goes 
beyond a pure avidity effect. These results show that the multivalent scaffold also 
affects T cell signalling pathways. Co-localization of several effector molecules in the 
same microcluster leads to a long lasting activation that cannot be achieved with 
free, unbound antibodies. Future studies will be directed at elucidating the 
mechanistic origin of this sustained T cell response. 
 
3.4 Experimental section 
Synthesis and characterization of synthetic dendritic cells (sDCs) 
Polymer synthesis (P1’-P3’) 
Water-soluble polyisocyanopeptides were synthesized as described in chapter 2.16 For the synthesis 
of P1’ and P2’, the functional azide monomer (N3) and the non-functional methoxy monomer (OMe) 
were polymerized in a 1:100 ratio. For P3’, a 1:70 N3:OMe ratio was used to increase the number of 
possible coupling sites. The polymer length was controlled by the amount of nickel catalyst added in 
the polymerization reaction. A 1:200 ratio of catalyst:monomer was used for the synthesis of P1’. For 
P2’ and P3’, a 1:10000 catalyst:monomer ratio was used (Table 3.1). The molecular weight of the 
polymers was determined from viscosity measurements (Table 3.1) as described in chapter 2.16 
Synthesis of polymer-streptavidin conjugates 
Streptavidin (SAv, Thermo Fisher Scientific) was functionalized with BCN-POE3-NH-
C(O)CH2CH2CH2C(O)OSu (BCN-NHS; Synaffix) to couple it to the azide-groups on the polymer in a 
strain-promoted azide-alkyne cycloaddition (SPAAC) reaction.18 The reaction was performed in borate 
buffer (10 mM, pH 8.5) using a 5 to 6-fold excess of BCN-NHS. Following incubation for 1.5 hours at 
room temperature, the mixture was purified by ultrafiltration (10 kDa cut-off) and gel filtration (PD-10 
desalting column; GE Healthcare) to remove non-reacted BCN-NHS. During purification, the buffer 
was changed to phosphate buffered saline (PBS, pH 7.4). Mass spectrometry analysis (ESI-TOF) 
revealed that 1-4 BCN moieties were coupled per streptavidin molecule (BCN-SAv). BCN-SAv was 
subsequently reacted with azide-bearing polyisocyanopeptide polymers. A 1:1 molar ratio of N3:BCN-
SAv was used for the synthesis of P1-SAv and P2-SAv. N3:BCN-SAv ratios of 1:0.5, 1:1 and 1:5 were 
used for the synthesis of P3a-SAv, P3b-SAv and P3c-SAv, respectively. All reactions were performed 
in PBS. The reaction mixtures were first incubated at room temperature for 1 hour and subsequently 
stirred at 4° C for 2.5 days. The resulting polymer-SAv conjugates were purified by ultrafiltration (100 
kDa cut-off). 
Characterization of polymer-streptavidin conjugates 
The average polymer length and SAv density was determined with atomic force microscopy (AFM) 
using the method described in chapter 216 (Figure A3.1.1). The resulting histograms, displaying the 
distribution of polymer length and SAv distance of at least 41 individual polymers, are shown in Figure 
A3.1.2 and Figure A3.1.3.  
 
Synthesis of sDCs (P1, P2, P3a-c) 
The polymer-SAv conjugates were incubated with biotinylated, monoclonal mouse anti-human CD3 
antibodies (αCD3; clone OKT3) to obtain the αCD3-functionalized polymers P1, P2, P3a, P3b and 
P3c. The polymer-SAv conjugates were incubated with the biotinylated antibodies in a 4:1 αCD3/SAv 
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molar ratio. As described in chapter 2,16 this 4:1 αCD3/SAv molar loading ratio yields a 1:1 binding 
ratio of αCD3 and SAv on the polymer backbone (αCD3-sDC). 
 
Cell preparation and cell culture  
Peripheral blood lymphocytes (PBLs) were obtained from buffy-coats of healthy individuals in 
accordance with institutional guidelines.16 Briefly, peripheral blood mononuclear cells were obtained 
from Ficoll density centrifugation. Monocytes were removed using the plastic flask adherence method. 
The non-adherent PBLs were then maintained at 37 °C and 5 % CO2 in complete medium: RPMI-1640 
(Lonza); containing 10 % (v/v) fetal bovine serum (FBS, Gibco), 1 % (w/v) glutamine (Lonza), and 1x 
Antibiotic-Antimycotic (Gibco). 
 
Analysis of T cell activation 
Single-cell Ca2+-signalling 
General procedure 
The fraction of T cells responding to the αCD3-sDC treatment was determined in a single-cell Ca2+-
signalling assay using the ratiometric Ca2+-indicator Fura-2. PBLs (105 cells) were loaded with 3 µM 
Fura-2 AM (Invitrogen) in complete medium supplemented with HEPES buffered saline (20 mM 
HEPES pH 7.4, 115 mM NaCl, 5.4 mM KCl, 1 mM CaCl2, 0.8 mM MgCl2, 13.8 mM glucose) for 1 hour 
at 37 °C and 5 % CO2. Fura-2-loaded PBLs were washed twice with HEPES buffered saline and 
allowed to adhere to poly-D-L-lysine-coated (0.05 mg/ml; Sigma-Aldrich) glass bottom dishes (Nunc) 
at room temperature. Single-cell Ca2+-measurements were performed as described before.24 Dishes 
were placed on the stage of an inverted microscope (Axiovert 200M; Zeiss) equipped with a 
temperature-controlled CO2 stage incubator (37 °C and 5 % CO2) and a 63x, 1.25 NA objective (Plan 
NeoFluar). Fura-2 was excited at 340 and 380 nm alternatingly, using a monochromator (Polychrome 
IV; TILL Photonics). The emitted light was directed through a 415 DCLP dichroic mirror (Omega 
Optical) and a 510WB40 emission filter (Omega) onto a CoolSNAP HQ monochrome CCD camera 
(Roper Scientific). The camera exposure time was 30 ms and the time between two ratio images was 
2-4 s. All hardware was controlled with Metafluor 6.0 software (Universal Imaging). 
The images obtained were analysed using Image-Pro Plus software (Media Cybernetics). 
Regions of interest (ROIs) corresponding to individual PBLs were selected together with a cell-free 
ROI for background correction. For each ROI, the average pixel intensity was calculated for each 
excitation wavelength. After subtraction of the corresponding background value, the 340 nm/380 nm 
fluorescence emission ratio was calculated as a measure of the cytosolic Ca2+-concentration. 
Increases in cytosolic Ca2+-concentration were identified with GraphPad Prism 5 (GraphPad 
Software), using as criterion that the increase in the 340 nm signal is mirrored by a decrease in the 
380 nm signal. 
Early effects on single-cell Ca2+-signalling 
To investigate the early effects of different αCD3-sDCs on Ca2+-signalling, a series of experiments 
was performed. These experiments include measurements to compare the effect of different αCD3-
sDCs (experiments 1 and 2 in Table 3.2) and the dose dependences of P3c and free αCD3 
(experiment c in Table 3.2). For these experiments, the Fura-2 loaded T cells were first placed onto 
the microscope and the baseline Ca2+-concentration was determined. The different stimulants were 
added while the T cells were placed on the microscope, 5 min after the onset of imaging. After 1 h of 
imaging, 1 µg/mL of ionomycin was added to test for cell viability (Figure A3.1.4). Each experiment 
was performed with PBLs from three independent healthy donors. 
Processed on: 10-10-2016
505747-L-bw-Hammink
Controlling T cell activation with synthetic dendritic cells using the multivalency effect 
! 65 
Table 3.2. Treatment conditions for the Ca2+-signalling experiments. The concentration always refers 
to the amount of αCD3 bound to the αCD3-sDCs or in soluble form. 
 
Experiment 
 
Stimulant 
 
Imaging time 
 
αCD3 concentration 
 
1. sDC length 
 
 
 
 
2. αCD3 density 
 
 
 
 
 
3. dose-response 
curves 
 
i. P1 
ii. P2 
iii. free αCD3 
iv. untreated  
 
i. P3a 
ii. P3b 
iii. P3c 
iv. free αCD3 
v. untreated 
 
i. P3c 
ii. free αCD3 
iii. untreated 
 
5 min (baseline Ca2+); 
1 h treatment; 
5 min ionomycin 
 
 
5 min (baseline Ca2+); 
1 h treatment; 
5 min ionomycin 
 
 
 
5 min (baseline Ca2+); 
1 h treatment; 
5 min ionomycin 
 
 
0.005, 0.5, 5, 25 ng/mL 
 
 
 
 
0.005, 0.5, 5, 25 ng/mL 
 
 
 
 
 
0.001, 0.01, 0.1, 5, 10, 25, 
50, 100 ng/mL 
 
A representative data set for PBLs treated with free αCD3 or with the αCD3-sDC P3c is shown in 
Figure A3.1.4. This data set shows that PBLs display different patterns of Ca2+ signalling. In this study, 
only the fraction of Ca2+ signalling cells was analysed and plotted as a function of the stimulant 
concentration. 
Long-term effects on single-cell Ca2+-signalling 
To determine the long-term effect of P3c on Ca2+-signalling, PBLs were treated with the respective 
stimulant for a short time (1 h), followed by incubation without stimulant for an extended period of time 
(15 h and 23 h). Following this post-stimulation period, the cells were imaged as described under 
3.1.1, with the only difference that Fura-2 loading was performed for 20 min. The following stimulants 
were used: untreated, P3c, free αCD3, P3-mIgG2a (isotype control; 40 nm mIgG2a spacing) and P3c-
SAv (lacking αCD3). 
In more detail, PBLs (105 cells) were incubated with the respective stimulant (12.5 ng/ml) for 
1 hour at 37 °C and 5 % CO2. The cells were then washed with RPMI-1640 medium without serum 
and antibiotics to remove the stimulant. They were re-suspended with fresh complete medium with 
serum and maintained at 37 °C and 5 % CO2 for another 15 h or 23 h. Fura-2 loading was performed 
20 min before the end of the respective incubation time (Figure A3.1.5). The respective samples were 
washed twice with PBS-1 % BSA (PBA) and the cells were imaged under the microscope for 1 h. 
Again, cell viability was assessed at the end of the measurement (treatment with ionomycin for 5 min). 
To be able to compare the results at 16 h and 24 h with the previously obtained data, a ‘0 h’ time point 
was taken where the PBLs (105 cells) were first loaded with Fura-2 for 20 min, placed onto the 
microscope and imaged exactly as described above. The results of this experiment are summarized in 
Figure A3.1.6 as well as in Figure 3.4a. A clear difference is observed between the post-stimulation 
signaling of αCD3-sDC treated and αCD3 treated cells, as well as the untreated control. The untreated 
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control shows a small fraction of PBLs that display spontaneous increases in the cytosolic Ca2+-
concentration (white bars), which is known to occur for up to 30 % of untreated cells. 
Enzyme-linked immunosorbent assay (ELISA; IFNγ secretion) 
To investigate the effect of the different αCD3-sDCs on IFNγ secretion, PBLs (105 cells/well) were 
seeded in 96 well plates and treated with P1, P2, P3a, P3b and P3c or unbound antibodies (αCD3) at 
different concentrations (0.05, 0.5, 5, 50 and 100 ng/mL) for 16 h at 37 °C and 5 % CO2. To determine 
the effect of polymer length, the treatment variables were P1, P2 and unbound αCD3 along with an 
untreated control. P3a, P3b, P3c were used to investigate the effect of αCD3 density (again using 
unbound αCD3 and untreated cells as a control). IFNγ released by the T cells was determined using a 
sandwich ELISA as described in chapter 2.16,17 Briefly, 96 well plates (Nunc Immunomodules) were 
coated with mouse anti-human IFNγ antibody (Thermo Fisher Scientific). After incubation at 4 °C 
overnight, the plates were washed and blocked with PBS/Tween (0.05 %) and PBS-1 % BSA (PBA), 
respectively. IFNγ standards (Thermo Fisher Scientific) and supernatants (from treated and untreated 
cells) were added into the respective wells and incubated for 1 h at room temperature. After washing 
3x with PBA, the concentration of IFNγ was detected using a biotinylated mouse anti-human IFNγ 
antibody (Thermo Fisher Scientific) and a streptavidin-horseradish peroxidase (HRP) conjugate (Life 
Technologies). HRP activity was detected using tetramethyl benzidine (TMB; Sigma Aldrich). 
Absorption at 450 nm was measured using an iMark Microplate Reader (Bio-Rad). The results of this 
experiment, normalized to the concentration of αCD3, are shown in Figure 3.2. Figure A3.1.7 shows 
the same data set re-normalized to the polymer concentration (i.e. αCD3-sDC concentration). 
To measure the long-term effect of the αCD3-sDC treatment, PBLs (105 cells/well) were 
seeded in 96 well plates and treated with the respective stimulant (at 5 ng/mL). The cells were 
incubated with the stimulant for 16 h at 37 °C and 5 % CO2. After this incubation, the cells were 
washed with RPMI-1640 medium without serum and antibiotics. They were then re-suspended with 
fresh complete medium with serum to observe the activation state of the cells after the treatment was 
removed. The IFNγ concentration was determined directly before the medium was removed (16 hours) 
and at the following time points after the initial stimulation: 24, 48, 72, 96 and 120 h. 
 
Flow cytometry (CD69 expression) 
To measure the long-term effect of the αCD3-sDC treatment on CD69 expression, PBLs 
(105 cells/well) were seeded in 96 well plates and treated with the respective stimulant (5 ng/mL). The 
cells were incubated with the stimulant for 8 h at 37 °C and 5 % CO2. After this incubation, a sample 
was taken for analysis. The remaining cells were washed with RPMI-1640 medium without serum and 
antibiotics. They were then re-suspended with fresh complete medium with serum to observe the 
activation state of the cells after the treatment was removed. The cell suspensions were collected at 
the respective time points (24, 48, 72, 96 and 120 h after the initial stimulation) and used for flow 
cytometric analysis (CyAn ADP; Beckman Coulter) following the same methodology as described 
chapter 2.16,17 
Briefly, PBLs (treated or untreated) were washed twice with PBA to remove unbound sDCs or 
antibodies. PBLs were stained with antibodies speciﬁc for the CD4/8+ T cell subpopulations (APC-
labelled mouse anti-human CD4/8 mAb; T cell marker; BD Pharmingen) and with PE-labelled mouse 
anti-human CD69 (marker for T cells, eBioSciences). After 1 hour of incubation, the cells were again 
washed twice with PBA before performing flow cytometric analysis. The data obtained were analysed 
by using FlowJo ver. 9.2 Software (TreeStar Inc.). The gating strategy to identify the population of 
CD69+ T cells is shown in Figure A3.1.8. Additional results of treatment concentrations not shown in 
the main text are summarized in Figure A3.1.9. 
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3.5 Appendix 3.1: Supporting figures
Figure A3.1.1. Representative AFM images of the polymer-SAv conjugates of P1-P3c drop-casted 
on poly lysine treated mica. Scale bar: 200 nm for a)-e).
Figure A3.1.2. Length distribution of the different polymer-SAv conjugates as determined from AFM 
images. Each histogram contains at least 41 polymers: a) P1-SAv, n = 48; b) P2-SAv, n = 74; c) P3a-
SAv, n = 72; d) P3b-SAv, n = 68; e) P3c-SAv, n = 41.
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Figure A3.1.3. Average distance between SAv molecules determined from the AFM images. Each 
histogram contains at least 41 polymers: a) P1-SAv, n = 48; b) P2-SAv, n = 74; c) P3a-SAv, n = 72; d) 
P3b-SAv, n = 68; e) P3c-SAv, n = 41. 
 
 
 
 
 
Figure A3.1.4. Single-cell Ca2+-signalling experiments. Representative time traces (340 nm/380 nm 
ratio) for PBLs treated with free αCD3 a) or P3c b). 
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Figure A3.1.5. Timeline of the long-term single-cell Ca2+-signalling experiment. To obtain the ‘0 h’ time 
point, the PBLs were loaded with Fura-2, treated with the stimulant directly under the microscope and 
imaged. For the ’16 h’ and ’24 h’ time points the cells were first treated with the respective stimulant 
for 1 h and then incubated without stimulant for 15 h or 23 h, respectively. Before imaging was started, 
the cells were loaded with Fura-2 for 20 min. At the end of the 1 h imaging period, all samples were 
treated with ionomycin to determine cell viability. In this experiment, the baseline intensity was only 
determined for the ‘0 h’ time point. 
 
Figure A3.1.6. Post-stimulation Ca2+-signalling. T cells were treated with 12.5 ng/ml P3c or αCD3 for 
1 h. The stimulant was removed and the cells were incubated in fresh medium. Ca2+-imaging was 
performed 16 h or 24 h after starting the treatment (15 h or 23 h after removal of the stimulant). As a 
reference, T cells were also imaged under the microscope while the stimulant was added (0 h). The 
graph further shows data obtained for T cells treated with the following controls: P3-SAv, P3-mIgG2a 
(isotype control) or medium (untreated). The asterisks represent the statistical significance at ‘p’ 
values of 0.001 (***). 
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Figure A3.1.7. IFNγ secretion of T cells treated with P3a, P3b or P3c normalized to polymer 
concentration. 
 
Figure A3.1.8. FACS analysis of sDC-treated (P3c) and untreated PBLs. After identification of 
CD4/8+ T cells, the percentage of CD69+ cells was determined. 
 
 
Figure A3.1.9. Long-term analysis of CD69 expression. Percentage of CD69 expressing T cells after 
treatment with different concentrations of P3c or αCD3. 
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Chapter 4: Polymer-based synthetic dendritic cells for tailoring 
robust and multifunctional T cell responses  
  
4.1 Introduction  
Vaccination is one of the most successful and cost-effective health 
interventions. Worldwide, it prevents several millions of deaths every year. Most 
commonly used vaccines consist of inactivated pathogens and an additional 
component (adjuvant) that potentiates the immune response. More recently, 
therapeutic vaccines have also been developed to fight cancer.1 Most vaccines 
designed so far target antigen presenting cells, in particular professional antigen 
presenting dendritic cells (DCs). DCs process exogenously encountered antigens 
and subsequently present them on their surface to T cells.2 Subsequent antigen 
specific activation and expansion of T cells is crucial for the development of 
protective immunity against pathogens or for eliciting cytotoxic responses against 
cancer.3  
An efficient and robust anti-cancer immune response critically depends on the 
induction of a multifunctional T cell response involving the activation and proliferation 
of helper, cytotoxic and memory T cells. Cytotoxic T cells directly attack the tumor 
cells and are responsible for their elimination. The recruitment of helper T cells aids 
the development and activation of cytotoxic T cells, while memory T cells provide a 
long-term response against reoccurring antigenic stimuli.4,5 Although vaccination 
studies have clearly demonstrated the immunogenicity of tumor antigen-loaded DCs, 
the number of objective clinical responses remains limited, hampering the 
implementation of DC-targeted vaccination as a novel form of standard treatment.6,7 
One possible reason for the low success of many currently used anti-cancer vaccines 
is that they also induce the hyperactivation of regulatory T cells (Tregs)8. Tregs are 
able to suppress tumor-specific responses, thus counteracting the function of 
cytotoxic T cells. It is now widely accepted that a successful anti-cancer vaccine 
should not stimulate Tregs.7,9,10 
Instead of using DC vaccines, new approaches directly target the T cells. The 
focus lies on the development of artificial antigen presenting cells (aAPCs) that 
replace natural, activated DCs.11–14 aAPCs can be synthesized as an “off-the-shelf” 
product thereby overcoming the need for preparing a tailor-made and expensive, 
natural DC vaccine for each patient. In order to achieve effective T cell activation, ex 
vivo or in vivo, the aAPCs need to engage with the T cell in a way similar to that of 
natural DCs. T cell activation involves three main signals.2,15 The first two of these 
signals are highly coordinated on the T cell surface. The T cell receptor (TCR) binds 
to the peptide antigen presented by the major histocompatibility (MHC) complex on 
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the DC (signal-1). Following binding, the TCR/CD3 complexes rearrange to form 
microclusters, leading to immediate T cell activation.16,17 Co-stimulatory molecules on 
the DC such as B7-1 and B7-2 provide the second signal for T cell activation 
lowering the activation threshold.1,18 These ligands bind to the CD28 receptor located 
in close proximity to the TCR.19 CD28 ligands (signal-2) are only present on activated 
DCs providing a safety mechanism against activation by self-antigens. T cell 
activation without proper co-stimulation of CD28 leads to naïve, memory and effector 
T cell anergy and immune tolerance.15,20 Together, signal-1 and signal-2 lead to the 
release of soluble cytokines (signal-3) that further shape the development of the 
immune response.21 In a later stage, the microclusters containing the TCR/CD3 
complex and the CD28 receptor rearrange to form the immunological synapse (IS). 
16,17,22 Ultimately, the immune response is terminated by endocytosis of the engaged 
receptors.23  
Bead-based aAPCs that carry effector molecules on their surface are currently 
in clinical trials.12,13 These aAPCs are used for the ex vivo activation and expansion 
of T cells allowing for their adoptive transfer into patients. Despite their clearly proven 
potential for activating T cells, their efficiency remains low as the rigid sphere 
geometry does not allow for the required movement of the effector molecules to 
facilitate T cell receptor clustering.11,14,17 Liposome-based aAPCs do provide this 
essential flexibility.11,14 Depending on their shape and size, however, only a limited 
number of effector molecules are able to interact with the T cell.24 To enhance ligand 
binding, a novel aAPC design utilizing semi-flexible polymers was introduced in 
chapters 225 and 3. In contrast to spherical bead- or liposome-based aAPCs, the 
polymer-based design features a semi-flexible geometry that allows both efficient 
multivalent binding and receptor clustering. When functionalizing the polymer with 
signal-1 (anti-CD3 antibodies known to cause polyclonal T cell activation),26 an 
enhanced and sustained T cell response was observed compared to soluble anti-
CD3 antibodies (αCD3) or αCD3-functionalized beads (PLGA particles; poly lactic-
co-glycolic acid). 
In this chapter, a new generation of sDCs is introduced with the ultimate goal 
of developing a functional synthetic dendritic cell (sDC) that can be used to activate 
and expand T cells. This new sDC design carries both signal-1 and signal-2 (anti-
CD28 antibodies; αCD28).19,20 The importance of the presence of signal-2 for T cell 
activation is investigated and the results are compared to sDCs that carry only signal-
1. More importantly, the immunophenotypes and functional states of the expanded 
polyclonal T cell population are characterized to determine if the bi-functional and 
semi-flexible sDC design is able to activate helper, cytotoxic and memory T cells 
without stimulating Tregs. 
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4.2 Results  
 
4.2.1 Design and characterization of sDCs 
A functional synthetic dendritic cell (sDC) needs to provide multiple 
interactions for stimulation of both the TCR/CD3 complex as well as the CD28 
receptor. The ideal design does not only carry a sufficient number of signal-1 (αCD3) 
but also signal-2 (αCD28) effector molecules. More importantly, the scaffold 
geometry needs to allow for efficient multivalent binding and receptor clustering. In 
contrast to PLGA particles, a semi-flexible polymeric scaffold based on 
polyisocyanopeptides combines these properties in an ideal way.25  On the polymer, 
all antibodies are in principle available for receptor binding. At the same time, the 
polymer flexibility allows for the spatial rearrangement required for optimal 
intracellular signaling and T cell activation. The polyisocyanopeptide polymer27,28 is a 
copolymer consisting of azide-functionalized monomers and methoxy-terminated 
monomers (Figure 4.1). The ratio of these monomers was chosen such that the 
average distance between azide groups was 10 nm. The average length of the 
complete polymer varied from 150 nm to 200 nm. To provide maximum flexibility in 
subsequent bioconjugation reactions, streptavidin was coupled to the azide groups 
using a strain-promoted azide-alkyne cycloaddition (SPAAC) reaction.29 In total 3–5 
streptavidin molecules were coupled per polymer with an average spacing between 
40 nm and 50 nm. In the next step, biotinylated monoclonal anti-human CD3 
antibodies (αCD3) were bound to the polymer in a 1:1 molar ratio so that on average 
one antibody was bound per streptavidin molecule.25 The obtained αCD3-sDC 
polymers were split into two fractions. One fraction was directly used for the T cell 
experiments. The second fraction was further functionalized with biotinylated anti-
human αCD28 antibodies (αCD28) to yield αCD3/αCD28-sDC. Again the 
concentration was adjusted such that one αCD28 antibody was bound per 
streptavidin molecule (Figure 4.1 and Supplementary Figure A4.1.1). Consequently, 
the αCD3/αCD28-sDC polymer contains exactly the same number of 3–5 αCD3 
antibodies plus the additional αCD28 antibodies in a 1:1 molar ratio. 
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Figure 4.1. Synthesis of the polymer-based sDCs. Copolymerization of a methoxy-terminated and an 
azide-terminated isocyanide monomer yields a random copolymer with a statistical spacing of azide 
groups (average distance ~10 nm). The azide groups were utilized in a strain-promoted azide-alkyne 
cycloaddition reaction. A total number of 4–5 BCN-functionalized streptavidin molecules were coupled 
to the polymer with an average spacing between 40–50 nm, leaving most available azides unreacted 
(1). Subsequently, the streptavidin-polymer was further functionalized with biotinylated anti-CD3 
antibodies (2) and biotinylated anti-CD28 antibodies (3) in a 1:1:1 molar ratio. 
 
4.2.2 Synthetic dendritic cells efficiently bind T cells 
In a first series of experiments the ability of sDCs containing both signal-1 and 
signal-2 to interact with T cells was investigated. Using the same procedure as 
shown in Figure 4.1, fluorescently labeled sDCs containing AlexaFluor488-lableled 
αCD3 (488αCD3) and ATTO565-labeled  CD28 (565αCD28) were prepared. The 
binding of these fluorescently labeled 488αCD3/565αCD28-sDCs was observed with a 
confocal microscope (Appendix 4.2). After only 10 min of incubation with 
488αCD3/565αCD28-sDC (at an αCD3 concentration of 50 ng ml-1), both 488αCD3 and 
565αCD28 fluorescence signals were detected on the T cell surface indicating binding 
of the sDC to the T cell. The fluorescence signals were co-localized in multiple stable 
complexes presumably representing the microclusters formed upon T cell activation 
(Appendix 4.2).17. After 16 hours of incubation these microclusters were concentrated 
in one area on the T cell surface as is expected once the immunological synapse (IS) 
has formed (Appendix 4.2). These findings show that the sDCs are able to bind to the 
T cell surface and allow microcluster and IS formation, which are important 
processes following T cell activation. 
 
4.2.3 αCD3/αCD28-sDCs are superior in activating and expanding human 
polyclonal T cells 
Having obtained a first indication that the αCD3/αCD28-sDC polymer does not 
only bind to T cells but also activates them, the next goal was to probe the T cell 
priming capacity of the sDCs. For this purpose the expression of the surface marker 
N3
N3
N3
poly(isocyano peptide) 1
2
3
anti-CD3
signal 1
anti-CD28
signal 2
OO
O
N
H
O
N
N
H
N O
O
O
O
3
4
n
x
y
N3 streptavidin
O
O NH
NHO H
HN
H S
O
N
H
NHO H
HN
H S
O
N
H
Processed on: 10-10-2016
505747-L-bw-Hammink
Chapter 4 
! 78 
CD69, the release of the cytokine interferon-γ (IFNγ) as well as the proliferation of T 
cells was followed. CD69 is an early activation marker as it is one of the first 
inducible cell surface glycoproteins expressed upon T cell activation. On the other 
hand, IFNγ secretion and T cell proliferation are typical late activation markers, 
indicating sustained T cell activation. 
 
 
Figure 4.2. Comparative T cell activation profile of αCD3/αCD28-sDC, αCD3-sDC and freely soluble 
antibodies. a) Percentage of T cells expressing the early activation marker CD69 after 16 h of 
treatment. b) Concentration of secreted IFNγ after 16 h of treatment. c) Proliferation of T cells depicted 
as the number of divisions, measured by CFSE dilution. The graph represents the fraction of T cells 
per generation after 4 days of treatment with the respective stimulants at a concentration of 5 ng ml-1. 
d) Total fraction of proliferated T cells after treating the T cells as indicated above. The values are 
corrected for the fraction of proliferated T cells in the untreated sample. For the αCD3/αCD28-sDC 
treatment, the antibody concentration refers to the concentration of αCD3 antibodies. The data 
represents the mean ± SEM of at least 3 independent experiments performed with T cells from 
different donors. The asterisks represent the statistical significance relative to the αCD3 treatment at 
‘p’ values of 0.05 (*), 0.01 (**) and 0.001 (***), respectively. 
 
Both polymeric sDCs (αCD3-sDC and αCD3/αCD28-sDC) activate T cells 
more efficiently than the freely soluble antibodies (Figure 4.2). This is evident for all 3 
markers and confirms our previous results for the αCD3-sDC polymer.25 Moreover, a 
clear difference is observed between the polymer carrying only signal-1 (αCD3-sDC) 
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and the polymer carrying both signals (αCD3/αCD28-sDC). Especially in the low 
concentration range (<5 ng ml-1), the expression of CD69 was increased when 
treating the T cells with αCD3/αCD28-sDC (Figure 4.2a). More importantly, 
significantly more IFNγ was secreted (Figure 4.2b) and an increased T cell 
proliferation was detected (Figure 4.2c and 4.2d). The co-functionalization of the 
polymer with signal-2 clearly leads to a more efficient T cell activation, proving that 
both the αCD3 and the αCD28 antibody are able to interact with the T cell in the 
desired way. 
The reason for the superior activity of the αCD3/αCD28-sDC polymer was 
investigated in more detail (Figure 4.3). Using the polymeric system, co-stimulation 
with αCD3 and αCD28 can be achieved in different ways. Both antibodies can be 
bound to the same polymer (αCD3/αCD28-sDC) or to different polymers, using a 
mixture. The results clearly show that the αCD3/αCD28-sDC polymer activated the T 
cells significantly better than an equimolar mixture of αCD3-sDC and αCD28-sDC 
polymers (Figure 4.3b). This result provides strong evidence that the superior 
performance of αCD3/αCD28-sDC requires both effector molecules to be bound in 
close proximity, i.e. on the same polymer molecule. 
To test the importance of scaffold flexibility, the αCD3/αCD28-sDC polymer 
was compared with rigid PLGA particles (diameter 1.8 µm25) functionalized with both 
αCD3 and αCD28 antibodies (see experimental section). Even though the PLGA 
particles also carry both signals on the same particle and the number of possible 
interactions is similar,25 their efficacy is lower than for αCD3/αCD28-sDC. This result 
supports the hypothesis that scaffold flexibility is a crucial requirement to allow for the 
required close proximity of the effector molecules. Taken together, these results 
show that a combination of multivalent binding and scaffold geometry as well as 
flexibility is important for effective T cell activation. 
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Figure 4.3. Geometry effects on T cell activation. a) Percentage of T cells expressing the early 
activation marker CD69 after 16 h of treatment. b) Concentration of secreted IFNγ after 16 h of 
treatment. c) Proliferation of T cells depicted as the number of divisions, measured by CFSE dilution. 
The graph represents the fraction of T cells per generation after 4 days of treatment with the 
respective stimulants at a concentration of 5 ng ml-1. d) Total fraction of proliferated T cells after 
treating the T cells as indicated above. The values are corrected for the fraction of proliferated T cells 
in the untreated sample. In all experiments, the antibody concentration refers to the concentration of 
αCD3 antibodies. The data represents the mean ± SEM of at least 3 independent experiments 
performed with T cells from different donors. The asterisks represent the statistical significance 
relative to the treatment with freely soluble αCD3 and αCD28 at ‘p’ values of 0.05 (*), 0.01 (**) and 
0.001 (***), respectively. 
 
4.2.4 αCD3/αCD28-sDCs predominantly activate effector CD8+ and effector 
memory CD4+ T cells 
Having obtained additional evidence that αCD3/αCD28-sDC is a highly potent 
inducer of T cell activation, the next step was to evaluate the immunophenotype and 
function of the expanded polyclonal T cell population. T cells were stimulated 
overnight with αCD3/αCD28-sDC, αCD3-sDC or cells were left untreated as a 
negative control. First, it was investigated whether helper T cells (TH cells; CD4+) or 
cytotoxic T cells (CTLs; CD8+) were responsible for the observed activation. After 
sorting the CD4+ and CD8+ T cell populations, CD69 expression and IFNγ secretion 
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were measured separately for these populations. Treatment with αCD3/αCD28-sDC 
induced a profound upregulation of CD69 on CD8+ cells, but much less on CD4+ cells 
(Figure 4.4a). In contrast, both the CD8+ and CD4+ cell populations secreted similarly 
high levels of IFNγ (Figure 4.4b). When comparing the effect of αCD3/αCD28-sDC 
with αCD3-sDC, a similar overall activation pattern was observed for both CD4+ and 
CD8+ cells. For all subpopulations the activation was stronger, however, when 
treating the T cells with αCD3/αCD28-sDC. This again confirms the importance of 
αCD28 on the αCD3/αCD28-sDC. 
 
 
 
Figure 4.4. Immunophenotypes of activated T cells. a) The CD69 expression profile shows the highest 
number of activated cytotoxic (CD8+) and helper (CD4+) T cells after 16 hours of treatment with 
αCD3/αCD28-sDC when compared to T cells treated with only αCD3-sDC. b) Both CD8+ and CD4+ T 
cells, treated with αCD3/αCD28-sDC for 16 hours, release significantly higher amounts of IFNγ when 
compared to T cells treated with αCD3-sDC. c) Immunophenotyping of the FACS-sorted, activated 
(intracellular IFNγ+) CD8+ T cells shows that the number of CD8+ effector T cells (CD45RA+ CD62L- 
CCR7-) is significantly increased after 4 days of treatment with the polymeric sDCs (both 
αCD3/αCD28-sDC and αCD3-sDC) while the number of CD8+ memory (CD45RA- CD45RO+) and 
CD8+ effector memory (CD45RA- CD62L- CCR7-) T cells is not significantly affected. In contrast, 
treatment with the polymeric sDCs results in a slightly lower number of CD4+ effector T cells while the 
number of CD4+ memory and CD4+ effector memory T cells is increased. In all cases the observed 
difference is bigger for αCD3/αCD28-sDC than for αCD3-sDC. In all experiments an αCD3 
concentration of 5 ng ml-1 was used. The data represents the mean ± SEM of 3 independent 
experiments with T cells from different donors. The asterisks represent the statistical significance at ‘p’ 
values of 0.05 (*), 0.01 (**) and 0.001 (***), respectively. 
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Depending on their function, CD4+ and CD8+ T cells can be further divided into 
the following subtypes: effector T cells, memory T cells and effector memory T 
cells.30 Activated human effector T cells are characterized by a CD45RA+ CD62L- 
CCR7- phenotype, memory T cells by CD45RA- CD45RO+, and effector memory T 
cells by CCR7- CD45RA- CD62L-. A detailed phenotypic analysis of the IFNγ+ CD8+ 
population revealed that predominantly effector CD8+ T cells were induced following 
treatment with αCD3/αCD28-sDC and αCD3-sDC (Figure 4.4c). In contrast, an 
increase in the number of memory and effector memory T cells was observed in the 
IFNγ+ CD4+ cell compartment along with a small decrease in the number of effector 
CD4+ T cells (Figure 4.4c). The activation of an effector memory CD4+ T cell 
population may play a supportive role, prolonging the cytotoxic effect. 
 
4.2.5 αCD3/αCD28-sDCs do not show any significant activation of regulatory T 
cells 
Having shown that sDCs activate the required CD8+ effector cells as well as 
CD4+ memory and effector memory cells, an important remaining question to be 
addressed is the effect of sDCs on CD4+ cells that develop into undesired regulatory 
T cells thereby inhibiting immune reactivity. The frequency of Tregs, characterized by 
a CD4+ FoxP3+ CD69+ phenotype, was evaluated after treatment with αCD3/αCD28-
sDC along with a number of controls. T cells incubated with soluble αCD3 and 
αCD28 showed a higher number of Tregs than untreated T cells (Figure 4.5a). 
Incubation with αCD3-sDC also caused Treg activation, but to a lower extend. 
Interestingly, a small reduction in the number of activated CD69+ Tregs was 
observed when the T cells were treated with αCD3/αCD28-sDC (Figure 4.5a). Taken 
together, these results clearly show that the polymeric sDC design carrying both 
signal-1 and signal-2 is a potent immunotherapeutic agent that predominantly 
activates CD8+ effector cells as well as memory and effector memory CD4+ TH1 cells 
without inducing the activation of Tregs. 
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Figure 4.5. Functional analysis of T cells. a) FACS analysis of the activated CD4+ T cell population 
shows that the number of regulatory T cells is lowest when the T cells are treated with αCD3/αCD28-
sDC when compared to T cells treated with freely soluble αCD3 and αCD28 antibodies (1:1 molar 
ratio) or polymer-bound αCD3 alone (αCD3-sDC). b) The number of cytotoxic T cells characterized as 
granzyme B+ and CD69+ in the population of activated CD8+ cells is highest upon treatment with 
αCD3/αCD28-sDC. c) Also the number of degranulated CD8+ T cells (CD107a+ CD69+) is highest 
upon treatment with αCD3/αCD28-sDC. In all experiments an αCD3 concentration of 5 ng ml-1 was 
used and the T cells were treated at each condition for 4 days. The data represents the mean ± SEM 
of 3 independent experiments with T cells from different donors. The asterisks represent the statistical 
significance at ‘p’ values of 0.05 (*), 0.01 (**) and 0.001 (***), respectively. 
 
4.2.6 αCD3/αCD28-sDCs activate multifunctional killer T cells 
Recent studies indicate that disease control depends on the quality rather than 
on the quantity of cytotoxic CD8+ T cells.31,32 CTLs only become effective killer cells if 
they are fully activated by the correct stimuli. They are characterized by multiple 
functions: proliferation, cytokine release as well as their killing capacity. Above, the 
capacity of αCD3/αCD28-sDCs to induce both proliferation and cytokine secretion by 
CD8+ T cells was already demonstrated. In Figure 4.5b and 4.5c the capacity of 
αCD3/αCD28-sDCs to induce T cells that are able to exert cytotoxic activity is shown. 
The secretion of the protease granzyme B and the expression of the degranulation 
marker CD107a on the cell surface was analyzed, which are typical markers 
characterizing active multifunctional killer cells.33 Expression of granzyme B was 
clearly induced for activated CD69+CD8+ T cells after stimulation with αCD3/αCD28-
sDCs. In contrast, the level of granzyme B expression was not increased above the 
level of untreated cells when the T cells were incubated with αCD3-sDC (Figure 
4.5b). Moreover, the CD107a degranulation marker was upregulated on activated 
CD69+ CD8+ T cells only upon stimulation with αCD3/αCD28-sDCs, but not with 
αCD3-sDC (Figure 4.5c). These findings reveal that providing co-stimulatory signals 
in the near proximity of CD3 stimulation not only warrants but also is crucial for the 
generation of multifunctional killer T cells. 
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4.3 Discussion and conclusion 
The results obtained in this chapter confirm and expand earlier findings that 
polymeric sDCs are highly potent activators of T cells. In contrast to spherical bead-
based designs, all effector molecules on the polymer can potentially interact with the 
cell surface. The efficiency of our polyisocyanopeptide scaffold may further be a 
direct result of the semi-flexible nature of the polymer. This semi-flexibility allows for 
the proper arrangement and clustering of antigen and co-stimulatory receptors 
warranting strong T cell activation and propagation. To facilitate stable multivalent 
binding, a certain stiffness is required for energetic reasons. When using a highly 
flexible polymer, multivalent interactions of the attached effector molecules are not 
favored as they lead to a loss of conformational entropy of the polymer.34 Stiff 
scaffolds cannot adjust to the optimal receptor spacing on the cell surface and might 
prevent receptor rearrangement. A semi-flexible polymer backbone facilitates 
multivalent binding and also allows for molecular rearrangements of the bound 
components. This is required for microcluster and IS formation, which are crucial 
requirements for downstream signaling during T cell activation. 
The activation of T cells by natural DCs is achieved mainly by two prime 
signals: signal-1, recognition of the MHC-peptide complex by the TCR/CD3 complex; 
and signal-2, acquisition of co-stimulation via the CD28 receptor. To investigate the 
efficacy of the sDC design as a potent inducer of T cell activation, the sDCs were 
decorated with αCD3 and αCD28 antibodies to mimic signal-1 and -2, respectively. 
The results clearly show that the highest level of polyclonal T cell activation is only 
obtained when the sDCs carry signal-1 and -2 on one and the same polymer. Adding 
signal-2 on different polymers (αCD3-sDC + αCD28-sDC) does not show any 
favorable effect on T cell activation when compared to αCD3-sDC alone. The 
presence of signal-1 and -2 on the same polymer might influence both binding itself 
but also T cell signaling in a number of ways. The additional αCD28 antibodies might 
cause stronger binding of αCD3/αCD28-sDC to the T cell. Compared to αCD3-sDC, 
αCD3/αCD28-sDC carries twice the amount of antibodies leading to an increased 
multivalency effect. No difference in the binding efficiency between αCD3-sDC and 
αCD3/αCD28-sDC was observed, however (Appendix 4.2). Even though the 
additional antibodies have only a minor effect on the overall binding strength of 
sDCs, the effective local concentration of the antibodies is higher after the first 
antibody has docked onto the cell. This high effective concentration combined with 
the spatial proximity of αCD3 and αCD28 on the polymer increases the probability for 
both antibodies to bind. Co-stimulation with αCD28 is known to decrease the number 
of TCR/CD3 complexes that need to be stimulated for T cell activation.18,19 This lower 
activation threshold might directly explain the higher efficiency of αCD3/αCD28-sDC 
in the low concentration range when compared to αCD3-sDC. Lastly, co-stimulation 
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with αCD28 might crucially influence T cell signaling, leading to a stronger and more 
defined T cell activation.19  
A functional sDC is required to induce helper, cytotoxic and memory T cells 
while preventing the activation of regulatory T cells. The results in this chapter show 
that αCD3/αCD28-sDCs predominantly induced the activation of CD8+ effector T 
cells and CD4+ TH1 cells. Moreover, the addition of αCD3/αCD28-sDC did not 
activate Tregs when compared to the addition of soluble αCD3 and αCD28. Further 
investigation showed that the activated CD8+ T cell population even developed 
cytotoxic functions producing the cytolytic effector molecule granzyme B and 
expressing the degranulation marker CD107a. This suggests that αCD3/αCD28-sDC 
induced cytotoxic T cells are acutely activated and can exert multiple effector 
functions. It is note worthy that also the polymer carrying only αCD3 was able to 
specifically activate CD8+ effector T cells and CD4+ TH1 cells, but to a smaller 
extend. Granzyme B expression and degranulation crucially required the presence of 
αCD28. Also the number of regulatory T cells was unfavorably higher for αCD3-sDC. 
The presence of αCD28 on the polymer clearly shapes the immune response 
ensuring that only the desired T cell populations are activated that are essential for 
effective anti-cancer immunotherapy. 
In this context it is important to discuss the requirement for both αCD3 and 
αCD28 to be bound on the same polymer from a mechanistic point of view. The 
obtained results suggest that αCD3 and αCD28 need to be bound to the T cell in 
close proximity, most likely in the same microcluster.17,19 If αCD3 and αCD28 are 
bound to the T cell in different surface areas, T cell activation is obtained but the 
immune response is less defined. It is currently not clear what shapes the immune 
response in the desired direction. The required co-localization of αCD3 and αCD28 in 
the same microcluster suggests that the fate of the activated T cell is determined 
shortly after sDC binding and does not require complete IS formation.17,22 The 
polymer provides a physical link between αCD3 and αCD28 that might keep both 
receptors in proximity even within a fully mature IS. This might directly affect both the 
structure and the dynamics within the IS, eventually leading to a sustained and long 
lasting activation.16,17 This cannot be achieved with PLGA particles due to their larger 
size and rigidity. In this context, sDCs provide a unique and promising tool for 
studying receptor rearrangements in the IS in more detail in future experiments. 
In conclusion, polymer-based DCs decorated with T cell receptor stimulating 
agents and co-stimulatory molecules are highly efficient activators of T cells. Their 
unique features, such as semi-flexibility, bi-functionality and capacity of multivalent 
binding, make them excellent mimics of natural DCs. Their ‘natural’ behavior, 
reminiscent of plasma membrane embedded proteins, is essential for lowering the 
activation threshold and the specific programming of T cells. As a consequence, 
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sDCs overcome crucial drawbacks of many previously reported aAPC designs and 
have the potential to emerge as a novel, fully synthetic system for inducing antigen 
specific immune responses. More importantly, this novel vaccine design might be 
tuned to maintain immune responses over prolonged periods of time without the risk 
of Treg development. This sDC design has the potential to fulfill all criteria required 
for a highly efficient and successful anti-cancer vaccine. 
 
4.4 Experimental section 
Purification of anti-CD3 antibodies 
For the production of αCD3 (mouse anti-human CD3, IgG2a monoclonal antibodies) OKT-3 hybridoma 
cells (ATCC, CRL-8001) were maintained in RPMI-1640 medium containing 10 % (v/v) FBS, 1 % (w/v) 
Glutamine and 1× AA. After reaching confluence, cells were transferred to protein free hybridoma 
medium (PFHM-II). After 3 days in culture, αCD3 antibodies were isolated from the supernatant by 
Protein G affinity chromatography (HiTrap Protein G HP; GE Healthcare), following the manufacturer’s 
protocol. 
 
Polymer synthesis 
The polyisocyanopeptide polymer molecule was synthesized and characterized according to our 
published method.25,35 Briefly, the sDC backbone was synthesized by polymerizing the azide-
functionalized and the methoxy non-functionalized isocyanopeptides in a 1:100 ratio. The obtained 
150–200 nm long polyisocyanopeptide possess an azide group every 10 nm (statistical average). 
Streptavidin (SAv; Thermo Fisher Scientific) was functionalized with BCN-POE3-NH-
C(O)CH2CH2CH2C(O)OSu (BCN-NHS; Synaffix). The reaction was carried out in borate buffer (10 
mM, pH 8.5) at 4 °C for 4 days. The reaction mixture contained a 6-fold molar excess of BCN-NHS. 
Unreacted BCN-NHS was removed by gel filtration, followed by ultrafiltration with a 10 kDa cut-off. 
These reaction conditions yielded approximately 1–4 BCN functional groups per SAv molecule as 
determined by MALDI-ToF. Subsequently, the BCN-functionalized SAv was conjugated to the azide-
bearing polyisocyanopeptide in a strain-promoted azide-alkyne cycloaddition (SPAAC) reaction.29 The 
conjugation reaction (BCN-SAv:N3 = 1:1) was performed in borate buffer. After incubating the mixture 
for 4 days at 4 ˚C, the resulting SAv-polymer conjugate was purified by dialysis against water using a 
membrane with a 100 kDA cut-off. The average polymer contained 3–5 SAv molecules as determined 
using AFM imaging. The characterization data for this previously used SAv-polymer conjugate is 
described in chapter 2. The characterization also includes negative controls testing for non-specific T 
cell activation of the polymer itself and the SAv-polymer conjugate. This previously described SAv-
polymer conjugate was subsequently incubated with biotinylated monoclonal anti-human CD3 
antibodies (αCD3) in a 4:1 αCD3:SAv molar ratio. As shown previously,25 this 4:1 ratio yielded a 1:1 
ratio of αCD3 and SAv bound to the polymer backbone (αCD3-sDC). αCD3-sDC obtained in this way 
was subsequently functionalized with biotinylated monoclonal anti-human CD28 antibodies (αCD28; 
clone CD28.2, isotype IgG1, κ; BioLegend) using a similar procedure (αCD3/αCD28-sDC). The ideal 
labeling ratio to obtain a 1:1:1 αCD3: αCD28:SAv molar ratio was determined using fluorescently 
labeled antibodies as described in the next section. 
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Preparation of fluorescently labeled sDCs 
The αCD3 and the αCD28 antibodies were labeled with AlexaFluor488-NHS (Life Technologies) and 
ATTO565-NHS (ATTO-TEC), respectively. In the first step the SAv-functionalized polymer was 
incubated with AlexaFluor488-labeled and biotinylated αCD3 (488αCD3) in the previously determined 
4:1 molar ratio (chapter 2 and reference 25). The sample was purified by ultrafiltration (300 kDa cut-
off) to remove unbound antibodies. Subsequently, the sample was incubated with ATTO565-labeled 
and biotinylated αCD28 (565αCD28) in a 4:1, 10:1 and 20:1 molar ratio. After overnight incubation, the 
sample was again purified by ultrafiltration (300 kDa cut-off) to yield 488αCD3/565αCD28-sDC in 
phosphate buffered saline (PBS). Following purification, the total protein concentration was 
determined using a standard BCA assay (Thermo Fisher Scientific) according to the manufacturer’s 
protocol. In addition, the concentrations of the fluorescently labeled 488αCD3 and 565αCD28 were 
determined based on the fluorescence intensity at the respective excitation wavelengths (495 nm for 
488αCD3; 563 nm for 565αCD28). Calibration curves were established using the fluorescently-labeled 
pure 488αCD3 and 565αCD28 antibodies. Knowing the total protein concentration as well as the 
concentrations of both antibodies, the molar ratios of all polymer-bound components could be 
determined (Figure A4.1.1). All tested conditions yielded approximately a 1:1 molar ratio of 
αCD3:αCD28 (Figure A4.1.1) showing that maximally 2 biotin binding sites are able to bind a 
biotinylated antibody. This is most likely a result of the reduced accessibility of the additional 2 binding 
sites after 2 biotin binding sites are occupied by the large, bulky antibody molecules. 
The results of this experiment formed the foundation for the preparation of non-fluorescently 
labeled αCD3/αCD28-sDC polymers. The previously described and characterized αCD3-sDC polymer 
(carrying 3-5 αCD3 antibodies25) was used as the starting point. This polymer was incubated with a 
4:1 molar excess of αCD28 antibodies over polymer-bound αCD3 antibodies. Assuming that the 
fluorescence labeling does not alter the binding of the antibodies to the polymer, this excess of αCD28 
yields the desired 1:1 molar ratio of bound αCD3 and αCD28 antibodies, corresponding to 3–5 αCD3 
and 3–5 αCD28 molecules per polymer. 
 
Preparation of antibody functionalized PLGA particles 
PLGA (poly lactic-co-glycolic acid) particles were synthesized as described in Cruza et al.37 The 
particles were covalently modified with streptavidin (SAv) following the same protocol as described in 
Mandal et al.25 In fact the same batch of SAv-functionalized PLGA particles (SAv-PLGA) was used as 
in Mandal et al.25 The size of the SAv-PLGA particles was determined to be 1.8 µm using 
Transmission Electron Microscopy (TEM; JEOL TEM 1010) and Differential Interference Contrast 
(DIC) microscopy (FluoView FV1000, Olympus). 
As described in chapter 2 and reference 25, the particle concentration was determined using a 
Bürker chamber and the number of bound antibodies was optimized using fluorescently-labeled 
antibodies. The amount of bound αCD3 per αCD3-PLGA particle was optimized in the same way as 
for the polymer using biotinylated and AlexaFluor488-labeled αCD3 antibodies (488αCD3). 
Subsequently, αCD28 antibodies labeled with ATTO647-NHS (ATTO-TEC; 647αCD28) were used to 
optimize the amount of αCD28 antibodies. Following the same method as described for the polymer, 
647αCD28 antibodies were incubated with 488αCD3-PLGA in different ratios to obtain 
488αCD3/647αCD28-PLGA. A 1:1 molar ratio of 488αCD3/647αCD28 on the PLGA particles was obtained 
when a 10:1 excess of 647αCD28 over bound 488αCD3 was used for the incubation step. Again 
assuming that the fluorescence labeling does not affect antibody binding to SAv-PLGA, the exactly 
same conditions were subsequently used to obtain non-fluorescent αCD3/αCD28-PLGA particles for 
the T cell activation experiments. 
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T cell activation studies 
Peripheral Blood Lymphocytes (PBLs) were obtained from buffy coats of healthy individuals in 
accordance to institutional guidelines. Peripheral blood mononuclear cells were obtained by Ficoll 
density centrifugation and monocytes were removed by plastic adherence. The non-adherent PBLs 
were maintained at 37°C in RPMI-1640 medium containing 10 (v/v) % FBS, 1% (w/v) glutamine and 
1× AA. PBLs (105 cells/well) were seeded in 96 well plates and treated with sDCs or soluble 
antibodies at different concentrations (0.5, 1, 5, 10, 50 and 100 ng ml-1) for 16 h at 37˚C and 5% CO2. 
The treatment variables were αCD3/αCD28-sDC, αCD3-sDC + αCD28-sDC (1:1 molar ratio), αCD3-
sDC, αCD3 + αCD28 (1:1 molar ratio) and αCD3 along with an untreated control. If αCD3 was used in 
the respective samples, the concentration refers to the amount of αCD3 bound to the sDCs or in 
soluble form. If αCD28 was present in the sample in addition, the overall antibody concentration was 
twice as high as when αCD3 was used alone. If no αCD3 was used, the antibody concentration refers 
to the amount of αCD28. Following treatment, the cells and the respective supernatants were 
analyzed further using either flow cytometry (CD69 expression, immunophenotyping and functional 
analysis), ELISA (IFNγ) or T cell proliferation tests (CFSE assay). 
 
T cell activation assays 
Flow cytometry 
Flow cytometric analysis was performed using a CyAn™ ADP Analyzer FACS instrument (Beckman 
Coulter). The treated PBLs were washed twice with PBS + 1% (w/v) BSA (PBA) to remove unbound 
sDCs or antibodies. For the characterization of CD69 expression in the complete T cell population and 
the CD4+ and CD8+ subpopulations the following procedure was used. The treated PBLs were stained 
with antibodies specific for the CD4+ and CD8+ T cell subpopulations (anti-CD4-FITC and anti-CD8-
APC, BD Pharmingen). In addition, an anti-CD69-PE antibody (eBioSciences) was added to test for 
CD69 as an early T cell activation marker. After 1 hour of incubation with the antibodies, the cells were 
washed twice with PBA before FACS analysis. The data was further analyzed using FlowJo Software 
(TreeStar Inc.). The gating strategy to identify the population of CD69+ T cells is shown in 
Supplementary Figure A4.1.2. 
For the immunophenotyping analysis CD8+ T cells and CD4+ T cells were first sorted from the 
overall cell population by positive selection using anti-CD4- or anti-CD8-conjugated magnetic 
microbeads (Miltenyi Biotec). Before sorting, the corresponding CD4+ and CD8+ T cell populations 
were visualized by FACS (Supplementary Figure A4.1.3a–b and Supplementary Figure A4.1.4a–b). 
The sorted CD8+ T cell and CD4+ T cell subpopulations were then activated as described above for 4 
days. To evaluate the phenotype of the activated CD8+ T cells and CD4+ T cells after treatment, the 
cells were stained with the specific markers as listed in table 4.1. The corresponding gating strategies 
are shown in the Supplementary Figs. A4.1.3 and A4.1.4. To determine the Treg population among 
the activated (CD69+) T cells, the expression level of the intracellular marker FoxP3+ was analyzed 
(Supplementary Figure A4.1.5). For characterizing the population of activated CD8+ T cells having 
cytotoxic function the following markers were used: granzyme B as cytolytic effector marker and 
CD107a as degranulation marker (Supplementary Figures. A4.1.6 and A4.1.7). 
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Table 4.1. List of antibodies used for FACS analysis 
phenotype marker antibody company 
 
early T cell activation 
 
CD69 
 
PerCP anti-CD69 
 
eBiosciences 
 
Late T cell activation 
 
IFN  (intracellular) 
 
PE anti-IFN  
 
eBiosciences 
CD8 subpopulation* CD8 FITC anti-CD8 BD Pharmingen 
CD4 subpopulation* CD4 FITC anti-CD4 BD Pharmingen 
effector and effector 
memory 
CCR7 
CD45RA 
PerCP anti-CCR7 
APC anti-CD45RA 
BD Pharmingen 
eBiosciences 
memory CD62L 
CD45RA 
CD45RO 
PECy7 anti-CD62L 
PECy5 anti-CD45RA 
APC anti-CD45RO 
eBiosciences 
BD Pharmigen 
eBiosciences 
cytotoxic T cells 
(CTLs) 
granzyme B PE anti-granzyme B eBiosciences 
degranulated CTLs intracellular CD107a PE anti-CD107a  
regulatory T cells FoxP3 PE anti-FoxP3  
        * MACS sorted subpopulation 
 
ELISA (IFNγ detection) 
IFNγ secretion was analyzed using a sandwich ELISA. 96-well microplates (Nunc Immunomodules) 
were coated at 4 °C with a mouse anti-human IFNγ antibody (Pierce). After overnight incubation, the 
plates were washed with PBS + 0.05 % (v/v) Tween 20 and blocked with PBA. In the next step, the 
plates were incubated with the supernatants (obtained from the complete PBL population or the CD4+ 
and CD8+ subpopulations, as mentioned in the flow cytometry section) as well as the respective 
standards (IFNγ, Pierce). After 1 hour of incubation at room temperature, the plates were washed 3x 
with PBA. The concentration of captured IFNγ was detected after adding a biotinylated mouse anti-
human IFNγ antibody (Pierce) and a horseradish peroxidase streptavidin conjugate (Molecular 
Probes). The color reaction was developed using 3,3',5,5'-Tetramethylbenzidine (TMB microwell 
peroxidase substrate, Lucron). The absorbance of the colored solution was measured at 450 nm and 
corrected for adsorption at 540 nm in an iMark Microplate Reader (Bio-Rad). 
 
T cell proliferation (CFSE assay) 
T cell proliferation induced by sDC treatment was assessed using the CFSE assay. PBLs (105) were 
pre-labeled with 5 µM carboxyfluorescein diacetate succinimidyl ester (CFSE; Life Technologies). 
After quenching free CFSE with fetal bovine serum (FBS), the CFSE-labeled cells were washed twice 
with PBA. The PBLs (105 cells/well) were then treated with αCD3, αCD3-sDC and αCD3/αCD28-sDC 
at an αCD3 concentration of 5 ng ml-1. In addition, PBLs were incubated with an equimolar mixture of 
αCD3 and αCD28 as well as with αCD3/αCD28-PLGA particles, again using an αCD3 concentration of 
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5 ng ml-1. Untreated cells were taken as control. At 0, 24, and 96 h after start of the experiment, the 
respective samples were incubated with a mouse anti-human CD4/8 mAb (APC labeled; BD 
Biosciences; T cell marker) as well as with propidium iodide (PI). The PI was used to assess the cell 
viability through the dye exclusion method. Live cells have intact membranes that exclude a variety of 
dyes that easily penetrate the damaged, permeable membranes of non-viable cells. T cell proliferation 
was measured using flow cytometry following the evolution of the CFSE signal. The data was 
analyzed using FlowJo version 9.2 software (TreeStar Inc.). Following gating for viable T cells (see 
Figure A4.1.8) for the gating strategy and the raw data), the generation gate width was set 
automatically by the program. 
 
Statistical analysis 
The results represent the mean ± standard error of the mean (SEM) of at least three independent 
experiments performed with different donors. Samples from each donor were measured in duplicate or 
triplicate as indicated. Because two categorical variables were used, two-way ANOVA tests were used 
for data analysis. Bonferroni post-tests were performed to compare the replicate mean by column 
using GraphPad Prism 5 software. The statistical significance level was defined as p < 0.05. The 
asterisks ‘*’, ‘**’, ‘***’ represent p values < 0.05, < 0.01 and < 0.001. 
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4.5 Appendix 4.1: Supplementary figures 
 
 
 
Figure A4.1.1. Number of αCD28 molecules bound per molecule of αCD3 on the polymer. The x-axis 
represents the excess of αCD28 added to the αCD3-sDC solution (relative to the concentration of 
αCD3). The y-axis shows the molar ratio of actually bound 565αCD28:488αCD3 on the 
488αCD3/565αCD28-sDC polymer after purification. The data represents the mean ± SEM of 4 
independent experiments. 
 
 
 
Figure A4.1.2. Expression of the early activation marker CD69. The flow cytometry plots show the 
relative number of cells in the respective populations (mean; %). a) Gating for live T cells, b) collective 
gating for CD4+ and CD8+ T cells and c) gating for CD69+ T cells. Isotype controls were used for 
setting the negative or positive gate. 
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Figure A4.1.3. Immunophenotype determination of CD8+ T cells. Shown are the flow cytometry plots 
of activated (intracellular IFNγ+) CD8+ T cell indicating the relative number of cells in the respective 
populations (mean; %). a) Gating for live T cells and b) gating for CD8+ T cells. The CD8+ T cell 
population was sorted before gating for intracellular IFNγ+ CD8+ T cells c). In the IFNγ+ CD8+ T cell 
population the relative number of effector cells (CD62L− CCR7− CD45RA−; left) and effector memory 
cells (CD62L− CCR7− CD45RA+; right) was determined d). Isotype controls were used for setting the 
negative or positive gate.  
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Figure A4.1.4. Immunophenotype determination of CD4+ T cells. Shown are the flow cytometry plots 
of activated (intracellular IFNγ+) CD4+ T cells indicating the relative number of cells in the respective 
populations (mean; %). a) Gating for live T cells and b) gating for CD4+ T cells. The CD4+ T cell 
population was sorted before gating for intracellular IFNγ+ CD4+ T cells c). In the IFNγ+ CD4+ T cell 
population the relative number of effector cells (CD62L− CCR7− CD45RA−; left) and effector memory 
cells (CD62L− CCR7− CD45RA+; right) was determined d). Isotype controls were used for setting the 
negative or positive gate. 
 
 
 
Figure A4.1.5. Identification of regulatory T cells (Tregs). The flow cytometry plots show the relative 
number of cells in the respective populations (mean; %) used to identify the population of activated 
(CD69+) CD4+ Tregs. a) Gating for live T cells, b) gating for CD4+ T cells, c) gating for FoxP3+ CD4+ T 
cells. d) selected population of active Tregs (CD69+ FoxP3+ CD4+). Isotype controls were used for 
setting the negative or positive gate. 
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Figure A4.1.6. Flow cytometry plots used to identify the population of granzyme B expressing T cells 
among the population of activated (CD69+) CD8+ T cells. The dot plots show the gating strategy as 
well as the relative number of cells in the respective populations (mean; %). a) gating for live T cells, 
b) gating for CD8+ T cells, c) gating for CD69+ CD8+. (d) Population of intracellular granzyme B 
positive T cells (granzyme B+ CD69+ CD4+). Isotype controls were used for setting the negative or 
positive gate. 
 
 
Figure A4.1.7. Flow cytometry plots used to identify the population of T cells expressing the 
degranulation marker CD107a among the population of activated (CD69+) CD8+ T cells. The dot plots 
show the gating strategy as well as the relative number of cells in the respective populations (mean; 
%). a) Gating for live T cells, b) gating for CD8+ T cells, c) gating for CD69+ CD8+. (d) Population of 
CD107a positive T cells (CD107a+ CD69+ CD8+). Isotype controls were used for setting the negative 
or positive gate. 
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Figure A4.1.8. FACS raw data of the CFSE assay (T cell proliferation). a) Gating for T cells. b) Gating 
for viable CD4+ and CD8+ T cells. Dead T cells were identified by staining with PI. c) CFSE staining 
profile of the CFSE+ T cell population at the start of the experiment (day 0). (d) CFSE staining profile 
of the CFSE+ T cell population measured after 1 and 4 days of treatment. The decrease in the CFSE 
staining intensity relative to the starting population indicates cell division. The brackets from right to left 
represent the number of generations from 0 to 7. The values above the brackets show the relative 
number of T cells belonging to each specific generation. 
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4.6 Appendix 4.2: Binding efficiency analysis of sDCs (confocal microscopy) 
  
The fluorescently labeled sDCs have not only been used for optimizing the number of αCD3 
and αCD28 bound to the polymer. Further, 488αCD3/565αCD28-sDC was used for confocal imaging, to 
determine the binding efficiency of sDCs to T cells. For confocal analysis, peripheral blood 
lymphocytes (PBLs; 106 cells/well) were treated overnight with different concentrations (5, 10, 50, 100 
ng ml-1) of 488αCD3/565αCD28-sDC, 488αCD3-sDC, 488αCD3 and 565αCD28. Moreover, to determine the 
effect of having signal-1 (488αCD3) and signal-2 (565αCD28) on the same polymer backbone, the above 
experiment was also performed with an equimolar mixture of 488αCD3-sDC and 565αCD28-sDC at a 
concentration of 50 ng ml-1. After incubation, the treated T cells were washed twice with PBS + 1 % 
(w/v) BSA (Sigma Aldrich; PBA). The washed T cells were fixed in 4 % formaldehyde for 10 min at 
room temperature and quenched in 0.1 M glycine solution for 20 min. These fixed cells were mounted 
onto microscope slides (Thermo Fisher Scientific) using MOWIOL (Calbiochem). They were analyzed 
under a confocal laser scanning microscope (CLSM, Olympus FV1000) using a 63× oil immersion 
objective. ImageJ software version 1.43 was used for image processing.36  
After 10 min of incubation, binding of 488αCD3/565αCD28-sDC (at a concentration of 50 ng ml-1) 
is observed on the T cells (Figure A4.2.1a). After overnight incubation (16 h) the fluorescence from 
both antibodies is concentrated at one area on the T cell surface suggesting formation of the 
immunological synapse (IS) (Figure A4.2.1b). A more detailed analysis of the confocal images 
obtained from the concentration series described above (Figure A4.2.1c) provides information about 
the binding efficiency of the 488αCD3/565αCD28-sDCs and the respective controls. 
In the high concentration range (>50 ng ml-1), the relative number of T cells that showed 
AlexaFluor488 fluorescence (in samples where the αCD3 was present) or ATTO565 fluorescence 
(αCD28 only) was similar for all treatment conditions indicating that all available binding sites were 
occupied by the sDC or the soluble antibody. In the low concentration range, however, both 
488αCD3/565αCD28-sDC and 488αCD3-sDC showed superior binding compared to the soluble αCD3 or 
αCD28 antibodies. The higher binding efficiency is a strong indication that the ability to form 
multivalent interactions increases the avidity of the sDCs. Interestingly, no difference in the binding 
efficiency is observed for the sDCs carrying only αCD3 and the sDCs carrying both the αCD3 and the 
αCD28 antibodies. Obviously, the presence of the additional αCD28 antibodies does not increase the 
avidity of the sDC any further. This observation was confirmed when also comparing the binding of 
efficiency of 565αCD28-sDC (Figure A4.2.1d). No significant difference in the number of fluorescently 
labeled T cells was observed for 488αCD3-sDC, 565αCD28-sDC and 488αCD3/565αCD28-sDC when only 
one of these polymers was added to the T cells. When the equimolar mixture of 488αCD3-sDC and 
565αCD28-sDC was used, however, a lower binding of 565αCD28-sDC was observed. It is currently not 
clear why the binding of 565αCD28-sDC was reduced in this experiment. 
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Figure A4.2.1. Confocal analysis of the binding efficiency of sDCs and free antibodies to the T cells. 
a) Representative confocal image of 488αCD3/565αCD28-sDC bound to a single T cell taken after 10 
min (early binding; microcluster formation as shown in the schematic image). b) Representative 
confocal image of 488αCD3/565αCD28-sDC bound to a single T cell taken after 16 h (late binding; 
accumulation at the immunological synapse as shown in the schematic diagram). An antibody 
concentration of 50 ng ml-1 488αCD3 and 50 ng ml-1 565αCD28 was used for the experiment. The 
sequence (I) – (IV) shows the following series of images: bound 488αCD3 (green); (II) 565αCD28 (red); 
(III) merge of image I and II showing co-localization (yellow); and (IV) image III merged with a bright 
field image. c) Statistical analysis of the sDC (488αCD3/565αCD28-sDC) binding efficiency at different 
antibody concentrations. The incubation time was 16 hours. The polymer carrying both antibodies was 
compared with the polymer containing only αCD3 (488αCD3-sDC) as well as with free signal-1 
(488αCD3) and free signal-2 (565αCD28). The x-axis represents the concentration of 488αCD3 on the 
sDCs or free in solution. In cases where both 488αCD3 and 565αCD28 were present in the sample, the 
total antibody concentration was twice as high. For the 565αCD28 sample the αCD28 concentration 
was used. d) Comparative binding analysis of sDCs. The cells were incubated with 50 ng ml-1 of (i) 
488αCD3-sDC and 565αCD28-sDC (1:1 molar ratio), (ii) 488αCD3-sDC or 565αCD28-sDC added 
separately to different samples, or (iii) 488αCD3/565αCD28-sDC. The cells were incubated with the 
sDCs for 16 h. The data represents the mean ± standard error of the mean (SEM) of 3 independent 
experiments with samples from different donors. The asterisks ** and *** presents the statistical 
significance at ‘p’ values < 0.01 and 0.001, respectively. 
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Chapter 5: Stress-stiffening-mediated stem-cell commitment switch 
in soft responsive hydrogels  
 
5.1 Introduction 
Cellular interactions with the extracellular matrix (ECM) mediate important cell 
functions such as survival, proliferation, migration and differentiation.1–5 The 
extracellular stimuli include soluble and adhesive ligands that provide chemical and 
mechanical cues which have been shown to govern cell physiology1. It has recently 
been demonstrated that physical cues from the matrix, especially the matrix stiffness 
and topography, can initiate intracellular biochemical signals through 
mechanotransduction and thus dictate the cell differentiation pathways.6–8 
Understanding the role of these microenvironmental physical cues has profound 
implications for realizing the full therapeutic potential of stem cell research in tissue 
engineering applications.9–17  
Three classical cell culture systems have been widely utilized to underpin the 
effect of the ECM properties on stem cell fate. Firstly, natural ECM-protein derived 
hydrogels prepared at different densities have been shown to significantly influence 
cell adhesion, cell shape and various cell functions.18 However, changing the density 
of these proteins does not only change the gel stiffness, but also alters the surface 
ligand concentration. Thus, in this type of culture system, it is difficult to de-couple 
and interpret the effect of the matrix stiffness and ligand density on cellular response. 
The second class of culture system employs synthetic polymer gels as ECM mimetic 
scaffolds for stem cell fate control.17,19,20 In this case, the gel stiffness can be 
modulated by altering the amount of a cross-linker, however, the porosity and the 
polymer surface chemistry also change as a function of the cross-linker amount.21,22 
The stem cells are therefore likely interpreting the combined effect of these 
parameters for their fate control, although it has recently been suggested that 
substrate porosity in 2D cell culture conditions does not affect stem cell fate.8 A third 
class of culture system is based on elastomeric micropost arrays, where different 
post heights are interpreted as different rigidities by the cells.16 This system provides 
an approach to de-couple the effect of the substrate stiffness from alterations in the 
surface chemical properties. The micropost diameter dictates a limiting size of the 
focal adhesions, however, and restricts focal contact maturation. The 2D nature of 
the micropost culture system further fails to mimic 3D physiological conditions. 
In this chapter, a new class of cell culture systems is introduced based on fully 
synthetic biomimetic physically cross-linked soft (~0.2-0.4 kPa) hydrogels derived 
from helical oligo ethylene glycol polyisocyanopeptides (PIC).23 The application of 
this novel 3D matrix for studying stem cell function is demonstrated. These soft 
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thermo-responsive hydrogels are formed at extremely low polymer concentrations 
(99.95% water) and possess pore sizes of nanometer dimension (~100-150 nm).24 
Their mechanical properties are similar to those of biopolymer hydrogels assembled 
from microtubules, F-actin, fibrin, and collagen. These hydrogels exhibit a non-linear 
stress response beyond a critical stress σC (stress-stiffening).24 When the stress is 
increased beyond this value, the matrices become stiffer with increasing applied 
stress.  
Janmey et al. demonstrated that different types of cells, for example, 
fibroblasts and human mesenchymal stem cells (hMSCs), adopt a stretched 
morphology when cultured on soft fibrin gels (2D substrates). This is a clear 
indication that the cells deform these gels and gain access to the high strain moduli 
in the stress-stiffening regime.25 It is important to note that the onset of stiffening for 
the ECM proteins occurs at extremely small values of the applied stresses. The PIC 
hydrogels introduced here show stress-stiffening in the biologically relevant stress 
regime, as demonstrated in Figure 5.1. PIC hydrogels are therefore the first fully 
synthetic system that allows for investigating how stress-stiffening influences 3D 
stem cell differentiation as part of the mechanisms underlying the physiology of adult 
stem cell niches. 
It is shown in this chapter that hMSCs encapsulated in these biomimetic gels 
(functionalized with cell-adhesive GRGDS peptides) prefer osteogenesis over 
adipogenesis. This differentiation can be induced in an extremely soft 
microenvironment simply by increasing the polymer length. Different polymer lengths 
only affect σC without altering the bulk gel stiffness and ligand density of the matrix. 
This fully synthetic culture system therefore presents a model to study the effect of 
this physiologically important parameter (stress-stiffening) on cells encapsulated in a 
3D microenvironment. It is further shown that the cellular sensing of stress-stiffening 
affects the microtubule-associated protein DCAMKL1 in the mechanotransduction 
pathway, suggesting a role of microtubule dynamics in hMSCs fate control.   
 
5.2 Results 
 
5.2.1 Synthesis and characterization of polymers. 
To construct a 3D cell culture matrix for studying the effect of stress-stiffening 
on stem cell fate, PIC hydrogels were chosen. This choice was motivated by the fact 
that they demonstrate stress-stiffening behavior24 in the biologically relevant stress 
regime (vide supra, Figure 5.1), unlike other synthetic materials. At the same time 
they allow for deconstituting some of the key parameters of generally complex 
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biological systems (lack of simultaneous control on ligand density and stiffness, 
enzyme degradability, etc.).  
 
 
  
These synthetic polymers were functionalized with the basic cell adhesive 
peptide GRGDS in order to promote stem cell adhesion to the matrix. This short 
peptide ligand can be homogeneously distributed and allows for a direct sensing of 
the substrate mechanical properties since there is a single anchoring point per 
ligand. This is a major advantage of the PIC system compared to previously 
developed substrates (e.g. collagen26) and facilitates an unambiguous interpretation 
of the effect of stress-stiffening. The peptide ligand has been grafted to the polymer 
via a short spacer, which is 24 atoms long and equivalent to a short PEG chain of 
approximately 8 units. This spacer was optimized according to molecular modeling 
so as not to play a role in cell-substrate interactions. However, the length of the 
peptide tether was not varied to investigate its influence on the cell-substrate 
interaction, although it may play a role.27 
Polyisocyanopeptides (P1ʹ-P6ʹ) were synthesized by a nickel(II)-catalyzed co-
polymerization of triethylene glycol functionalized isocyano-(D)-alanyl-(L)-alanine 
monomer 1 and the azide-appended monomer 2 (Figure 5.2a), with the molar ratio of 
1/2 = 100. This ratio should yield polymers with statistically one azide-functionality 
every 11.5 nm of the polymer chain.  
Figure 5.1. Differential modulus Kʹ as a function of stress σ for intracellular and extracellular 
filamentous biopolymer gels that show stress-stiffening. For comparison, the rheology data for a 
representative synthetic gel (polyacrylamide) and the biomimetic stress-stiffening polyisocyanopeptide 
hydrogel are included. Go indicates the equilibrium bulk stiffness and σC denotes the critical stress for 
the onset of stress-stiffening of the polymer gel. 
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Table 5.1. Characterization of the synthesized polymers and the gels in alpha-MEM.
The catalyst to monomer molar ratio was varied from 1:1000 to 1:8000 to 
obtain polymers of increasing molecular weight (P1ʹ-P6ʹ; determined by viscosity 
measurements, Table 5.1). These azide-functionalized polymers were then 
subjected to a strain-promoted azide-alkyne cycloaddition (SPAAC) reaction with 
BCN-GRGDS (BCN: Bicyclo[6.1.0]non-4-yn-9-ylmethyl) to obtain cell adhesive 
GRGDS functionalized polymers P1-P6 (Figure 5.2b-c and Experimental Section). of 
increasing chain lengths. The resulting polymers were characterized with atomic 
force microscopy (AFM) to determine the polymer length (Table 5.1; Figure A5.1.1 
and A5.1.2). To determine the concentration of azide groups, a rhodamine dye-
functionalized with a strained alkyne was reacted with the azides on the polymer 
(Table 5.1 and Experimental section). This control experiment revealed a spacing of 
14-18 nm for the azide groups on the polymer, which is close to the predicted value 
of 11.5 nm. 
After dissolving these polymers in alpha-MEM (Minimum Essential Medium) at 
a fixed concentration of 2 mg/mL they formed transparent gels upon warming (above 
~15 °C; determined by temperature sweep rheology; Figure 5.2d). The mechanical 
properties of the GRGDS-functionalized polymer gels were further investigated in 
more detail using rheological analysis. Temperature sweep experiments (heating up 
to 37 °C) followed by a time sweep at 37 °C revealed that all the gels P1-P6 were 
soft and exhibited a similar stiffnesses (0.2-0.4 kPa at 37 °C; Figure 5.2e). It has 
already been shown that hydrogels of non-functionalized PIC polymers show a 
biomimetic stress-stiffening behavior.24 Using the same pre-stress protocol28, the 
critical stresses (σC) of P1-P6 hydrogels were measured (Figure A5.1.3). The critical 
stress (σC), describing the non-linear behavior of these gels, was found to increase 
linearly as a function of the polymer chain length (Figure 5.2f and Table 5.1).29 The 
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σC values range from ~9 Pa in the P1 gel (average polymer length = 182 nm) to ~19 
Pa in the P6 gel (average polymer length = 434 nm). Although there seems to be a 
1.5-fold increase in the mean gel stiffness upon increasing the mean polymer length 
from ~180 nm to ~240 nm (Figure 5.2e), this difference is small in the context of 
cellular perception of bulk stiffness.17 Regarding the σC values, a linear relationship 
is observed between this parameter and the mean polymer length (Figure 5.2f). As 
the error range for σC is smaller, this increase is considered to be significant. 
 
 
Figure 5.2. Synthesis of polymers of different chain length and characterization of polymer hydrogels. 
a) Co-polymerization of the non-functionalized monomer 1 and the azide-functionalized monomer 2 at 
different catalyst to monomer molar ratios yields polymers of different chain lengths (P1ʹ-P6ʹ). b) and 
c) Functionalization of the azide-functionalized polymers P1ʹ-P6ʹ with the GRGDS-peptide. d) 
Representative temperature sweep rheology experiment of a PIC hydrogel. The onset of gelation was 
observed to occur at ~15 oC. e) The storage modulus (Go) at 37 ºC appears to be independent of 
polymer length (0.2-0.4 kPa), considering the error in this experiment. f) The critical stress σC varies 
linearly as a function of polymer length. The error bars represent standard errors of the mean (n = 3). 
 
5.2.2 Stress-stiffening-mediated hMSC differentiation 
To investigate the effect of stress-stiffening on stem cell fate, hMSCs were 
mixed with a cold polymer solution (~10 oC) in alpha-MEM. The mixture was then 
warmed to 37 ºC to form the 3D matrix with encapsulated hMSCs. The polymer 
solution forms a gel immediately after incubation at 37 °C as revealed by kinetic 
rheology experiments (Figure A5.1.4). Afterwards, the gel becomes stiffer with time 
and attains the final stiffness in 2-3 minutes. This strategy ensures that the cells are 
supported in 3D and prevents settling of the cells at the bottom. The cells were 
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homogeneously distributed throughout the gel as indicated by confocal microscopy 
(Figure A5.1.5). Investigation of hMSCs morphology after 36 h in culture revealed 
that the cells remained spherical in all of the gels (P1-P6; Figure 5.3a). The cells 
exhibited only limited cortical F-actin protrusions into the surrounding 
microenvironment (Phalloidin staining, Figure A5.1.6) and showed no significant 
modifications in their nuclear morphology, as shown by a representative DAPI 
fluorescence image of the cell nucleus after 36 h of culture (Figure 5.3b). These 
observations are consistent with recent reports of hMSCs in 3D cell cultures.19,30 
Live/dead assays (calcein-AM and MTT) performed after 36 h of culture in growth 
media indicated excellent viability (>95%) of the encapsulated cells in all the gels 
and the non-functionalized control gel (Figure 5.3c and d and Figure A5.1.7), as also 
confirmed by confocal microscopy (Figure A5.1.5). In addition, no significant cell 
proliferation was detected for the various gels as determined using the PicoGreen 
assay (Figure A5.1.8). 
The lineage commitment of the gel-encapsulated hMSCs after 96 h of culture 
was investigated in bipotential differentiation medium (1:1 v/v osteogenic and 
adipogenic media). The cells were first stained (immunofluorescence) for STRO-1, a 
mesenchymal stem cell specific marker.31 A significant decrease in the average 
STRO-1 expression was observed for the cells in all of the gels after 96 h of culture, 
indicating the onset of stem cell differentiation (Figure 5.3e). The expression of 
osteogenic and adipogenic differentiation markers was then examined. For cells 
cultured in the gel with the lowest critical stress (σC ~9.4 Pa, constructed from the 
shortest polymer P1) predominantly adipogenic commitment was observed (Oil-red 
O staining, Figure 5.3f; and Figure A5.1.9). With increasing σC (i.e. increasing the 
polymer length), osteogenesis was progressively favored over adipogenesis. This is 
demonstrated by immunofluorescent staining of Osterix, an osteogenic specific 
marker (Figure 5.3g) and is confirmed when considering the mean percentages of 
osteogenic and adipogenic commitments (Figure A5.1.10) in the various hydrogels 
(P1-P6). hMSCs cultured in the gel with the highest σC (P6) preferentially exhibited 
osteogenic commitment. This predominant osteogenesis observed for the cells 
grown in hydrogels made from the longer polymers (P4-P6) was further confirmed by 
differentiation tests after 3 weeks of culture (Figure A5.1.11).  
Finally, hMSC osteogenic commitment was verified using RT-PCR to 
determine the expression of the osteogenic biomarker Core-binding factor alpha 1 
(Cbfa-1), also called RUNX2, and the expression of the adipogenic biomarker 
PPARγ. After 96 h of culture, an increase in RUNX2 gene expression was observed 
with increasing σC (Figure 5.3h). This result is in agreement with the 
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immunofluorescence staining results. Simultaneously, a decrease in gene 
expression of the adipogenic marker PPARγ is observed (Figure 5.3i). 
 
 
Figure 5.3. Effect of stress-stiffening on hMSC commitment. a) Representative micrographs showing 
cross-sections of hMSCs 36 h after encapsulation into 3D matrices made from the shortest (P1) and 
the longest polymer (P6) and constant GRGDS density, visualized by bright-field microscopy. b) 
Confocal image of fluorescence staining (DAPI) of the cell nucleus after 36 h of culture for the P3 
polymer. c) Live/dead viability test (calcein-AM) of hMSCs after 36 h of encapsulation. In the 
representative image, almost all cells in the matrix from polymer P3 seem to be alive (green). Nuclei 
were stained with DAPI (Blue). d) Cell viability was assessed using the MTT assay in all matrices 
(from shortest to longest polymers). e) STRO-1 protein expression in the hMSCs is expressed as 
average fluorescence intensity, normalized by the number of cells. Compared to the control, STRO-1 
expression decreased for all of the matrices, indicating that the hMSCs have lost their “stemness” and 
initiated differentiation. f) Total cellular area of immunofluorescence intensity of neutral lipid 
accumulation quantified for hMSCs cultured for 96 h in the various matrices. g) Total cellular Osterix 
protein immunofluorescence intensity was quantified for hMSCs cultured for 96 h in the various 
matrices. h) and i) Quantitative PCR analysis for RUNX2 and PPARγ, significant differences were 
observed between the matrices displaying a high or low critical stress. For all the experiments, a non-
functionalized soft polymer gel (cell culture in growth medium) served as the control (**P < 0.001, *P < 
0.01).   
 
To investigate the role of the GRGDS-ligand interaction with its receptors on 
the stem cell surface, cell commitment studies were performed where this interaction 
was blocked. Using the GRGDS-modified polymers P1, P3, P4 and P6, cell culture 
Shortest Polymer 
 
Longest Polymer 
10 m 
a b 
100 m 
e 
0 
0,2 
0,4 
0,6 
0,8 
1 
1,2 
1,4 
C
on
tro
l 
P1
 
P2
 
P3
 
P4
 
P5
 
P6
 
R
el
at
iv
e 
In
te
ns
ity
  
STRO-1 
** 
i 
c d 
h f 
5 m 
P3 P3 
0 
20 
40 
60 
80 
100 
P1
 
P2
 
P3
 
P4
 
P5
 
P6
 
M
TT
 (%
 c
on
tr
ol
) 
Cell Viability 
0 
1 
2 
3 
4 
5 
6 
7 
C
on
tro
l 
P1
 
P2
 
P3
 
P4
 
P5
 
P6
 
R
el
at
iv
e 
In
te
ns
ity
  
Osterix 
* 
** 
0 
1 
2 
3 
4 
5 
6 
C
on
tro
l 
P1
 
P2
 
P3
 
P4
 
P5
 
P6
 
R
el
at
iv
e 
A
re
a 
 
LIP 
* ** 
g 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
C
on
tro
l 
P1
 
P2
 
P3
 
P4
 
P5
 
P6
 
R
el
at
iv
e 
m
R
N
A 
le
ve
l 
PPAR  
N.S 
** 
N = 3 
* 
N.S 
N.S 
0 
1 
2 
3 
4 
5 
C
on
tro
l 
P1
 
P2
 
P3
 
P4
 
P5
 
P6
 
R
el
at
iv
e 
m
R
N
A 
le
ve
l 
RUNX2 
C
on
tro
l 
Processed on: 10-10-2016
505747-L-bw-Hammink
Stress-stiffening-mediated stem-cell commitment switch in soft responsive hydrogels  
!
!
!
! 109 
experiments were performed in the presence of antibodies recognizing specific 
integrin subunits (α1, 2, 3 and 5; β1 and 2). In the presence of these integrin-
blocking antibodies, osteogenic commitment was suppressed. However, adipogenic 
commitment was maintained for all the polymers tested (Figure A5.1.12 and 
A5.1.13). This result is in agreement with the recent literature19 and highlights the 
importance of the interaction between integrin receptors and the RGD ligands for 
mediating the stress-stiffening induced commitment switch. Interestingly, the 
presence of blebbistatin (a small molecule inhibitor of actomyosin contractility 
showing high affinity and selectivity toward myosin II) inhibited the hMSCs 
commitment. Stemness was mainted for all the polymer gels, as revealed by the high 
levels of STRO-1 in the encapsulated cells (Figure A5.1.14). This suggests that the 
inhibition of actomyosin contraction interferes with the mechanisms of hMSCs 
commitment both towards adipogenesis and osteogenesis. This is most likely due to 
the fact that the cells cannot apply any traction force to sense their 
microenvironmental (incl. its stress-stiffening properties). These results are 
consistent with previously published studies.17 Finally, in order to demonstrate the 
direct interaction between the hMCSs and the polymer-bound GRGDS, the cell 
commitment studies were performed in the presence of soluble GRGDS ligands. 
Soluble ligands block the interaction between the cells and the matrix by competing 
for the integrin binding sites. Using the GRGDS-functionalized polymers P1, P3, P4 
and P6, no significant osteogenic or adipogenic commitment was detected. This 
clearly confirms that integrin disengagement from the matrix-bound RGD is 
interfering with the cell’s ability to sense stress-stiffening (Figure A5.1.15 and 
A5.1.16). These data also suggest that the cells need a direct engagement with the 
bound RGD ligand, and not with the secreted ECM, for mediating the stress-
stiffening induced commitment switch.  
Although the macroscopic ligand density is kept constant in this study (one 
ligand every 14-18 nm of a polymer chain), the longer polymer chains (P4-P6) have 
an almost 2-fold higher number of ligands per chain (20-26), as compared to the 
corresponding shorter chains (P1-P3: 13-18). This could indeed impact the extent of 
cell-mediated local ligand clustering. To study the effect of ligand-density on the 
observed hMSC commitment switch, the commitment study was performed as a 
function of ligand density (RGD every 7 nm, 28 nm and 70 nm) for gels of the 
shortest (P1) and the longest polymer (P6). Varying the ligand density for both 
polymers, no indication was found that the ligand density interferes with the cell 
differentiation outcome (Figure A5.1.17). These results suggest that stress-stiffening 
is the primary governing variable in the system, without excluding the possibility that 
cell-mediated ligand clustering is occurring. The data demonstrates that hMSC fate 
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can be switched from adipogenesis to osteogenesis in a soft microenvironment 
(~0.2-0.4 kPa), simply by increasing the critical stress for the onset of stress-
stiffening.  
 
5.2.3 Role of DCAMKL1 in stem cell differentiation 
Several reports have indicated that the cytoskeletal contractility as well as 
actin polymerization are responsible for osteogenic differentiation on 2D substrates. 
In this study, treatment with cytochalasin D (inhibitor of actin polymerization) resulted 
in an overall decreased commitment of the cultured stem cells towards both 
osteogenesis and adipogenesis (Figure A5.1.18a). Also this result suggests a role of 
actin polymerization in the stress-stiffening mediated hMSCs differentiation. At the 
same time, a decrease in hMSC commitment was observed after treatment with 
Taxol, a well-characterized microtubule-stabilizing agent known to inhibit tubulin de-
polymerization (Figure A5.1.18b). Taxol treatment did not affect cell viability as 
indicated by a live/dead assay after 48 h and 96 h of culture (Figure A5.1.19). The 
effect of Taxol on the cell commitment outcome indicates that, in addition to actin, 
the microtubule dynamics could also be involved in the mechanotransduction 
pathways underlying hMSCs differentiation in the PIC matrix. 
A recent report has indicated that the microtubule-associated protein 
DCAMKL1 represses RUNX2, an early osteogenesis marker, and thus regulates 
osteogenic differentiation in vitro and in an in vivo rat model.32 DCAMKL1 is also 
known to enhance microtubule polymerization. Furthermore, it has been reported 
that microtubule de-polymerization can alter the myosin mechanochemical activity 
through myosin regulatory side chain phosphorylation, thus resulting in increased 
actomyosin contraction.33 In this context, also the role of DCAMKL1 in the stress-
stiffening mediated control of hMSC differentiation was investigated as a function of 
critical stress. Interestingly, Western blot analysis revealed a negligible DCAMKL1 
expression for the polymer gel with the highest σC (P6) and a significant increase in 
the expression of this protein with decreasing σC (Figure 5.4a). Concomitantly, 
RUNX2 expression was not observed in the gels with lower σC (P1-P3) while the 
protein was clearly expressed in the hydrogels with higher σC (P4-P6). This result 
correlates with the observed osteogenic commitment in these gels. This is also in 
agreement with the observed overall increase in the RUNX2 mRNA expression when 
comparing hydrogels assembled from the shorter (P1-P3) and longer (P4-P6) 
polymers (Figure 5.3h). This difference is smaller, but still significant. These 
observations correlate well with preferential osteogenesis in gels of higher critical 
stress and a lack of osteogenic commitment as the critical stress is lowered. A plot of 
the relative intensities (protein expression) of RUNX2 versus DCAMKL1 for all the 
conditions (P1-P6) shows a switch-like relationship between these two proteins with 
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the existence of a threshold value for the expression of DCAMKL1 (Figure 5.4a and 
Figure A5.1.20). The observation that RUNX2 antagonizes the adipogenic lineage 
commitment has functional relevance for mechanistic interpretations as it correlates 
with the observed stress-stiffening mediated commitment switch.  
In order to further confirm the functional relationship between DCAMKL1 and 
RUNX2 in the stress-stiffening gel system, DCAMKL1 gene silencing (through 
shRNA) and overexpression (via transient transfection) were performed for the 
hMSCs cultured in the P1 and P6 polymer gels. DCAMKL1 silencing resulted in the 
increased expression of RUNX2 for the P1 polymer gel as well as for the P6 polymer 
gel, but to a smaller extent (Figure A5.1.21). In contrast, DCAMKL1 overexpression 
did not significantly alter the expression of RUNX2 in the P1 polymer gel, while a 
significant decrease was observed for P6 (Figure A5.1.22). These data confirm the 
functional relationship between the two proteins in this gel system. DCAMKL1 
functions “upstream” of RUNX2 and directs its expression in a switch-like manner. 
Along with this, a threshold value exists that determines the expression of 
DCAMKL1, which inhibits the expression of RUNX2. These data are in agreement 
with a previous in vivo and in vitro study.32
Figure 5.4. a) Western Blot analysis of DCAMKL1 and RUNX2 protein expression in hMSCs after 96 
h of culture in all of the matrices (short and long polymers; P1-P6). The Western blot was performed 
in triplicate. A plot of the relative protein expression intensities of RUNX2 versus DCAMKL1 for all the 
conditions (P1 to P6) shows a switch-like relationship between these two proteins. b) Schematic 
model illustrating the proposed mechanisms that underlies the stress-stiffening mediated hMSC 
commitment and differentiation towards adipogenesis and osteogenesis via modulation of the protein 
expression of DCAMKL1.
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Altogether these results are the first report of the microtubule-associated 
protein DCAMKL1 being involved in a new stress-stiffening mediated 
mechanotransduction pathway involving microtubule dynamics for the control of 
hMSC differentiation (Figure 5.4b). These data indicate that stem cell fate is 
regulated by ECM stress-stiffening via a different molecular mechanism than the one 
described for classical 2D substrate rigidity sensing.  
 
5.3 Discussion and conclusion 
This chapter introduces polyisocyanopeptide-based hydrogels as a new class 
of 3D cell culture system for studying the physical cues of the microenvironment 
involved in stem cell fate control. Despite being fully synthetic, the gels discussed in 
this chapter closely resemble natural biopolymer gels. They exhibit stress-stiffening 
behavior, a property that is widely observed in biological tissues and is believed to 
have important ramifications for the design of artificial ECM mimetic scaffolds. In 
contrast to other synthetic polymer matrices such as polyacrylamides or polyethylene 
glycol gels, the bulk stiffness of this new class of gels does not need to be modulated 
in order to access different differentiation lineages of the encapsulated stem cells. 
Uniquely, despite being embedded in a soft microenvironment, the hMSC 
commitment can be switched from adipogenesis to osteogenesis simply by altering 
the polymer chain length, and thus the critical stress. This keeps the matrix stiffness 
and ligand density unaltered in the process. Such precise control of mechanical 
properties provides a platform for varying the stiffness and ligand density 
independently and allows for extracting their individual effects on stem cell fate. This 
culture system mimics the stiffness (0.2-0.4 kPa) of all the adult stem cell niches 
present in the human body (for example bone marrow, brain and adipose tissue) and 
hence provides a physiologically relevant soft 3D microenvironment for stem cells. 
This new system thus allows for assessing the effect of stress-stiffening on stem cell 
differentiation in a biologically relevant stress regime (Figure 5.1). It represents a soft 
3D physiological microenvironment that can be tuned independently of matrix 
stiffness, ligand density and matrix porosity, thereby improving upon the traditional 
synthetic ECM mimetic scaffolds. Moreover, the thermoresponsive behavior of this 
hydrogel is advantageous for tissue engineering applications as the material can be 
injected as a fluid, which can then form a gel in vivo (37 ºC).  
 In recent years, after the seminal study of Engler and coworkers, bulk matrix 
stiffness has emerged as the most important mechanical cue to direct stem cell 
differentiation,17 especially for 2D hydrogels. Recent work culturing stem cells in 3D 
hydrogels has, however, identified other crucial factors such as cellular traction-
induced local deformation of the matrix (leading to integrin-ligand clustering),19 cell-
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mediated matrix degradation20 and mechanical constraints. All these factors act in 
concert and are independent of the bulk matrix stiffness. This indicates that the 
actual mechanism of MSC lineage selection is likely to be considerably more 
complex than solely being the result of a response to tissue matrix elasticity. For 
instance, altering the degree of cell spreading in 2D was shown to impact MSC 
osteogenic differentiation.9 This is not the case in vivo where the process of 
spreading in 3D is mechanically or physically constrained. When comparing with 2D 
cultures, most 3D systems show enhanced MSC osteogenesis with increased 
osteogenic gene expression, matrix formation and up-regulated autocrine BMP2 
signaling.34–37 The 3D culture system presented in this chapter mediates MSC 
osteogenesis in a very soft microenvironment similar to the one of the bone marrow 
niche, but different from the one reported in the study of Engler et al.17 The results 
identify stress-stiffening as a new key regulator of stem cell differentiation, and 
suggest that the mechanical response (stiffening) of a matrix to cellular traction may 
be as important as bulk matrix stiffness in cellular fate determination. Based on the 
present data, a synergy between cell-mediated ligand clustering and stress-stiffening 
may be crucial for determining stem cell fate. 
The exact sequence of events and the molecular mechanisms that determine 
the observed response to stress-stiffening remain to be unravelled. In this chapter a 
potential role of the microtubule-associated protein DCAMKL1 is shown. It is known 
from previous studies that DCAMKL1 regulates osteogenesis by antagonizing 
RUNX2, the master transcription factor for the osteoblast lineage.32 Using the PIC 
hydrogel system, a correlation is established between the critical stress of the 
hydrogels and the expression of RUNX2 and DCAMKL1, on both the mRNA and the 
protein level. RUNX expression was only detectable when the hMSCs were grown in 
gels with high critical stress, while the expression of DCAMKL1 decreased with 
increasing critical stress. A functional relationship between DCAMKL1 and RUNX2 
was further confirmed via DCAMKL1 gene silencing and overexpression. Overall, the 
critical stress of the 3D hydrogel system affects the expression of DCAMKL1 and 
RUNX2, which in turn is responsible for the observed switch in hMSC differentiation 
from adipogenesis to osteogenesis. 
In summary, the results and the previous reports have established a working 
model for understanding stress-stiffening mediated control of stem cell differentiation 
in polyisocyanopeptide 3D matrices. Initially, hMSCs sense the surrounding 
environment through the classical mechanisms described for 2D substrate rigidity 
perception via focal adhesion contacts and the actin cytoskeleton. Beyond the critical 
stress, this induces stress-stiffening of the surrounding polymer matrix. This can 
exert an overall tension on the cell in this 3D environment, which in turn is perceived 
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via the microtubule cytoskeleton that supports and controls cell shape. As previously 
shown, this can lead to microtubule reorganization and deformation. The extent of 
these deformations depends on the degree of stress-stiffening. Deformations can 
induce different conformational changes of signaling molecules co-localized at these 
deformation sites or of microtubule-associated proteins in order to activate or 
inactivate them. The activated proteins then mediate signal transduction via different 
signaling pathways in order to control the expression of various genes like for 
example different transcription factors for stem cell differentiation control. Further 
experiments are required with the new 3D culture system in order to precisely 
elucidate these mechanisms and the role of the stress-stiffening parameter in cell 
fate determination. 
 
5.4 Experimental section 
General procedure for the synthesis of azide-functionalized polymers38 
A solution of the catalyst Ni(ClO4)2 .6H2O (1 mM) in toluene/ethanol (9:1) was added to a solution of 
non-functionalized monomer 1 and azide-appended monomer 2 in freshly distilled toluene (50 mg/mL 
total concentration; molar ratio 1/2 = 100). The reaction mixture was stirred at room temperature 
(20 ºC) for 72 h. The resultant polymer was precipitated 3 times from dichloromethane in di-isopropyl 
ether and dried overnight in air. The polymer was characterized by rheology, viscometry and AFM 
analysis. 
Synthesis of P1ʹ: The catalyst to monomer (1 + 2) molar ratio used : 1/1000 
Synthesis of P2ʹ: The catalyst to monomer (1 + 2) molar ratio used : 1/2500 
Synthesis of P3ʹ: The catalyst to monomer (1 + 2) molar ratio used : 1/3000 
Synthesis of P4ʹ: The catalyst to monomer (1 + 2) molar ratio used : 1/4000 
Synthesis of P5ʹ: The catalyst to monomer (1 + 2) molar ratio used : 1/6000 
Synthesis of P6ʹ: The catalyst to monomer (1 + 2) molar ratio used : 1/8000 
 
Conjugation of azide-functionalized polymers with GRGDS peptide 
The GRGDS peptide was dissolved in borate buffer (pH 8.4) at a concentration of 2 mg/mL. A solution 
of 2,5-dioxopyrrolidin-1-yl 1-(bicyclo[6.1.0]non-4-yn-9-yl)-3,14-dioxo-2,7,10-trioxa-4,13-
diazaoctadecan-18-oate (BCN-NHS) in DMSO was added to the peptide solution in borate buffer in 
1:1 molar ratio and incubated for 3 h at room temperature (20 ºC). The formation of the BCN-GRGDS 
conjugate was confirmed by mass spectrometry.  MS calc.: 910.4, obtained: 911.4 
The azide-functionalized polymer (P1ʹ-P6ʹ) was dissolved in acetonitrile at a concentration of 
3 mg/mL. The appropriate volume of BCN-GRGDS dissolved in borate buffer was added to this 
solution (based on the molar equivalent of azide-functions of the polymer). This mixture was 
incubated for 72 h at room temperature (20 ºC). The resulting polymer-peptide conjugates (P1-P6) 
were precipitated by adding the reaction mixture drop wise to di-isopropyl ether. 
 
Determination of the amount of azides on the azide-functionalized polymer 
A dichloromethane solution of a BCN-functionalized lissamine dye was added to a dichloromethane 
solution of the polymer (1 mg/mL) in a 1:1.2 molar ratio w.r.t. the calculated amount of azides in an 
azide-functionalized polymer. The reaction mixture was rotated at 15 rpm in the dark for 12 h at room 
temperature (20 ºC). The polymer-dye conjugate was precipitated 4 times from dichloromethane in di-
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isopropylether. The precipitate was dried in air overnight and re-dissolved in dichloromethane. To 
determine the amount of dye coupled, the absorption spectra of all samples were recorded. An 
extinction coefficient of 138,428 mol-1 cm-1 was used at a wavelength of 559 nm to determine the 
amount of dye attached to the polymer and to calculate the amount of azide present on the polymer 
(Table 5.1).     
 
Rheology analysis  
The polymers were dissolved at a concentration of 2 mg/mL in alpha-MEM (without serum) by gentle 
rotation (7-8 rpm) at 4 oC on a 90o-rotor for 36 h. For determining the bulk stiffness of the gel, a 
temperature sweep rheology experiment was performed (plate-plate geometry; 250 µm geometry 
gap), by heating the solution from 5 oC to 37 ºC at a heating rate of 2 oC/min at a constant strain of 
2% and constant frequency of 1 Hz. This experiment was immediately followed by a time sweep 
experiment (5 min) at 37 ºC at a constant frequency of 1 Hz. The Gʹ value observed at the end of the 
experiment was taken as the equilibrium bulk stiffness of the gel at this temperature. For non-linear 
rheology, the previously described pre-stress protocol28 was employed immediately after the 
aforementioned time sweep experiment. 
 
Atomic force microscopy 
To visualize individual polymer chains and to determine the average length of the polymers, solutions 
(~1 µg/mL in CHCl3) were spin-coated (300 rpm for 20 seconds) on freshly cleaved mica substrates 
and imaged by AFM using tapping mode. Polymer lengths were determined using ImageJ software. 
The length of at least 150 polymer chains was determined to obtain the distribution and the mean of 
the polymer chain length for any particular sample. 
 
Cell culture 
Human Mesenchymal Stem Cells (hMSCs) were obtained from Lonza, Inc. (Switzerland). Cells were 
then cultured in alpha-MEM medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS), 
1% penicillin/streptomycin and incubated in a humidified atmosphere containing 5% (v/v) CO2 at 
37 °C. For the encapsulation of cells in the gels, the cell pellets were first obtained by centrifugation. 
Then, 500 µL of the cold polymer solution (~10 ºC) was added directly to the pellet, followed by a 
gentle pipetting up and down 3-4 times to ensure homogeneous mixing. This mixture was directly put 
onto a cover slip in a 6-well plate (also kept cold). Thereafter, the solution was sandwiched between 
two cover slips and the well plate was transferred to a 37 ºC incubator. The volume of the suspension 
was chosen (500 µL) in order to obtain hydrogel thickness in the range of 3 mm. After gel formation, 
the two cover slips were removed and alpha-MEM medium (without serum) was added. All cell culture 
experiments were carried out without any serum in the medium for the first 6 h of culture.12 Then, 
alpha-MEM medium with 10% serum was added. All cells were used at low passage numbers (≤4). 
They were subconfluently cultured and were seeded at 106 cells/mL for the purpose of the 
experiments and in order to avoid cell-cell contacts. 
The lineage commitment and differentiation of the gel-encapsulated hMSCs after 96 h and 3 
weeks of culture, respectively, were investigated with bipotential differentiation medium (1:1 v/v 
osteogenic and adipogenic media, Lonza). For all the experiments, a non-functionalized soft polymer 
gel (cell culture in growth medium) served as control. The live/dead viability assay at 3 weeks in these 
control gels indicated excellent cell viability. 
The pharmacological agents used were 50 µM Blebbistatin (EMD Biosciences-Calbiochem), 1 
µM cytochalasin D (Sigma) and 50 nM Taxol (Abcam). The hMSCs were exposed to each 
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pharmacological agent for 1 h, 24 h and 72 h, respectively, after seeding them in a modified polymer
gel. For the antibody inhibition studies, cells were pre-incubated with 5 ng/mL anti-α1, 2, 3 and 5-β1, 2 
(all from Santa Cruz Biotechnology). For competition experiments with soluble GRGDS peptides, the 
cells were incubated in 1 mL of cell culture media containing 200 µg of GRGDS peptides during 20 
min on plastic and then transferred to the polymer gels. To evaluate proliferation, total double-
stranded DNA content was determined using the PicoGreen assay as previously reported.39
Confocal microscopy
In order to assess the homogeneous distribution of the cells in the hydrogels, very thin slices of the 
gel were cut transversely at various depths, including the two interfaces. The fluorescently labeled 
cells encapsulated in the gel slices were imaged by confocal microscopy with a Leica SP5 confocal 
microscope, 10x objective, 0.3 NA. 400 µm thick z-stacks were then acquired every 2.39 µm and the 
3D images were reconstructed using the Imaris 7.0 software.
MTT assay
Cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay as described in the literature.40 The data are presented as a percentage of control 
viability. 
Live/dead staining
Cell viability was determined with the live/dead viability/cytotoxicity kit (Molecular Probes), according 
to the manufacturer’s protocol.
Real-time PCR analysis of gene expression
RT-PCR was performed as previously described.41,42 Briefly, total RNA was extracted using the 
RNeasy total RNA kit from Qiagen in accordance with the manufacturer’s instructions. Purified total 
RNA was used to obtain cDNA in a reverse transcription reaction (Gibco BRL) using random primers 
(Invitrogen). Real-time PCR was performed with SYBR green reagents (Bio-Rad). The data were 
analyzed using the iCycler IQTM software. The cDNA samples (1 µL in a total volume of 20 µL) were 
analyzed for the gene of interest and for the house-keeping gene GAPDH. The comparison test of the 
cycle-threshold point was used to quantify the gene expression level in each sample. The primers 
used for the amplification are listed in Table 5.2.
Table 5.2. Nucleotide sequences of primers used for quantitative RT-PCR detection.
Gene Primer Sequences 
Runx2 5'-GACGTGCCCAGGCGTATTTC-3'(Forward)
  5'-AAGTCTGGGGTCCGTCAAGG-3'(Reverse)
PPAR 5'-GGCTTCATGACAAGGGAGTTTC-3‘'(Forward)
5'-AACTCAAACTTGGGCTCCATAAAG-3‘ (Reverse) 
GAPDH 5'-GCAGTACAGCCCCAAAATGG-3'(Forward)
  5'-ACAAAGTCCGGCCTGTATCCAA-3'(Reverse)
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Western blotting 
After 96 h, the polymer gels were exposed to a cold environment (around 10 oC). The cell pellet was 
obtained by centrifugation. The cells were permeabilized (10% SDS, 25 mM NaCl, 10 nM pepstatin 
and 10 nM leupeptin in distilled water and loading buffer), boiled for 10 min and analyzed with 
reducing SDS-PAGE (Invitrogen). The proteins were transferred onto nitrocellulose, blocked, and 
labeled with HRP-conjugated antibodies (Invitrogen). The microtubule associated protein DCAMKL1 
was detected using the monoclonal anti-DCAMKL1 antibody (Santa Cruz Biotechnology). The 
transcriptional factor RUNX2 was detected with a monoclonal anti-Runx2 antibody (Abcam). All 
Western blots were run in triplicate, along with an additional blot for tubulin and Coomassie Blue 
staining to ensure consistent protein loading between samples. In order to construct the plot of the 
relative intensities of RUNX2 versus DCAMKL1 and to illustrate the switch-like relationship between 
the two proteins, the “zero” of the RUNX2 relative intensity was set at the corresponding level of 
expression of RUNX2 in hMSCs cultured on plastic, which was set to 1. 
 
Immunostaining 
After 96 h or 3 weeks of culture, the gels were exposed to a cold environment (~ 10 ºC). The cell 
pellet was collected from the fluid by centrifugation, transferred into the well plate and allowed to 
adhere to the well plate surface by culturing in alpha-MEM with serum for 16 h. The cells were then 
fixed for 20 min in 4% paraformaldehyde/PBS at ~37 °C. After fixation, the cells were permeabilized in 
a PBS solution containing 1% Triton X-100 for 15 min. The cells were then incubated with the 
corresponding primary antibodies (mouse anti-vinculin for adhesion; mouse anti-STRO-1 for 
differentiation) for 1 h at 37 °C. After washing, cells were stained with Alexa Fluor® 647 rabbit anti-
mouse IgG secondary antibody for 30 min at ~ 37 °C. Cell cytoskeletal filamentous actin (F-actin) was 
visualized by treating the cells with 5 U/mL Alexa Fluor® 488 Phalloidin (Sigma, France) for 1 h at 37 
°C. Vinculin was visualized by treating the cells with 1% (v/v) monoclonal anti-vinculin (clone hVIN-1 
antibody produced in mouse) for 1 h at 37 °C. The cells were then stained with Alexa fluor® 568 
(F(ab′)2 fragment of rabbit anti-mouse IgG(H + L)) during 30 min at room temperature. After 96 h, 
Osterix was visualized by treating the cells with 1% (v/v) rabbit monoclonal anti-Osterix (antibody 
produced in rabbit) for 1 h at 37 °C. The cells were then stained with Alexa fluor® 568 (F(ab′)2 
fragment of mouse anti-rabbit IgG(H + L)) during 30 min at room temperature. Tubulin (stained by 
Anti-Tubulin β3 (Sigma, France)) was visualized by treating the cells with 1% (v/v) monoclonal anti-
Tubulin β3 (Abcam, Cambridge), for 1 h at 37 °C and then with Alexa Fluor® 588 (F(ab’)2 fragment of 
goat anti-rabbit IgG(H+L)) for 30 min at room temperature. There was no detection of the muscle 
transcription factor MyoD1 (stained with anti-MyoD1 (Santa Cruz Biotechnology, USA)). To stain lipid 
fat droplets, the cells were fixed in 4% paraformaldehyde, rinsed in PBS and 60% isopropanol, 
stained with 3 mg ml−1 Oil Red O (Sigma, France) in 60% isopropanol and rinsed in PBS at ~ 37 °C. 
For the purpose of assessing cell differentiation in 3D via Oil Red O staining, gel slices of the middle 
of the gel (height range at around 1.2-1.6 mm depth) are usually stained and imaged.  
For quantification14,15,43,44 of STRO-1, Osterix, Tubulin β3, MyoD1 and lipid fat droplets, 
positive contacts number and areas, the freeware image analysis ImageJ® software was used. First 
the raw image was converted to an 8-bit file, and the “unsharp mask” feature (settings 1:0.2) was 
used to remove the image background (rolling ball radius 10). After smoothing, the resulting image, 
which appears similar to the original photomicrograph but with minimal background, was then 
converted to a binary image by setting a threshold. The threshold values were determined by 
selecting a setting, which gave the most accurate binary image for a subset of randomly selected 
photomicrographs with varying glass substrates. The total contact area and mean contact area per 
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cell were calculated by “analyse particules” in Image J. A minimum of 20-30 cells were analyzed per 
condition.  
 
Statistical analysis 
In terms of fluorescence intensity, sub-cell contact area and real-time PCR assay, the data were 
expressed as the mean ± standard error, and were analyzed using the paired Student’s t-test method. 
Significant differences were designated for P values of at least <0.01.  
 
Overexpression of DCAMKL1 
The overexpression of DCAMKL1 was performed as previously described by Lin et al45. Briefly, 
Human DCAMKL1 was cloned by RT-PCR using primers directed toward the human sequence and 
subsequently sequenced. Full-length human DCAMKL1 was subsequently cloned into the KpnI site of 
pcDNA3.1C(-) (Invitrogen, Carlsbad, CA) and overexpressed by transient transfection with Super-
fectamine (Qiagen, Chatsworth, CA) according to the manufacturer’s recommendations. The 
efficiency of the DCAMKL1 overexpression was assessed by Western blot for hMSCs cultured on 
plastic. A 180-200% increase in protein level was observed after 72 h.  
 
DCAMKL1 shRNA silencing 
DCAMKL1 silencing has been performed by transfecting hMSCs with a pool of 3 target-specific 
lentiviral vector plasmids each encoding 19-25 nt (plus hairpin) shRNAs designed to knock down 
gene expression (Santa Cruz Biotechnology). A mock plasmid was transfected as a control. Transient 
transfection was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's 
protocol. The efficiency of the DCAMKL1 silencing was assessed by Western blot for hMSCs cultured 
on plastic. The DCAMKL1 silencing decreased the DCAMKL1 mRNA level by 50-60% (not shown) 
and the DCAMKL1 protein level by 60-70% after 24 h. 
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5.5 Appendix 5.1: Supplementary figures 
Figure A5.1.1. a)-f) Representative AFM images of dilute (1 µg/mL) chloroform solution of polymers 
P1-P6, respectively, drop-casted on freshly cleaved mica. Scale bar: 500 nm for a)-e) and 1 µm for f).
Figure A5.1.2. a)-f) Histograms showing the length distribution of single polymer chains in individual 
polymers (P1-P6), as obtained by observing at least 150 single polymer chains in AFM for dilute (1 
µg/ mL) chloroform solution of the polymers, drop-casted on freshly cleaved mica. These data were 
used to obtain the mean polymer length for the polymers.
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Figure A5.1.3. a) Non-linear rheology data of polymer gels P1-P6 in alpha-MEM at 2 mg/ mL. The 
differential modulus Kʹ, scaled with the storage modulus Go, is plotted as a function of applied stress 
σ. The experiments were repeated in triplicate and the mean plots are shown. b) Overlay of the plots 
of differential modulus Kʹ as a function of applied stress σ, for the gels of shortest (P1) and the longest 
(P6) polymer. σC denotes the critical stress for the onset of stress-stiffening. 
 
Figure A5.1.4. Representative time sweep rheology experiments after incubating the cold polymer 
solution at 37°C at an applied strain of 1% at a frequency of 1 Hz. 
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Figure A5.1.5. Confocal microscopy. 400 µm Z-stack side view (X,Z projections) images showing the 
top, middle and bottom distribution of gel-encapsulated hMSCs (after 96 h of culture) stained with 
calcein-AM. Scale bar: 200µm.
Figure A5.1.6. Representative micrographs showing cross-sections of hMSCs (DAPI staining) 36 h 
after encapsulation into the 3D soft hydrogel. On the right, hMSCs are shown in bright-field, DAPI, F-
actin and vinculin stainings. Left scale bar: 50 µm and right scale bar: 10 µm.
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Figure A5.1.7. Live-dead viability test at different time points, for hMSCs encapsulated in control 
polymer gels (non-functionalized) in growth medium by a) calcein-AM (live cells fluoresce green), and 
by b) MTT assay. Scale bar: 20 µm.  
Figure A5.1.8. Total DNA content for hydrogels assembled from short and long polymers (P1, P3, P4
and P6) after 48 h and 96 h of cell culture as determined by the PicoGreen assay. A non-
functionalized hydrogel served as a control. Error bars, s.e.m. (n ≥ 3). NS. not significant (P > 0.05), 
Student’s t-test.
Figure A5.1.9. Representative bright-field images (Oil red O staining) of hMSCs encapsulated in gels 
assembled from the polymers P1-P6 after 96 h of culture in bipotential (osteogenic/adipogenic) 
medium. Scale bar: 10 µm.  
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
Pl
as
tic
 4 14
 
21
 
M
TT
 (%
 c
on
tr
ol
) 
Time (days) 
a b 
4d 14d 21d 
N.S 
0 
5 
10 
15 
20 
25 
30 
C
on
tro
l 
P1
 
P3
 
P4
 
P6
 
D
N
A 
co
nt
en
t (
ng
) 
D
N
A 
co
nt
en
t (
ng
) 
D
N
A
48h 
96h 
Processed on: 10-10-2016
505747-L-bw-Hammink
Stress-stiffening-mediated stem-cell commitment switch in soft responsive hydrogels
123 
Figure A5.1.10. Mean percentages of hMSC osteogenesis a) and adipogenesis b) in different 
hydrogel materials from polymers P1-P6 after 96 h of culture in bipotential medium. A non-
functionalized hydrogel (cell culture in growth medium) served as a control. Error bars, s.e.m. (n ≥ 3). 
NS. not significant (P > 0.05), *P < 0.05; Student’s t-test. 
Figure A5.1.11. a) Immunofluorescent staining for OPN (red), actin (green), and nucleus (blue) in 
hMSCs encapsulated in different hydrogel materials from polymers P1-P6 after 3 weeks of culture in 
bipotential medium. Scale bar: 100 µm. b) Total cellular immunofluorescence intensity of osteopontin
quantified for hMSCs cultured for 3 weeks in different matrices. c) Triglyceride detection on hMSCs 
after 3 weeks on cell culture. A non-functionalized hydrogel (cell culture in growth medium) served as 
a control for all the experiments. Error bars, s.e.m. (n ≥ 3). NS. not significant (P > 0.05), *P < 0.05; 
Student’s t-test. 
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Figure A5.1.12. hMSCs commitment studies after 96 h of culture in different polymer gels in the 
presence of anti-integrin antibodies α1, 2, 3, 5 and β1, 2. a) Quantitative PCR analysis for RUNX2. No 
significant differences were observed between the matrix with the highest critical stress (P6) and the 
matrices displaying lower critical stress. b) Total cellular immunofluorescence area of neutral lipid 
accumulation in hMSCs. For all the experiments, a non-functionalized hydrogel (cell culture in growth 
medium) served as the control (*P < 0.01).
Figure A5.1.13. Mean percentage of hMSC osteogenesis a) and adipogenesis b) in different polymer 
gels in the presence of anti-integrin antobodies α1, 2, 3, 5 and β1, 2. A non-functionalized hydrogel 
(cell culture in growth medium) served as the control. Error bars, s.e.m. (n ≥ 3). NS. not significant (P
> 0.05), *P < 0.01; Student’s t-test.
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Figure A5.1.14. The amount of STRO-1 present in the hMSCs. The values represent the average 
fluorescence intensity, normalized by the number of cells. Compared to the control (non-
functionalized hydrogel), STRO-1 activity is present on matrices + blebbistatin, indicating that the 
hMSCs have kept “stemness” after 96 h of culture in bipotential medium.
Figure A5.1.15. hMSCs commitment studies after 96 h of culture in different polymer gels in the 
presence of soluble GRGDS ligands. a) Quantitative PCR analysis for RUNX2. No significant 
increase in RUNX2 gene expression was observed for all the matrices and no significant differences 
could be detected between matrices displaying a higher (P4 and P6) and lower (P1 and P3) critical 
stress in the presence of soluble GRGDS. b) Total cellular immunofluorescence area of neutral lipid 
accumulation quantified for hMSC cultured for 96 h in different matrices. No significant increase in 
lipid accumulation was observed for all the matrices and no significant differences could be detected 
between the different polymers. For all the experiments, a non-functionalized soft polymer gel (cell 
culture in growth medium) served as a control. NS. not significant (P > 0.05). Student’s t-test. 
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Figure A5.1.16. Mean percentage of hMSC osteogenesis a) and adipogenesis b) for different 
polymer gels (P1, P3, P4 and P6) in the presence of soluble GRGDS ligands. A non-functionalized 
hydrogel served as a control. Error bars, s.e.m. (n ≥ 3). NS. not significant (P > 0.05), Student’s t-test.
Figure A5.1.17. Commitment of hMSCs at different ligand densities (7 nm, 28 nm and 70 nm) in 
polymer gels displaying the lowest and highest critical stress (P1 and P6, respectively). a) 
Quantitative PCR analysis for RUNX2. b) Total cellular immunofluorescence area of neutral lipid 
accumulation quantified for hMSC cultured for 96 h in bipotential medium. For all the experiments, a 
non-functionalized soft polymer gel (cell culture in growth medium) served as the control (*P < 0.005).
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Figure A5.1.18. Immunofluorescent staining for MyoD, Tubulin β3 and Osterix in hMSCs 
encapsulated in different hydrogel materials from polymers P1-P6 in the presence of a) Cytochalasin 
D and b) Taxol (inhibitor of actin and inductor of microtubule cytoskeleton polymerization) after 96 h of 
culture in bipotential medium. For the control naïve hMSCs were encapsulated in a non-functionalized 
soft hydrogel and cultured in growth medium. 
Figure A5.1.19. Calcein-AM live-dead viability test (live cells fluoresce green) at different time points 
(48 h and 96 h) for hMSCs treated with Taxol and encapsulated in polymer gel P3 in growth medium. 
Scale bar: 20 µm. 
Figure A5.1.20. a) Western blot showing RUNX2 protein expression for hMSCs cultured on plastic for 
24 h and 96 h. b) Relative protein expression for RUNX2 and DCAMKL1 of hMSCs grown in polymer 
gels P1-P6. The values have been obtained from the Western blot presented in Figure 5.4a. The 
graph clearly showing a switch-like relationship between the two proteins.
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Figure A5.1.21. a) shRNA mediated DCAMKL1 silencing was induced, as shown by Western blot for 
hMSCs cultured on plastic for 24h. b) Overexpression of DCAMKL1 was enabled by transient 
transfection with a plasmid subcloned with the DCAMKL1 gene, as shown by Western blot for hMSCs 
cultured on plastic for 72h. c) Non transfected cells or cells at 48 h post-transfection (mock plasmid, 
shRNA or DCAMKL1) were incorporated into GRGDS-functionalized hydrogels (P1 or P6) for 96 h. 
Relative RUNX2 mRNA levels were then measured using RT-PCR. Non-transfected cells 
incorporated into non-functionalized hydrogels served as a control. *P < 0.001; ** represents the 
comparison between GRGDS-functionalized polymers and +DCAMKL1 for the P6 hydrogel and P < 
0.05 ; Student’s t-test. 
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Chapter 6: DNA-responsive polyisocyanopeptide hydrogels with 
stress-stiffening capacity 
 
6.1 Introduction 
Biomimetic stimuli-responsive hydrogels have gained a lot of attention in the 
materials science community, both from a fundamental and an application point-of-
view.1–5 In particular, the high specificity and predictability of DNA self-assembly has 
allowed for the design and synthesis of many functional DNA-hybrid hydrogels that 
are responsive to various external stimuli (such as  pH,6 temperature,7 DNA8) with 
applications in sensing,9  purification,10 controlled release7,11 and as bio-scaffolds.12,13 
Just as most other synthetic hydrogels, DNA-hybrid hydrogels lack one crucial 
property present in natural materials: the ability to stress-stiffen, i.e. to become stiffer 
when stressed beyond a certain critical stress (σC). Furthermore, these hydrogel 
assemblies are limited by slow reaction kinetics and the large DNA quantities needed 
for a measurable response. In this chapter a novel DNA cross-linked hydrogel is 
presented. This hydogel stress-stiffens in the biologically relevant stress range and  
is sensitive to micromolar concentrations of DNA.   
This hydrogel is based on a previously developed synthetic, thermo-
responsive hydrogel that consists of helical oligo(ethylene glycol)-functionalized 
polyisocyanopeptides (PIC).14,15 These PIC hydrogels form a biomimetic network that 
stress-stiffens in a stress regime similar to natural scaffolds assembled from 
extracellular (collagen, fibrin) or intracellular (F-actin, microtubules) biopolymers.16,17 
Moreover, the onset of stress-stiffening was identified as an important parameter for 
controlling stem cell fate in these 3D biomimetic hydrogel scaffolds.18 In this chapter, 
the favorable properties of DNA as a stimuli-responsive supramolecular assembly 
unit are combined with the stress-stiffening PIC hydrogel to achieve full user-defined 
control of its mechanical properties.19 Single stranded (ss) DNA was grafted to PICs 
and these anchor points were used to cross-link the PIC polymers with a bridging 
complementary DNA strand. A thorough rheological analysis was used to precisely 
determine the influence of various parameters (cross-linker DNA, polymer 
concentration, polymer length and temperature) on the mechanical properties of the 
hydrogel. The stress-stiffening properties of the PIC hydrogel are shown to be 
retained in the DNA cross-linked hydrogel, and the stiffness and critical stress of the 
hydrogel network can be conveniently tuned by the DNA cross-linker concentration. 
Furthermore, the DNA-mediated gelation process can be reversed by adding 
toeholds on the bridging DNA, thereby allowing full bi-directional control of the 
mechanical material properties. This combination of thermo-responsive PIC polymers 
Processed on: 10-10-2016
505747-L-bw-Hammink
DNA-responsive polyisocyanopeptide hydrogels with stress-stiffening capacity 
 
 
133 
with controllable and responsive DNA elements offers a versatile platform with 
various potential applications in biomedical and materials sciences. 
 
6.2 Results 
 
6.2.1 Synthesis and characterization of DNA-responsive polyisocyanopeptide 
hydrogels 
The synthesis and working principle of the DNA-responsive hydrogel are 
depicted in Figure 6.1. It is based on tetra(ethylene glycol)-functionalized PIC 
polymers. Azide-functionalized PICs were synthesized via a nickel(II)-catalyzed co-
polymerization of the tetra(ethylene glycol)-functionalized isocyano-(D)-alanyl-(L)-
alanine monomer and the corresponding azide-appended monomer, similar as 
described in chapter 2 of this thesis.20 Using a 30:1 molar ratio of the corresponding 
monomers, the statistical average distance between the functional azide groups on 
the polymer chains was 3.5 nm. These azide moieties were subsequently used to 
couple ssDNA oligonucleotides functionalized with a strained alkyne.21 For DNA 
coupling,  5’-NH2-DNA A and 3’-NH2-DNA B (Table 6.1) were first reacted with the 
NHS ester-functionalized azadibenzocyclooctyne DBCO-PEG4-NHS. The DBCO-
groups were subsequently coupled to the azide-functionalized PIC using a strain 
promoted azide-alkyne cycloaddition reaction22, resulting in two different DNA 
functionalized polymers PIC-DNA A and PIC-DNA B, respectively. The 3’-11 
nucleotides of DNA A and 5’-11 nucleotides of DNA B were designed to complement 
DNA C (22 nucleotides) to form cross-links between the PIC-DNA A and PIC-DNA B 
polymers. A high reaction efficiency (~90 % ssDNA coupling) was obtained as 
determined using a fluorogenic coumarin dye assay that quantifies the concentration 
of DBCO (Figure A6.1.1). 
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Figure 6.1. Synthesis of the DNA-responsive PIC hydrogel. The N3-containing PIC polymer is 
functionalized with DNA carrying a DBCO reactive group. The resulting PIC-DNA A and PIC-DNA B 
conjugates are mixed with cross-linker DNA C to induce hydrogel formation at room temperature. 
Staining the dsDNA elements with ethidium bromide in an inverted Eppendorf tube proves the 
formation of a stable hydrogel network. 
 
Table 6.1. DNA sequences used in this study.  
Single-stranded DNA DNA Sequence (5'-->3') 
No. of 
Nucleotides 
DNA A NH2-TTT TTT TCA ACA TCA GT 17 
DNA B CTG ATA AGC TAT TTT TT-NH2 17 
DNA C TAG CTT ATC AGA CTG ATG TTG A 22 
Non-complementary DNA 
(NC) TCA ACA TCA GTC TGA TAA GCT A 22 
DNA C' C CAC ATA CAT TAG CTT ATC AGA CTG ATG TTG A 32 
DNA D TCA ACA TCA GTC TGA TAA GCT AAT GTA TGT GG 32 
DNA M TAG CTT ATC AGA CTG ATG TTA A 22 
 
The PIC polymer exhibits a temperature-dependent sol-to-gel transition as a 
result of polymer bundling induced by the hydrophobic aggregation of the 
tetra(ethylene glycol) tails.17,18 To obtain a first proof that DNA cross-links can 
promote gel formation below the PIC transition temperature, the rheological 
properties of samples prepared from polymers of different length were investigated 
over a range of different temperatures. Four DNA-functionalized PIC polymers were 
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synthesized with different average lengths of 125 nm (P1), 225 nm (P2), 297 nm (P3) 
and 350 nm (P4) by varying the nickel catalyst to monomer ratio (a lower ratio 
corresponds to a higher average polymer length). Polymer lengths were estimated 
using atomic force microscopy (Figure A6.1.2 and Figure A6.1.3). PIC-DNA A and 
PIC-DNA B polymers of identical length were mixed with complementary DNA C at 
4 °C to facilitate easy handling. The total polymer concentration was kept constant at 
1.8 mg mL-1 for all experiments.  
Hydrogel formation was analyzed using rheological measurements over a 
range of different temperatures in the absence or presence of complementary DNA C 
in near stoichiometric amounts. For the longest DNA-functionalized polymer P4,  a 
sharp sol-to-gel transition was observed at ~39 °C in the absence of DNA C (Figure 
A6.1.4a). In contrast, no sol-to-gel transition was detected for the shortest polymer 
P1 measured under identical conditions. A very weak gel was only formed when the 
sample was heated above 50 °C (Figure A6.1.4b). When DNA C was added, 
however, stable hydrogels already formed at room temperature, independent of 
polymer length (Figure 6.2a). The presence of a network was confirmed by cryo-
scanning electron microscopy of the DNA cross-linked P4 hydrogel, which showed a 
fibrous and porous structure (Supporting Information, Figure A6.1.5). The addition of 
a non-complementary DNA strand (Figure 6.2b) did not result in hydrogel formation 
at room temperature. These results clearly show that the DNA interaction is able to 
induce gel formation below the PIC gelation temperature, independent of the 
previously established gelation mechanism dominated by hydrophobic interactions 
between PIC polymers. 
 
6.2.2 Detailed rheological analysis of DNA-responsive polyisocyanopeptide 
hydrogels 
The mechanical properties of the DNA cross-linked gels were subsequently 
characterized in more detail at 30 °C, where the PIC-DNA polymers do not gelate 
without the addition of cross-linker DNA. First, the kinetics of gel formation were 
determined by following the time evolution of the storage modulus (Gʹ) after the 
addition of cross-linker DNA C to a pre-mixed solution of PIC-DNA A and PIC-DNA B. 
All four polymers formed DNA cross-linked gels within seconds, as demonstrated by  
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Figure 6.2. Kinetic rheology measurements of DNA cross-linked hydrogels at fixed frequency (1 Hz) 
and strain (2%) at 30 °C in PBS, 10 mM MgCl2, pH 7.4. a) Time evolution of the storage modulus (G') 
after addition of cross-linker DNA C to DNA A and DNA B functionalized PIC polymers P1-P4 at 1.8 
mg mL-1 with cross-linker ratio (R) of 0.9. The inset shows the plateau modulus (G0) as a function of 
polymer length. b) Time evolution of G' after addition of cross-linker DNA C at R = 0.1, 0.3, 0.6, 0.9 
and 1.2 as well as non-complementary DNA NC. The inset shows the dependence of G0 on R. c) G0 
as a function of concentration of the DNA functionalized polymers P3 and P4 (cp = 0.6, 0.9, 1.2, 1.5, 
and 1.8 mg mL-1) at R = 0.9. The solid lines are power law fits and show that P3 scales with cp2.4 and 
P4 scales with cp2.1. d) Differential modulus (K’) against stress (σ) for the DNA cross-linked P4 
hydrogel at different R (0.1, 0.3, 0.6, and 0.9) showing stress-stiffening behavior of the PIC-DNA 
hydrogel. The inset shows that the critical stress (σC) scales directly with R. 
 
a
P1 P2
P3 P4
St
or
ag
e
M
od
ul
us
G
'(P
a)
Time(seconds)
0 1000 2000 3000 4000
10-1
100
101
102
0.1 0.3
0.6 0.9
1.2 NC(0.9)
b
R (cross- linker DNA equivalents)
100 10110-110-2
St
or
ag
e
m
od
ul
us
G
’(P
a)
Time (seconds)
0 1000 2000 3000 4000
10-1
100
101
102
m
od
ul
us
G
0(P
a)
100
101
102
Pl
at
ea
u
G0~R
1.4
Polymer Length (nm)
100 200 300 400
100
101
102
G0~L
2.3
m
od
ul
us
G
0(P
a)
Pl
at
ea
u
c d
10-1 100 101
100
101
102 constant R
G0~Cp
2.4
G0~Cp
2.1
P3 P4
Polymer concentration (mgml-1)
Pl
at
ea
u
m
od
ul
us
G
0
(P
a)
10-1 100 101 102
100
101
102
103
0.1 0.3
0.6 0.9
10-1 100 101
10-1
100
101
C
rit
ic
al
st
re
ss
(
m
c
)
Pa
R
D
iff
er
en
tia
l M
od
ul
us
 K
’ (
Pa
)
Stress mPa	 
10-2
R 0.8~mc
Processed on: 10-10-2016
505747-L-bw-Hammink
DNA-responsive polyisocyanopeptide hydrogels with stress-stiffening capacity 
 
 
137 
a rapid increase of Gʹ. The storage modulus levels off to plateau modulus G0 over a 
period of 1 hour (Figure 6.2a). G0 scales with polymer length L as G0  L2.3 (Figure 
6.2a inset). This is in perfect agreement with theoretical predictions for hydrogels 
derived from semi-flexible biopolymers23 and compares to values reported for non-
functionalized PIC hydrogels.17,18 These results suggest that the DNA cross-linked 
hydrogel possesses similar mechanical properties at 30 °C as the original 
hydrophobically bundled PIC hydrogel that only forms at temperatures above 50 °C.  
The mechanical properties of semi-flexible polymer networks do not only 
depend on polymer length, but also on the density of cross-links. Using the P4 
hydrogel, the influence of the DNA C concentration on gel stiffness was investigated. 
An optimal response, as expressed in the highest G0 value, was obtained at 0.9 
equivalents of cross-linker DNA C with respect to the DNA concentration (50 µM) on 
the PIC-DNA A and PIC-DNA B polymers (Figure 6.2b). As expected, an excess (1.2 
eq.) of DNA C led to a lower gel stiffness due to saturation of the A and B binding 
sites. Importantly, stable DNA cross-linked hydrogels were already formed at DNA 
cross-linker concentrations as low as 5 µM. This is much lower than observed for 
other synthetic DNA cross-linked hydrogels, which generally require DNA 
concentrations above 1 mM to maintain a well-defined gel state.9,24–26 G0 scales with 
the cross-linker DNA concentration (defined as the ratio R: DNA C/DNA A or  DNA B)  
as G0  Rn with n = 1.4 for P4  (Figure 6.2b). Additionally, G0 scales with the polymer 
concentration (cp) as G0  cpn with n = 2.3 for P3 and 2.1 for P4 at constant R (0.9) 
(Figure 6.2c). These observations are fully consistent with theoretical predictions27,28 
(G0  cp11/5) and experimental observations of bundle formation in cross-linked semi-
flexible biopolymer networks. For example, in fascin-directed self-assembly of the 
cytoskeletal protein actin G0 scales with the actin polymer and fascin cross-linker 
concentrations with n equals ~1.5 and ~2.4, respectively.29,30 For the assembly of 
intermediate filaments G0  cp2-2.5 was observed.31  
  The DNA cross-linked PIC hydrogels exhibit the same mechanical response 
as the original PIC hydrogel and typical protein-based networks in the linear 
rheological regime. As mentioned before, the key fundamental property of semi-
flexible biopolymer networks is their stress-stiffening behavior. The next goal was 
therefore to establish if this similarity also extended to the nonlinear regime. 
Accordingly, the mechanical behavior of the DNA cross-linked P4 gel (at 0.9 eq. 
DNA C) was studied in the non-linear regime, using a previously described pre-stress 
protocol at 30 °C.17 The gel was subjected to a constant increasing pre-stress (σ) 
with a small oscillatory stress (δσ) superposed upon it. The resultant oscillatory strain 
(δγ) was recorded to extract the differential modulus Kʹ (= δσ/δγ) at a specific 
frequency (1 Hz) for each value of σ. To validate the suitability of this measurement, it 
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was first experimentally verified using low-frequency rheological measurements that 
the cross-linked P4 gel did not relax on a time scale 10 times the measurement time, 
even in very soft regimes (Figure A6.1.6). Plotting K′ as a function of applied stress 
for different concentrations of cross-linker DNA, clearly showed a linear regime at low 
σ and a non-linear regime at higher σ for all tested concentrations (Figure 6.2d). G0 
showed a G0  σC1.5 dependence (Figure A6.1.7), which is again in perfect 
agreement with theory as well as experimental observations for intermediate filament 
gels.31 The critical stress σC scaled linearly with the cross-linker concentration (Figure 
6.2d) even at very low stress values of 0.5 - 4 Pa.  
 These results establish that this new class of DNA cross-linked PIC hydrogels 
perfectly mimics the mechanical properties of semi-flexible biopolymer networks. This 
newly developed hybrid material shows a biomimetic mechanical response in the 
biologically relevant stress range, spanning across both the linear and non-linear 
regime. The scaling response of G0 and σC towards DNA cross-linker concentration 
makes this an effective parameter to tune the mechanical properties of this new 
biomimetic hydrogel.   
 
6.2.3 Dual responsiveness of DNA cross-linked polyisocyanopeptide hydrogels 
   To better define the contribution of cross-link stability to gel formation and to 
explore the interplay between DNA-cross-linked hydrogels and hydrophobically-
cross-linked PIC hydrogels, the rheology temperature profiles of the P4 DNA-cross-
linked hydrogel were examined in more detail. At high DNA C ratios (> 0.3 eq. 
DNA C), first a slight increase followed by a decrease in G' is observed upon raising 
the temperature (Figure 6.3a). The increase originates from the onset of PIC gelation 
as the same trend is observed in the absence of DNA C or at very low DNA C ratios 
(0.1 eq.). Simultaneously, the storage to loss modulus ratio G'/G'' starts to decrease, 
however. It is lowest at the melting temperature of the 22 base pair (bp) nicked DNA 
duplex  (45 °C, Figure A6.1.8), indicating a transformation from gel to viscous 
material upon DNA dissociation. When the temperature is further increased, the 
G'/G'' ratio starts to increase again and eventually follows the trend observed for the 
non-cross-linked PIC polymer. Apparently, the hydrophobic bundling of the 
tetra(ethylene glycol) tails of the PIC polymers starts to dominate at temperatures 
above the DNA melting temperature, causing the material to adopt the mechanical 
properties of a normal PIC hydrogel (Figure 6.3a, Figure A6.1.9). 
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Figure 6.3. Temperature dependent gelation of PIC-DNA hydrogels. a) G' as a function of 
temperature for the P4 hydrogel at different cross-linker C ratios (R = 0.1, 0.3, 0.6 and 0.9), including a 
control sample without cross-linker DNA (PBS, 10 mM MgCl2, pH 7.4). b) G' as a function of 
temperature for the DNA-P4 at R = 0.9 upon raising (orange) and lowering (yellow) the temperature. 
The insets show schematics of different gelation states.
The observed temperature profiles are consistent with an additive effect of 
DNA and hydrophobically-induced gelation of PIC hydrogels. Upon heating, the 
material undergoes a transition from a DNA-cross-linked hydrogel to a PIC-bundled 
hydrogel. It should therefore be possible to control the temperature-dependent 
mechanical properties of the hydrogel using DNA cross-links of different 
thermodynamic stability. Indeed, the downward transition attributed to DNA melting 
was shifted to lower temperatures when using a DNA cross-link containing a single 
mismatch (DNA M, Table 6.1). The observed 8 °C shift is in perfect agreement with 
the 8 °C lower melting temperature of the mismatched DNA duplex (Figure A6.1.10). 
We next introduced a DNA linker with the highest possible stability by introducing a 
covalent DNA cross-link. This covalent cross-link was obtained by enzymatic splint-
ligation of the DNA ABC duplex. In this case a gradual increase in G’ was observed 
(Figure A6.1.11), clearly showing the additive effect of DNA and hydrophobic cross-
links. This interplay between DNA hydrogel and PIC hydrogel stability, which can be 
controlled by base pair composition and polymer length, opens the possibility for 
tuning and further separating the gel-to-sol and sol-to-gel transitions upon raising the 
temperature.  
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These observations are consistent with a model of gel formation as depicted in 
Figure 6.3b. Addition of DNA C to PIC-DNA A and PIC-DNA B at temperatures below 
the DNA melting and PIC gelation temperatures initially zips single polymer chains 
together to form a partially bundled network. A zipping mechanism instead of a 
random intermolecular interaction can be expected. The distance between adjacent 
DNA molecules on the polymers is only ~6 nm. In contrast, the average cross-
distance between polymers as estimated from the total polymer length per volume 
unit (0.21 x 1015 m-2 at 1.8 mg mL-1 PIC) is ~52 nm. After linking, the DNA cross-
linker length of ~13.5 nm (12 nt ssDNA + 22 bp double stranded DNA) brings the PIC 
polymers closer together, which can promote PIC bundling. Upon raising the 
temperature, the DNA cross-links are disrupted at the DNA melting temperature, 
thereby allowing the partially bundled network to evolve into a bundled network 
dominated by hydrophobic interactions. This is confirmed by the temperature 
dependence of σC and the independence of σC from the DNA cross-linker ratio at 
60 oC (Figure A6.1.9). This simple model predicts hysteresis for the first heating-
cooling cycle. If a DNA-functionalized PIC bundled network is cooled down, cross-
linker C can anneal to already bundled PIC polymers thereby stabilizing the existing 
structure. Indeed, cooling the network back to 30 oC shows a different profile resulting 
in a higher G' when compared to the original DNA cross-linked gel. This clearly 
suggests a higher order of the re-assembled DNA hydrogel. This effect of pre-
bundling remains identical with subsequent heating-cooling cycles (Figure 3b, Figure 
A6.1.12). 
 
6.2.4 Dynamic control of the mechanical properties of DNA cross-linked 
polyisocyanopeptide hydrogels 
Modulating the mechanical properties of hydrogels in a user-defined dynamic 
way is of critical importance in a variety of materials science applications.12,32 In order 
to demonstrate dynamic control over the DNA cross-linked P4 gel, a soft gel (G0 ~10 
Pa) was prepared by adding 0.3 equivalents of the cross-linker DNA C (Figure 6.4a). 
Within 1 hour after adding a higher amount (0.3 or 0.6 eq.) of  DNA C the preformed 
gel was converted into a stiffer gel with G0 ~25 Pa and ~31 Pa, respectively, while σC 
remained similar (Figure 6.4a,b and A6.1.13a,b). Conversely, softer gels could be 
generated from stiffer hydrogels using toehold-mediated strand displacement (Figure 
A6.1.14). Using this approach, an incoming DNA strand first binds to a short stretch 
of single-stranded nucleotides (the toehold) next to a double-stranded duplex. 
Toehold binding is followed by displacement of one or more pre-hybridized strands in 
the original duplex through branch migration.33 DNA cross-linker C was extended with 
a 10 nucleotide toehold sequence to yield DNA C’ (Table 6.1). This sequence was 
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used to prepare a hydrogel at 0.9 equivalents of DNA C’. The DNA C’ hydrogel 
showed the same mechanical properties as the original DNA cross-linked gel (Figure 
A6.1.15). Strand displacement was initiated by adding the complement of C', DNA D 
(Table 6.1) at 0.3 or 0.6 equivalents to this pre-formed gel. The network dissolved 
rapidly into a softer gel with a marked decrease in G0 as well as σC (Figure 6.4c,d 
and Figure A6.1.13c,d). Together, these results clearly demonstrate that the DNA 
cross-linked PIC hydrogel can be turned into a stiffer or softer network in a user-
defined fashion, allowing for unprecedented control over the gel mechanical 
properties. Interestingly, the combination of cross-linker concentration, toehold 
strategy and temperature dependence opens up the possibility for designing 
oscillating gel networks with dual input.    
 
Figure 6.4. Tunable control of PIC-DNA hydrogels. a) Changes in G0 and σC after adding 0.6 
equivalents of DNA C to a pre-formed DNA-P4 gel cross-linked with 0.3 equivalents of DNA C (PBS, 
10 mM MgCl2, pH 7.4, 30 °C). b) Changes in G0 and σC after adding 0.6 equivalents of DNA D to a 
pre-formed gel cross-linked with 0.9 equivalents of toehold cross-linker DNA C' (PBS, 10 mM MgCl2, 
pH 7.4, 30 °C). 
 
6.3 Conclusion 
In summary, a novel DNA-responsive hydrogel system composed of DNA 
cross-linked PIC polymers was designed. This hydrogel forms at micromolar 
concentrations of the DNA cross-linker and exhibits striking similarity with bundled 
networks formed from semi-flexible biological filaments. A thorough rheological 
analysis did not only show that this hydrogel does stress-stiffen, but also that its 
mechanical response can be tuned by changing a number of variables such as  
polymer length and concentration. Most importantly, the easily accessible cross-linker 
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ratio allows for controlling the gel stiffness as expressed in G0 and σC. Furthermore, 
the bidirectional dynamic behaviour of the material is demonstrated by facile and 
rapid tuning of the gel stiffness by exogenous DNA delivery. Although relatively 
simple ssDNA sequences were selected as model systems to form the DNA cross-
links, more complicated sequences with additional functionalities can also be applied 
to this hydrogel system, such as the pH-responsive i-motifs,34 endonuclease 
restriction sites or aptamers specific for an analyte or protein.35 The material 
developed in this chapter potentially allows for the design and synthesis of stimuli-
responsive biomimetic scaffolds. Their controlled mechanical properties in 
physiologically relevant environments will allow for a large number of potential 
applications in 3D cell culture, tissue engineering, drug delivery and diagnostics.  
 
6.4 Experimental section 
Synthesis of azide-functionalized polyisocyanopeptides (P1-P4) 
The azide-functionalized, water-soluble polyisocyanopeptide polymers (PIC) and the corresponding 
isocyanopeptide monomers were synthesized as described in chapter 2 of this thesis.20 For all 
polymers, the ratio between the non-functional methoxy (OMe) and the functional azide (N3) 
monomers was 30:1. After mixing the two monomers in freshly distilled toluene, the Ni(ClO4)2•6H2O 
catalyst (dissolved in 9/1 toluene/ethanol) was added. The mixture was stirred for 2-3 days before it 
was precipitated 3x in di-isopropyl ether. A different molar ratio of catalyst over monomer was used to 
control the length of the polymers. Catalyst/monomer ratios of 1/1000 (P1), 1/2000 (P2), 1/5000 (P3) 
and 1/10000 (P4) were used to obtain polymers spanning a range from 125-350 nm. 
 
Polymer characterization 
The polymer length was determined using atomic force microscopy (AFM). The polymers (1 µg mL-1) 
were drop-casted from water on freshly cleaved mica and incubated for 10 minutes. The remaining 
liquid was removed and the sample was dried in a stream of N2. AFM images were recorded in 
tapping mode in air using Nanoscope IV or Dimension 3100 instruments (Bruker) and NSG-10 
cantilevers (NT-MDT). The polymer length was determined manually using the program ImageJ36 
(Figure A6.1.3 and A6.1.4). 
 
Functionalization of DNA with DBCO-PEG4-NHS 
DNA oligonucleotides (Table 6.1) were obtained from Integrated DNA Technologies either in HPLC-
purified or ‘desalted-only’ grades. ‘Desalted-only’ DNA was purified further in-house using preparative 
denaturing polyacrylamide gel electrophoresis (PAGE; 20%).37 The DNA was eluted from the gel, 
concentrated using an ion exchange column (Resource Q, 1 ml column, ÅKTA FPLC; GE Healthcare) 
and desalted by ethanol precipitation. To functionalize the DNA with the strained alkyne 
azadibenzylcyclooctyne (DBCO), the NH2-modified DNA was reacted with the heterobifunctional 
reagent DBCO-PEG4-NHS (Jena Bioscience). For a typical experiment, a solution of 500 µM NH2-
modified DNA and 1.25 mM DBCO-PEG4-NHS was prepared in 50 mM borate buffer pH 8.5 and 
incubated at 25 °C for 2 hours. The product was subsequently purified using Illustra Microspin G-25 
columns (GE Healthcare). The final yield of DNA was determined from an absorption measurement at 
260 nm on a Nanodrop fibre-optic spectrophotometer (ND-1000, Thermo Scientific). To confirm the 
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presence of DBCO on the DNA molecule, a small amount of the product was reacted with a 
fluorescent ATTO647-azide dye. After incubating the DNA with a 10-fold excess of dye, the DNA was 
purified by ethanol precipitation and analyzed using denaturing 20% PAGE (Figure A6.1.1a).  
 
Synthesis of the DNA-functionalized PIC polymer 
Stock solutions of the PIC polymers P1-P4 were prepared by dissolving 5 mg mL-1 of PIC polymer 
(corresponding to 13.9 mM monomer concentration) containing statistically 1/30 azide-functionalized 
monomer (0.46 mM) in ultrapure water. DBCO-functionalized DNA A or DNA B were mixed with the 
azide-functionalized PIC polymer in a 1:50 ratio (125 µM DNA : 6.25 mM PIC monomer) in phosphate 
buffered saline (PBS, pH 7.4) and incubated at 25 °C for 12 hours. The yield of this conjugation 
reaction was determined based on the amount of non-conjugated DNA molecules, containing 
unreacted DBCO. The concentration of DBCO in the reaction mixture was quantified using a 
fluorogenic 3-azido-7-hydroxycoumarin dye, which shows an increase in fluorescence upon ‘clicking’ 
to DBCO. The fluorescence intensity of coumarin was measured using a Tecan Infinite 200 microplate 
reader and related to a calibration curve of clicked product (Figure A6.1.1b). As the yield of the 
reaction was ~90 % (Figure A6.1.1c), the polymer conjugate was used without further purification. 
 
Hydrogel formation 
PIC-DNA A and PIC-DNA B conjugates were mixed at 4 °C in PBS, 10 mM MgCl2, pH 7.4. To induce 
gel formation, complementary DNA C or C' was added at defined ratios. 
 
Enzymatic ligation of DNA-functionalized PICs 
5’-Phosphorylated DNA B was conjugated to the PIC polymer using the procedure described above. 
DNA C was used as a splint to ligate DNA A and 5’-PO4-DNA B coupled to the PIC polymers. The 
reaction was performed at 30 °C (PBS, 10 mM MgCl2) using T4 DNA ligase (Thermo Fisher Scientific). 
Before performing an enzymatic ligation with polymer conjugated DNA, the reaction was first 
evaluated under identical conditions using non-conjugated DNA and confirmed with denaturing 20% 
PAGE (Figure A6.1.11). 
 
Rheology 
The total polymer concentration was kept constant at 1.8 mg mL-1 corresponding to 50 µM of the 
respective DNA linkers for all experiments. Time-sweep oscillatory rheology measurements were 
carried out with a stress-controlled rheometer (Discovery HR-1, TA Instruments). A parallel plate 
geometry (40'mm diameter; aluminum) was used with a gap of 200'µm. All measurements were 
performed in a temperature-controlled environment and an oil sealing was used to minimize sample 
evaporation. Linear rheology experiments were performed at a fixed frequency (1 Hz) and strain (2%). 
For the variable temperature rheology experiments, the temperature was ramped at 1 °C min-1. 
The non-linear regime (critical stress, σc) was investigated using a previously described pre-
stress protocol.17 The gel sample (kept at 30 °C) was subjected to a constant pre-stress with a small 
oscillatory stress (δσ) superposed upon it. The resultant oscillatory strain (δγ) was recorded in a 
frequency sweep experiment (0.1-10.0 Hz). The measurement was repeated for increasing values of 
applied pre-stress (σ) to extract the differential modulus Kʹ (δσ/δγ) at a specific frequency (1 Hz) at 
each value of σ. σc is defined as the stress at which the ratio between the stress σ and the strain γ is 
not constant, but increases with increasing stress (or strain). The onset of the non-linear region was 
defined as the stress regime where σ increased by at least 10 % over its original value. 
For the experiments where the mechanical properties of the hydrogel were varied by the step-
wise addition of new DNA, gels with a pre-defined cross-linker DNA C or DNA C' (including the 10 
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nucleotide toehold) concentration were pre-formed on the rheometer. Subsequently, additional 
aliquots of cross-linker DNA C or complementary DNA D were added. The time evolution of G' was 
then followed on the rheometer as described above. 
 
Cryo-SEM of DNA cross-linked hydrogels  
Cryo-scanning electron microscopy (cryo-SEM) was performed on a JEOL 6330 cryo-scanning 
electron microscope. All samples were loaded onto suitable stub holders with a 20 µL micropipette 
fitted with sterile tips. Samples were cryo-fixed by plunging them into sub-cooled nitrogen (nitrogen 
slush) close to the freezing point of nitrogen at -210 °C. The samples were then transferred in vacuo to 
the cold stage of the SEM cryo-preparation chamber. Images were acquired using an electron beam 
of 7–22 kV. 
 
Melting temperature determination of the different DNA sequences 
The melting temperature (Tm) of the DNA duplexes used was determined from UV absorption 
measurements at 260 nm. Temperature-ramping experiments were carried out from 10 °C to 90 °C at 
a rate of 1 °C min-1 using a Cary 300 Bio UV-VIS spectrometer (Varian) equipped with a temperature 
controller. The Tm was calculated from the first derivative of the melting curve according to van der 
Werf et al. 38 
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6.5 Appendix 6.1: Supplementary figures  
Figure A6.1.1. Experiments to confirm conjugation of DBCO to DNA. a) PAGE analysis (20 %) of the 
DBCO-functionalized DNA after reaction with the fluorescent dye ATTO647-azide. The left lane shows 
the DBCO-DNA A conjugate stained with Stains-All. The right lane shows the fluorescent signal of 
DBCO-DNA A labeled with ATTO647. b, c) 3-azido-7-hydroxy-coumarin dye assay used to quantify 
the concentration of free DBCO-functionalized DNA before and after reaction with the azide-
functionalized PIC polymer. A calibration curve was first established to correlate the fluorescence 
intensity to the amount of clicked product (b). Comparing the amount of free DBCO before and after 
incubation with the polymer (12 hours) reveals a high reaction efficiency of ~90 % (c).
a b
Samples Fluorescence Intensity DBCO concentration 
( M) 
PIC 20641 17.8 
PIC-DNA-A (P4), 
Zero time 
22588 19.3 
PIC-DNA-A (P4), 
After 12 hours 
2065 2 
c
Fluorescence
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Figure A6.1.2. AFM analysis. AFM images showing the PIC polymers P1-P4, dropcasted on freshly 
cleaved mica. 
 
  
P1 P2
P3 P4
a b
c d
Processed on: 10-10-2016
505747-L-bw-Hammink
DNA-responsive polyisocyanopeptide hydrogels with stress-stiffening capacity 
 
 
147 
 
Figure A6.1.3. Polymer lengths obtained from the AFM images. a) The mean length of P1 was 133 
nm (n = 277), b) the mean length of P2 was 218 nm (n = 203), c) the mean length of P3 was 296 nm 
(n = 296) and d) the mean length of P4 (n = 209) was 335 nm. 
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Figure A6.1.4. Temperature-induced gel formation. a) G' as a function of temperature of a mixture for 
P4-DNA A and P4-DNA B in the absence of cross-linker DNA C (PBS, 10 mM MgCl2, pH 7.4, 1.8 mg 
mL-1 polymer). The sample shows a sol-to-gel transition above 40 °C indicating that gelation is a result 
of the hydrophobic interaction between the tetra ethylene glycol side chains. b) Comparison of the 
gelation behavior of the non-functionalized P1 polymer and the DNA cross-linked P1 polymer (0.9 eq. 
DNA C; PBS, 10 mM MgCl2, pH 7.4; 1.8 mg mL-1 polymer). The two samples show very different 
profiles. At 30 °C, a stable hydrogel is only formed in the case of the DNA cross-linked P1 polymer.
Figure A6.1.5. Cryo-scanning electron micrographs of freeze-dried DNA cross-linked P4 hydrogels at 
different cross-linker concentrations. a) 0.1 eq. DNA C and b) 0.9 eq. DNA C. The scale bar is 1 µm.
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Figure A6.1.6. Frequency dependent rheology of DNA cross-linked hydrogels. Using either 0.1 eq. a) 
or 0.9 eq. b) of DNA C. The hydrogels, made from polymer P4, were stable and did not relax as 
demonstrated by measuring G' and G'' over a range of frequencies (10-3 to 10 Hz). All measurements 
were performed at 30 °C (PBS, 10 mM MgCl2, pH 7.4; 1.8 mg mL-1 polymer). 
 
 
 
 
Figure A6.1.7. Relationship between G0 and σC obtained from a series of measurements determined 
at different concentrations of cross-linker DNA C. The polymer concentration (P4) was constant at 1.8 
mg mL-1. The exponent of 1.45 was obtained from a power law fit. 
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Figure A6.1.8. Melting curve of the non-conjugated DNA ABC complex in PBS, 10 mM MgCl2, pH 7.4. 
Curve fitting and first derivative analysis yields a Tm of 44.7 ± 1 °C.
Figure A6.1.9. Non-linear rheology of the DNA cross-linked P4 hydrogel. Differential modulus K’ a) 
and critical stress σC b) showing similar non-linear behavior for all samples at 60 °C. At 60 °C σC is 
independent of the DNA cross-link ratio. c) Critical stress measured at a range of temperatures from 
30 °C to 60 °C, showing the transition from a DNA cross-linked hydrogel to a PIC-bundled hydrogel.
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Figure A6.1.10. Temperature-dependent hydrogel formation using a DNA cross-linker with a single 
mismatch. a) Melting curve of the non-conjugated DNA ABM complex (PBS, 10 mM MgCl2, pH 7.4). 
The Tm was determined to be 36.2 °C. b) G' and G'' as a function of temperature for the DNA M cross-
linked P4 hydrogel. The G’ and G” temperature profiles are shifted with respect to the DNA C cross-
linked hydrogel due to the less stable DNA ABM cross-links (PBS, 10 mM MgCl2, pH 7.4; 1.8 mg mL-1
polymer).
Figure A6.1.11. Hydrogel formation following ligation of DNA A and B. a) Analysis of the non-
conjugated ABC splint ligation product on 20 % denaturing PAGE. Lane I: DNA A; Lane II: DNA B; 
Lane III: DNA C; Lane IV: Ligated DNA A and B. b) G' and G'' as a function of temperature for the 
covalently cross-linked (i.e. ligated) P4 hydrogel (PBS, 10 mM MgCl2, pH 7.4, 30 °C; 1.8 mg mL-1
polymer).
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Figure A6.1.12. Heating and cooling cycles. Series of temperature scans for one DNA cross-linked 
hydrogel sample (P4-DNA A and P4-DNA B cross-linked with 0.9 eq. of DNA C; 1.8 mg mL-1 polymer). 
The sample was subjected to 3 consecutive cycles of heating (30 °C to 60 °C) and cooling (60 °C to 30 
°C). 
 
 
Figure A6.1.13. Tunable control of DNA-PIC hydrogels. a,b) Changes in G0 a) and σC b) when 
increasing the concentration of DNA C from 0.3 eq. to 0.6 eq. (1.8 mg mL-1 polymer). c,d) Changes in 
G0 c) and σC d) following toehold-initiated strand displacement (addition of 0.3 eq. of complementary 
DNA D to a P4 gel cross-linked with 0.9 eq. of DNA C'; 1.8 mg mL-1 polymer). 
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Figure A6.1.14. Toehold strategy. A DNA hydrogel is formed with cross-linker DNA C' containing a 10 
nucleotide toehold at the 5'-end. Complementary DNA D binds the toehold sequence, initiating 
displacement of the DNA A and DNA B sequences by branch migration.
Figure A6.1.15. Control experiment to compare the properties of DNA C and toehold DNA C’ cross-
linked P4 hydrogels. The measured G' values demonstrate a similar stiffness of both hydrogels over 
the frequency range tested (PBS, 10 mM MgCl2, pH 7.4, 30 °C; 0.9 eq. DNA C or DNA C’; 1.8 mg mL-1
polymer).
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Chapter 7: Affinity-based purification of polyisocyanopeptide 
bioconjugates 
 
7.1 Introduction 
Over the last years, water-soluble polyisocyanopeptides (PICs) have proven 
their application potential as novel and versatile biomaterials1. These polymers are 
long, helical and semi-flexible, thereby matching the properties of many filaments 
found in nature.2,3,4 PIC polymers are build up from isocyanide monomers that carry 
two alanine substituents to stabilize the helix. In addition, they are functionalized with 
either tri- or tetra ethylene glycol side chains to provide water solubility. When 
functionalized with a tri ethylene glycol chain, the corresponding PICs form a hydrogel 
material at room temperature which has been used in many biological applications like 
tissue engineering, cell growth or sensing.5,6 On the other hand, tetra ethylene glycol 
bearing polymers undergo a sol-to-gel transition at 40-45 °C. These PICs are therefore 
in a liquid state at physiologically relevant temperatures. They are excellent scaffolds 
for the synthesis of polymer-drug conjugates as tested for the immunotherapeutic 
applications described in chapters 2-4 of this thesis.7,8 
All these applications have in common that the PICs have to be functionalized 
with biomolecules to make them biofunctional. To provide cell adhesion to the 
hydrogel, for example, a short integrin-binding GRGDS peptide was grafted onto PIC 
polymers (chapter 5). In the sensing application (chapter 6), short DNA 
oligonucleotides were coupled to the PIC that were subsequently cross-linked upon 
binding of the analyte. For the immunotherapeutic application, the polymers were 
functionalized with streptavidin to allow for the binding of biotinylated T cell stimulating 
antibodies (chapters 2,3 and 4). 
PICs are long (100-1000 nm), semi-flexible polymers that adopt a stable helical 
conformation. As a consequence, they do not form a typical random coil in solution, 
making the purification of PIC-bioconjugates troublesome. Standard size exclusion 
and field flow fractionation methods were tested to separate unreacted biomolecules 
from the PIC-bioconjugates, but without any success. Ultrafiltration was identified as 
the only possible method for the purification of freshly synthesized PIC-bioconjugates, 
but more than 99% of the material was lost during the process (chapters 2,3 and 4).7,8 
As an alternative, the reaction between the PIC and the biomolecule was carefully 
optimized so that an almost quantitative coupling of the biomolecule was achieved and 
no purification was needed (chapters 5 and 6). For small molecules, such as short 
peptides and DNA oligonucleotides, this method was successful. For larger proteins 
and antibodies the reaction with the PIC is difficult to optimize, however, as steric 
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effects start to limit the reaction efficiency. Clearly, an alternative and efficient 
purification method is needed to obtain pure PIC-bioconjugates in good yield. 
Affinity tags such as hexahistidine, Strep-tag or biotin are frequently used for 
the purification of recombinantly expressed proteins from crude cell extracts.9–11 
Inspired by this method, a PIC polymer bearing the affinity tag biotin was designed. 
Using this biotin-functionalized PIC, affinity purification on a mono-avidin resin can 
potentially be used to remove unreacted biomolecules (Figure 7.1). Mono-avidin is a 
monomeric derivative of avidin that possesses a highly reduced affinity for biotin. It is 
frequently used for the purification of biotinylated proteins. Biotinylated molecules bind 
to mono-avidin agarose beads in a reversible manner and can be eluted competitively 
when adding high concentrations of free biotin. 
 
 
Figure 7.1. Principle of the affinity-based purification method. During synthesis of the PIC-
bioconjugates, the PICs are biotinylated first and then reacted with the biomolecule of interest. The 
resulting reaction mixture, containing biotinylated PIC-bioconjugates and non-reacted biomolecules, is 
incubated with mono-avidin agarose beads, followed by washing to remove the non-reacted 
biomolecules. The PIC-bioconjugate remains bound to the beads and is released using a high 
concentration of biotin to compete with the biotin-tagged PIC-bioconjugates.  
 
This chapter describes the synthesis and characterisation of biotin-containing 
PIC polymers. It is further tested if a mono-avidin resin can reversibly bind these 
polymers and if this affinity purification strategy can be used for the purification of PIC-
bioconjugates. Two model proteins, an antibody and an enzyme, were selected for 
coupling to the PIC polymer. The antibody of choice is the same anti-CD3 antibody 
(αCD3) that has already been used for stimulating T cells (chapters 2, 3 and 4). To 
further develop these therapeutic PICs, an easy, efficient and reproducible purification 
method is needed. As an alternative to the antibody, the synthesis and purification of 
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an enzyme-PIC conjugate was investigated. As a model enzyme, alkaline phosphatase 
(PhoA) was used to show the versatility of the purification method developed in this 
chapter. 
 
7.2 Results and discussion 
 
7.2.1 Synthesis and characterization of biotin-functionalized 
polyisocyanopeptides 
To investigate if the biotin affinity tag can be used for the purification of PIC-
bioconjugates, first biotin-containing polymers were synthesized (Figure 7.2). For this 
purpose, PICs with azide groups were synthesized using the same method as 
described in chapter 2 of this thesis. The ratio of non-functional methoxy to functional 
azide monomers was chosen to be 30:1, yielding a statistical average distance 
between azides of 3 nm.12 Subsequently, the azide-functionalized PIC was reacted 
with different amounts of biotin-azadibenzocyclooctyne (biotin-EG4-DBCO)carrying a 
short poly ethylene glycol (PEG) spacer. Assuming a quantitative yield of the reaction, 
PICs with an average biotin spacing of 5, 7.5, 10 and 40 nm were prepared.13 Using 
this strategy, the remaining azide groups can be used for the subsequent coupling of 
DBCO-functionalized biomolecules as described in the previous chapters. 
 
Figure 7.2. Conjugation strategy for the synthesis of biotin-functionalized polyisocyanopeptides that can 
be used for the subsequent coupling of DBCO-containing biomolecules. In this chapter, the biomolecule 
is either an antibody (αCD3) or an enzyme (PhoA). 
 
To optimize the biotin density necessary to bind and elute the PICs from mono-
avidin containing beads in a batch purification process, an incubation and elution 
protocol was developed. The polymers were diluted to 0.1-0.2 mg/ml in phosphate 
buffered saline (PBS) and mixed with mono-avidin beads in a 1:1 (v/v) ratio. The 
N3
N3
N3
N3
N3
N3
N3
N3
Affinity tag coupling Biomolecule coupling
Poly(isocyano peptide)
O
O
O
N
H
O
N
N
H
N
O
O
O
O
3
4
n
x
y
N3
N3
N3
N3
N3
=
N
H
NH
O
H
H
NH
S
O
O
O
O
N
H
N
O
3=
DBCO-biotin
= DBCO-biomolecule
(antibody or enzyme)
Processed on: 10-10-2016
505747-L-bw-Hammink
Affinity-based purification of polyisocyanopeptide bioconjugates
161 
binding of the PICs to the beads was determined by measuring the concentration of 
unbound PIC in the supernatant using circular dichroism (CD) spectroscopy. Due to 
the helical conformation of the PICs, this technique provides an indication of the 
polymer concentration, assuming that the polymer conformation is not altered during 
the experiment.1,14,15 The CD spectrum of the biotinylated PIC is characterized by a 
negative peak at λ = 360 nm and a larger positive peak with a maximum at λ = 272 
nm. Calibration curves of the azide-functionalized PIC were determined at both 
wavelengths, showing that the corresponding peak heights scale linearly with polymer 
concentration (Figure  7.3a, Figure  A7.1.1). The analysis of the supernatants after 2.5 
and 4 hours of incubation shows no significant differences in binding of the biotin-PIC 
polymers, indicating that maximal binding was already achieved after 2.5 hours.
Figure 7.3. Binding and elution of biotin-PICs to and from mono-avidin beads. a) CD spectra of the 
azide-functionalized PIC measured at different concentrations. b) CD spectra taken at different steps of 
the purification. The supernatant was measured at different time points (2.5 and 4 hours). In addition, 
the eluted fraction is shown (data shown for 1 biotin in 7.5 nm. c) Binding and elution profiles for biotin-
PICs containing a different biotin density (EG4 linker). Shown is the relative amount of biotin-PIC in the 
supernatant after binding or elution. d) Binding and elution profile of biotin-PIC prepared with the long 
(3000 Da) PEG linker and a biotin density of 7.5 nm. Shown is again the relative amount of biotin-PIC 
in the supernatant after binding and elution. 
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More pronounced differences in binding efficiency were found when comparing 
the samples with increasing biotin density. Polymers containing 1 biotin every 40 nm 
showed binding of the biotin-PIC to the mono-avidin beads, however, the relative 
amount of bound material was small (~12%). Increasing the biotin density to 10 nm 
increased the amount of bound polymer to ~30% and maximum binding was found for 
the samples with a biotin density of 7.5 or 5 nm (both ~65-70%, Figure 7.3c). No biotin-
PIC binding was observed for azide-PICs that did not carry any biotin. The biotin 
density was not increased further as this would yield polymers that do not have a 
sufficient amount of azides left for further bioconjugation. 
After having confirmed binding of the biotin-PICs to mono-avidin beads, the 
elution protocol was optimized. The beads were first washed with PBS containing 0.1% 
Tween 20 (PBS-T, 2x) and PBS (4x) to remove any non-specifically bound polymers. 
During this extensive washing protocol, ~30% of the beads were lost, which reduces 
the total yield of eluted polymers. Following washing, PBS containing 2 mM biotin was 
added to the beads to elute the bound biotin-PICs competitively. The CD spectrum of 
the eluted fractions is not altered when compared to the original polymer samples 
before purification, which indicates that the helical structure is not affected during the 
whole process (Figure 7.3b). The amount of eluted biotin-PICs clearly correlates with 
the amount of biotin-PIC initially bound to the beads and, consequently, also with the 
density of biotin on the polymer. Only a small amount (4 % of the original amount) was 
obtained for the polymer with a biotin density of 40 nm. Higher amounts of 17, 34 and 
35 % were obtained for the other polymers with biotin densities of 10, 7.5 and 5 nm, 
respectively (Figure 7.3c). Considering the loss of beads during the washing steps and 
the fraction of polymer that did not bind, elution with 2 mM biotin is sufficient to release 
more than 50 % of the bound biotin-PIC polymers from the beads. 
In addition to the biotin density, also the linker length between biotin and the 
PIC polymer backbone was investigated. To test for possible steric hindrance, the 
length of the PEG spacer between the between the biotin moiety and the DBCO 
functional group was increased. Using a PEG linker with a molecular weight of 3000 
Da, biotin-PIC polymers were prepared with an average biotin density of 7.5 nm. 
Binding of this polymer to the beads was considerably slower when compared to the 
previously used biotin-PICs containing only the EG4 linker. After 15 hours of incubation 
more than 90% of the polymer was bound. Unfortunately, elution of this polymer 
recovered only 15 % of the original amount (Figure 7.3d). Overall, it appears that the 
longer linker does not reduce, but instead increase steric hindrance thereby affecting 
both the kinetics of the interaction as well as the yield of the purification protocol. 
Taken together, these results show that the biotin-PIC with a biotin density of 
7.5 nm coupled via the short linker performs best when considering both the 
requirements for an efficient purification as well as its future application. It shows good 
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binding and a reasonable amount is eluted from the mono-avidin beads. At the same 
time, a sufficient amount of azides is left for further conjugation. This biotin-PIC was 
therefore selected as a model system to test whether this purification method can be 
used for the purification of PIC-bioconjugates.               
 
7.2.2 Purification of anti-CD3 functionalized PICs using the biotin affinity tag 
To investigate if PIC-bioconjugates can be purified with the newly developed 
affinity-based method, biotin-PICs were functionalised with antibodies. To improve the 
efficiency of the synthetic dendritic cells described in chapters 2-4 of this thesis, the 
same anti-CD3 antibody (αCD3) was used. In chapters 2 and 4 it was shown that PICs 
bearing this antibody (αCD3-sDCs) are more efficient in stimulating T cells when 
compared to the antibody in solution or coupled to bead-like particles. Moreover, in 
chapter 3 it was shown that multivalency is an important parameter responsible for this 
higher efficiency.7,8 Although these αCD3-PIC conjugates are a very promising starting 
point for immunotherapeutic applications, their usefulness is limited because of the 
difficult purification. To obtain an acceptable purity, the samples had to be purified 
extensively using ultrafiltration that resulted in a huge loss of both polymer and 
antibody (<1 % yield). These low yields also complicated the analysis of the antibody-
PIC bioconjugates. 
The affinity-based purification method proposed here has the potential to 
overcome these problems, providing bioconjugates with increased yield and purity. 
This would not only allow for a more straightforward analysis with UV or CD 
spectroscopy, but also facilitate the development of large-scale synthesis and 
purification protocols. In the previous method, αCD3 was biotinylated and bound to a 
streptavidin-functionalized PIC polymer. As biotin is now used as the affinity tag for 
purification, the original design had to be adjusted to allow for a direct conjugation of 
αCD3 to the azide-functionalized PIC. To achieve this, αCD3 was functionalized with 
DBCO (DBCO-αCD3) and coupled to biotin-PIC with a 7.5 nm biotin density. To 
synthesize DBCO-αCD3, a N-Hydroxysuccinimide (NHS) ester of DBCO was reacted 
with the lysine residues of the antibody (Figure 7.4a). The degree of labelling, as 
determined by UV/VIS spectroscopy, was between 2 and 2.5 DBCO molecules per 
antibody.16 
To investigate the influence of the antibody density on the performance of the 
biotin-tag based purification method, 4 different αCD3-PIC bioconjugates were 
synthesized. DBCO-αCD3 was reacted with biotin-PIC in PBS using 0.1, 0.3, 0.5 and 
1 equivalents of antibody compared to the azide groups. The resulting reaction 
mixtures were purified using the protocol described above. The ability to bind to the 
mono-avidin beads was estimated by analysing the supernatant with CD at a 
wavelength of 360 nm (Figure 7.4b, Figure A7.1.1). The binding efficiency of the αCD3-
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PIC to the mono-avidin beads was typically in the range of 35-55 %, which was lower 
than for the biotin-PIC without αCD3 (65-70 %). This may be due to the large antibodies 
blocking some of the biotin tags from binding. After extensive washing (2x PBS-T, 4x 
PBS), typically 10-25 % of the original amount of αCD3-PIC could be eluted (Figure 
7.4b). Compared to biotin-PIC without αCD3 these yields are slightly lower, but still 
significantly better then the yields obtained with the ultrafiltration protocol used before 
(<1 % yield). 
 
Figure 7.4. Purification of αCD3-PIC bioconjugates using a biotin affinity tag. a) Reaction scheme for 
the synthesis of DBCO-αCD3. b) Binding and elution profile of αCD3-PIC to and from mono-avidin 
agarose beads. Shown is the relative amount of αCD3-PIC in the supernatant, determined using CD 
measurements. c) Non-reducing SDS-PAGE of the PIC-αCD3 sample (1 eq. of antibody with respect to 
azide groups) in comparison to different concentrations αCD3. Shown are relative concentrations with 
respect to the amount of αCD3 used in the reaction mixture. d) Calculated average distances between 
αCD3 on the biotin-PIC backbone obtained for different equivalents of DBCO-αCD3 during the reaction.  
 
In addition to the yield, also the purity of the αCD3-PIC bioconjugates is 
important. A combination of methods was used to determine the remaining amount of 
non-conjugated αCD3 in the samples. Gel electrophoresis (SDS-PAGE) was 
performed under non-reducing conditions to keep the disulfide bonds of the antibody 
intact (Figure 7.4c). As the polymer bioconjugate is too large to enter the SDS-PAGE 
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gel (Figure A7.1.2), it can be directly concluded that any protein of the size of ~150 
kDa represents non-conjugated antibody. Comparing the PIC-αCD3 sample (1 eq. of 
antibody with respect to azide groups) with different concentrations of free αCD3 
shows that more than 92 % of the antibody was conjugated to the polymer. 
This high purity of the αCD3-PIC conjugates allows for a simple determination 
of the number and the spacing of αCD3 on the polymer backbone. Knowing the molar 
concentrations of both the antibody and the biotin-PIC, the number of αCD3 per 
polymer can simply be determined by dividing the two values (Figure 7.4d). The biotin-
PIC concentration was again determined by CD measurements and the αCD3 
concentration was obtained from a BCA assay. For 0.1, 0.3, 0.5 and 1 equivalents of 
αCD3 during the reaction, average antibody distances of around 70, 40, 30 and 20 nm 
were found, respectively. These results clearly show that the purification of PIC 
bioconjugates with an affinity tag is a powerful method to obtain pure bioconjugates in 
high yield that can now be easily analysed with standard spectroscopic methods. 
 
7.2.3 Purification of alkaline phosphatase PIC conjugates 
To further demonstrate the versatility of the new purification method, also an 
enzyme was conjugated to the biotin-PIC scaffold. As a model enzyme, alkaline 
phosphatase (PhoA) from E. coli was used. PhoA is a dimeric metalloenzyme involved 
in the dephosphorylation of molecules.17 The active form of this enzyme is an allosteric 
dimer that possesses negative cooperativity and allosteric communication across the 
dimer interface. The factors affecting this negative cooperativity are currently 
investigated using single-molecule fluorescence experiments.18,19 These experiments 
require the immobilisation of PhoA onto a surface. Many different methods have been 
tested for enzyme immobilization for this type of experiment, ranging from non-specific 
adsorption to gel encapsulation and covalent coupling utilizing heterobifunctional poly 
ethylene glycol linkers.20–22 Enzyme-PIC conjugates can potentially be used for the 
formation of enzyme-PIC hydrogels. In this way, the enzymes are immobilized in a 
nature-like hydrogel with a large pore size2 that allows for free substrate and product 
diffusion. 
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Figure 7.5. Synthesis and purification of PhoA-PIC bioconjugates. a) Reaction scheme used for 
coupling the NHS-esters of DBCO and AlexaFluor647 to PhoA in a one-pot reaction. b-c) AFM images 
of PIC with 0.2 eq. PhoA or PIC with 0.1 eq. PhoA drop-casted on mica. The bright ‘dots’ correspond to 
the enzyme while the connecting ‘line’ represents the polymer. d) Calculated PhoA distances on the PIC 
backbone, determined either from the measured bulk concentrations (BCA) or the AFM measurement. 
e) Enzyme activity measurements of the PhoA-PIC conjugates in comparison to non-conjugated PhoA. 
The curves display the mean of three independent measurements. 
To investigate this possibility, DBCO- and fluorophore-functionalized PhoA was 
prepared by reacting the NHS esters of DBCO and AlexaFluor647 with the lysine 
residues of the enzyme (Figure 7.5a). To determine the degree of labelling, the protein 
concentration was estimated with a BCA assay and the DBCO and AlexaFluor647 
concentrations were determined with UV/VIS spectroscopy. On average, 1.1 
fluorophore molecules and 2.4 DBCO functional groups were coupled to the PhoA 
dimer. DBCO- and AlexaFluor647-labelled PhoA was then reacted with the biotin-PIC 
polymer (7.5 nm biotin spacing). Three different ratios of PhoA:azide were used for
coupling the enzyme to the polymer (0.1, 0.2 and 0.5 eq. of PhoA with respect to azide 
groups). Assuming a quantitative reaction, this leads to average PhoA distances of 50, 
25 and 10 nm. 
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The PhoA-PIC bioconjugates were again purified over mono-avidin beads using 
the method described earlier and the purified PhoA-PICs were analysed with atomic 
force spectroscopy (AFM). The AFM images were used to count the number of 
enzymes attached to every individual polymer chain (Figure 7.5b and c, Figure A7.1.3) 
and the average distances between PhoA molecules were determined to be 55 nm 
(PIC 0.2 eq PhoA) and 100 nm (PIC 0.1 eq PhoA). These values are similar to the 
distances determined from the overall biotin-PIC (CD) and PhoA (BCA assay) 
concentrations (70 nm for the PIC sample with 0.2 eq. PhoA and 155 nm for the PIC 
sample with 0.1 eq PhoA sample; Figure 7.5d), which proves that these PhoA 
conjugates are highly pure. Unfortunately, the PIC 0.5 eq PhoA sample could not be 
visualised with AFM, but the spacing determined from the bulk concentrations was 
34 nm. On average the determined distances are a factor 3 larger than the distances 
expected for a quantitative reaction, indicating a coupling efficiency of 30 %.  
Next, it was examined if the PIC-conjugated PhoA was still able to perform its 
function (Figure 7.5e). The activity of the enzyme was tested using the fluorogenic 
substrate 9H-(1,3-dichloro-9,9-dimethylacridin-2-one-7-yl) phosphate (DDAO-
phosphate). Dephosphorylation by PhoA alters the photophysical properties of the 
DDAO chromophore so that substrate and product are easily distinguished in a 
fluorescence measurement (Figure A7.1.4).23 Enzymatic activity results in an increase 
in product fluorescence (λex = 645 nm) allowing for a straightforward kinetic 
measurement. The increase in product fluorescence was determined for the three 
PhoA-PIC conjugates and for a control sample containing non-conjugated enzyme of 
the same concentration. All samples show very similar enzyme activities (Figure 7.5e), 
indicating that the coupling and purification process does not affect the enzyme. Taken 
together, these results show that the new purification protocol is a highly powerful 
method for the purification of enzyme-PIC without altering their function. The next step 
will clearly be to prepare PIC hydrogels that contain a small concentration of PhoA-PIC 
conjugates and to perform single-molecule experiments with PhoA conjugated to this 
biomimetic scaffold. 
 
7.3 Conclusion 
In this chapter, an affinity-based purification method was developed that 
increases both the total yield as well as the purity of the PIC bioconjugates. PIC 
polymers were equipped with biotin tags that allow for the reversible binding of the 
resulting biotin-PIC polymers to mono-avidin beads. For optimal binding, a minimum 
statistical distance between individual biotin moieties of at least 7.5 nm was required. 
To demonstrate the application potential of this new purification method, two different 
PIC-bioconjugates were successfully synthesized and purified. Although the final yield 
of the purification is only 10-25 %, it is still significantly better than the previous 
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ultrafiltration method where the yield was below 1 %. More importantly, the new 
method was able to remove almost all non-reacted biomolecules (>95 %) leading to 
highly pure PIC-bioconjugates. As a consequence of this high purity, the analysis of 
these constructs was straightforward and the spacing of the conjugated biomolecules 
could be calculated by simply dividing the concentration of polymer by the 
concentration of the respective biomolecule. The densities calculated from bulk 
concentrations were in good agreement with the results from AFM imaging, where 
every individual biomolecule coupled to the polymer was visualized and counted. 
Furthermore, the developed purification method preserved the activity of the coupled 
biomolecule as was demonstrated with activity measurements for alkaline 
phosphatase. Altogether, a new versatile and standardized protocol for the synthesis 
and purification of PIC-bioconjugates was developed that will be highly useful for future 
applications of these molecules. 
  
7.4 Experimental Section 
Materials  
Unless stated otherwise, all chemicals were obtained from Sigma Aldrich and used without further 
purification. DBCO-EG4-biotin and DBCO-EG4-NHS were purchased from Click Chemistry Tools. 
DBCO-PEG3000Da-biotin was obtained from Nanocs Inc. and DIBO-AlexaFluor647, AlexaFluor647-NHS 
and DDAO-phosphate were obtained from Thermo Scientific, as well as the mono-avidin beads 
(agarose-based). Monoclonal mouse anti-human αCD3 antibodies were obtained from bioXcell (clone 
OKT3). Ultrafiltration units with a cut-off of 30 kDa (Amicon Ultra-15 Centrifugal Filter Units) were 
purchased from Merck Millipore and the Micro BCA assay was obtained from Thermo Scientific. 1 ml 
columns with a 20 µm frit were obtained from Screening Devices. Recombinant alkaline phosphatase 
(PhoA-His) was obtained from an E. coli expression system,24 followed by purification on a Zn2+-NTA 
column. The enzyme was provided by Reinhild Dünnebacke (Max Planck Institute of Colloids and 
Interfaces, Potsdam, Germany). UV/VIS spectra were recorded using a Nanodrop ND1000 (Thermo 
Scientific) and CD spectra were recorded using a J-810 (JASCO) instrument. Tapping mode AFM 
imaging was performed in air using a Nanoscope IV instrument (Bruker) and NSG-10 tapping mode tips 
(NT-MDT). The PhoA activity was measured using a microplate reader (Tecan Infinite M200 PRO). 
 
Polymer synthesis  
The PIC polymer used in this study was synthesized according to the procedure described in chapter 2 
of this thesis.7 In short, a 30:1 ratio of methoxy-terminated (1.124 g, 3.12 mmol) and azide-terminated 
(0.0038 g, 0.104 mmol) isocyanopeptide monomers were mixed in toluene (50 mg/ml) in a round bottom 
flask and stirred for 2 days until IR measurements showed the complete disappearance of the isocyanide 
peak. The solution was diluted with dichloromethane and precipitated in diisopropyl ether three times, 
resulting in an off-white solid (0.937 g, 82%). The resulting polymer contains a statistical density of 1 
azide per 3 nm. The polymer was analysed using viscometry as described in chapter 2 of this thesis7 
(Mv= 490 kg/mol).  
 
Biotin-functionalization of PICs 
The PIC polymer was dissolved in PBS in a concentration of 1 mg/ml. Biotin-EG4-DBCO dissolved in 
DMSO was added to this solution in the required amount (less than 5% of the total volume, see below). 
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The mixture was stirred overnight and subsequently used for testing the mono-avidin purification 
protocol or for the conjugation of biomolecules. Four different biotin-PIC polymers were prepared with a 
different density of biotin. To achieve this, the molar ratio of biotin-EG4-DBCO: monomer was varied 
from 1:75, 1:100 and 1:400. Assuming a quantitative reaction, this yields an average biotin distance of 
7.5, 10 and 40 nm, respectively. During the synthesis of the fourth polymer with a 1:50 molar ratio (5 
nm biotin spacing) DIBO-AlexaFluor647 was added in a 1:500 ratio of dye: monomer to obtain a 
fluorescently labelled biotin-PIC polymer for control experiments. After stirring overnight, the mixture 
was precipitated in diisopropyl ether and dried in air. The dried material was dissolved in a concentration 
of 1 mg/ml in PBS. 
   
Synthesis of αCD3-DBCO  
DBCO-EG4-NHS was dissolved in DMSO to prepare a stock solution of 50-100 mM. The αCD3 
antibodies were dissolved in PBS (pH 7.4). DBCO-EG4-NHS (3.5 equivalents) was added to the 
antibody solution. The final concentration of αCD3 in the reaction mixture was 4 mg/ml. The mixture was 
stirred for 2 hours at 4 °C and subsequently purified using ultrafiltration (30 kDa cut-off) to remove non-
reacted DBCO-EG4-NHS. The degree of labelling was determined from absorption measurements at 
309 nm (DBCO) and 280 nm (αCD3). The signal at 280 nm was corrected for the absorption of DBCO 
using the following equation: Corrected absorption (280 nm) = absorption at 280 nm – (1.089 * 
absorption at 309 nm).16 The DBCO concentration was calculated from the absorption at 309 nm (ε = 
12,000 M-1cm-1). To obtain the αCD3 concentration, the corrected absorption at 280 nm (ε = 210,000 
M-1cm-1) was used. Typically, this reaction yields a degree of labelling of 2-2.5 DBCO molecules per 
antibody.   
 
Synthesis of AlexaFluor647-DBCO-PhoA 
PhoA was labelled with AlexaFluor647-NHS and DBCO-EG4-NHS simultaneously. The enzyme was 
dissolved in a concentration of 15.4 µM in borate buffer (pH 8.5). Using DMSO stock solutions, 4 
equivalents of AlexaFluor647-NHS and 4 equivalents of DBCO-EG4-NHS were added, yielding a final 
concentration of 62 µM AlexaFluor647-NHS and DBCO-EG4-NHS. The DMSO content was ~10% of the 
total volume. The reaction was incubated for 3-4 hours at 4 °C, followed by ultrafiltration with a 10 kDa 
cut-off. During ultrafiltration, the buffer was changed to 50 mM HEPES pH 8.0. To determine the degree 
of labelling of the resulting AlexaFluor647-DBCO-PhoA, the protein concentration was first determined 
with a BCA assay. The DBCO and AlexaFluor647 concentrations were determined from UV/VIS 
measurements using an extinction coefficient of 12,000 M-1cm-1 for DBCO (309 nm) and of 270,000 M-
1 cm-1 for AlexaFluor647 (650 nm). This analysis yielded a degree of labelling of 2.5 DBCO and 1.1 
AlexaFluor647 molecules per PhoA dimer. 
 
Synthesis of PIC-bioconjugates 
All PIC-bioconjugates were prepared using a similar protocol. A solution of biotin-PIC (1 mg/ml stock 
solution in PBS) was added to the DBCO-functionalized biomolecules to obtain the desired ratios. The 
reaction mixture was stirred overnight at 4 °C and directly used for purification over mono-avidin beads. 
PBS was used for the coupling and purification of αCD3-DBCO. HEPES was used for AlexaFluor647-
DBCO-PhoA. 
 
Circular Dichroism (CD) measurements 
To prepare the CD standard curves, the azide-functionalized PIC was dissolved in a concentration of 
1 mg/ml in PBS (Figure A7.1.1). This stock solution was used to prepare the following concentrations of 
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the polymer: 0.025, 0.05, 0.1, 0.2 and 0.3 mg/ml. The CD spectrum of these samples was measured 
and corrected using a PBS blank. Standard curves were constructed for the CD signals measured at 
272 nm or 360 nm, yielding calibration factors of ε272nm= 525.6 mdeg mg-1 ml-1 and ε360nm= -121.1 mdeg 
mg-1 ml-1. 
 
Purification with mono-avidin agarose 
All buffers were freshly prepared and filtered before use. In general, 500-800 µl of a 50 % slurry 
containing regenerated and blocked mono-avidin beads was spun down in a Eppendorf tube and the 
supernatant was removed. The PIC-biomolecule mixture was added (250-400 µl) and the beads were 
incubated for 2.5-4 hours. Following incubation, the beads were again spun down, the supernatant was 
removed and the remaining beads were washed with PBS containing 0.1% (v/v) Tween 20 (PBS-T, 2x) 
and with PBS (4x). The beads were then incubated with PBS containing 2 mM biotin for 1-2 hours to 
release the purified PIC-bioconjugate. The samples were filtered to remove a small portion of remaining 
beads in the elution fraction. Filtering the samples with standard filters of 0.2-0.45 µm pore size did 
result in a huge loss of polymer so that a 20 µm pore size was used instead. Using this larger pore size, 
the loss of polymer during filtration was reduced to 10%. During all steps of the purification, PBS was 
used for the αCD3-PIC bioconjugate, while HEPES was used for the PhoA-PIC samples.  
 
BCA assay 
To determine the protein concentration, a micro BCA Protein Assay Kit was used. The assay was 
performed using the protocol supplied by the manufacturer. When determining the αCD3 or PhoA 
concentration, non-reacted αCD3 was used as the standard, spanning a concentration range from 7.8 
µg/ml to 1 mg/ml. αCD3-PIC samples were freeze-dried before the BCA assay and re-dissolved in PBS, 
to increase the sample concentration by a factor of 5-6. 
 
AFM measurements 
The mono-avidin purified and filtered PhoA samples were drop casted (20 µl) onto freshly cleaved mica. 
After incubation on the surface for 20 seconds, the samples were removed and the surface was dried 
in a nitrogen stream. The samples were imaged using tapping mode in air and analysed with ImageJ 
software.25 The average spacing of PhoA molecules was calculated from the number of enzymes 
counted on a polymer of given length (Figure A7.1.3). 
 
PhoA activity measurements 
The fluorogenic substrate DDAO-phosphate (9H-(1,3-Dichloro-9,9-Dimethylacridin-2-One-7-yl) 
phosphate, diammonium salt) was used for measuring the activity of the PhoA-PIC bioconjugates. The 
substrate was dissolved in dry DMSO at a concentration of 40 µM. The PhoA-PIC bioconjugates were 
diluted in activity buffer (50 mM HEPES pH 8.0, 100 mM KCl, 20 mM MgCl2, 100 µM ZnCl2) to obtain a 
PhoA concentration of 500 pM. DDAO-phosphate was added to a final concentration of 2 µM to start 
the measurement. The release of the fluorophore DDAO was followed in a microplate reader (λex = 620 
nm; λem = 660 nm). The measurement was performed at 37 °C for 40 min (30 s intervals). All 
measurements were performed in triplicate. The data was corrected for auto-hydrolysis of the substrate. 
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7.5 Appendix 7.1: Supplementary figures  
Figure A7.1.1. Calibration curves for determining the polymer concentration from CD spectroscopy. a) 
Standard curve determined at 272 nm at 1 cm path length (slope: 525.6 mdeg mg-1 ml-1) b) Standard 
curve determined at 360 nm at 1 cm path length (slope: -121.1 mdeg mg-1 ml-1).
Figure A7.1.2. SDS-PAGE (non-reducing conditions) of an AlexaFluor647-labelled and mono-avidin 
purified αCD3-PIC bioconjugate (biotin-PIC, 1 in 50 nm biotin). The gel has been scanned at a 
wavelength of 700 nm to visualize the AlexaFluor647 fluorophores. The gel clearly shows that the αCD3-
PIC bioconjugate does not enter the gel. 
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Figure A7.1.3. Average distance between PhoA molecules on the PhoA-PIC conjugates determined 
from AFM imaging. a) PIC sample with 0.2 eq. PhoA and b) PIC sample with 0.1 eq. PhoA.  
 
 
 
Figure A7.1.4. Enzymatic reaction converting DDAO phosphate into DDAO 
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Chapter 8: Epilogue 
This thesis introduces a general strategy for the synthesis of a new class of 
functional bioconjugates. These bioconjugates are based on a polymeric scaffold that 
is made from water-soluble polyisocyanopeptides. The scaffold carries a defined and 
controllable number of azide-functional groups that can be used for the conjugation 
of a large variety of different biomolecules functionalized with strained alkynes. Using 
functional polymers based on either PIAA-OEG3-OMe or PIAA-OEG4-OMe, different 
applications of these bioconjugates were explored. Freely soluble PIAA-OEG4-OMe-
based polymers were used as scaffolds for the multivalent display of effector 
molecules in immunotherapy applications. Using PIAA-OEG3-OMe-based polymers, 
different bio-functional hydrogels were synthesized and tested in cell culture and 
sensing applications. Clearly, polyisocyanopeptides bioconjugates represent highly 
powerful molecular entities that may find application in many different areas, ranging 
from nanomedicine to diagnostics and biomaterial synthesis. This chapter discusses 
several aspects considering the envisioned applications of these functional polymer 
bioconjugates. The chapter starts with a critical assessment of the risks and societal 
impacts of nanomedicine, with a special focus on the polymer bioconjugates 
developed in this thesis. Subsequently, the chapter discusses the current status of 
the newly developed bioconjugates as well as future developments to improve these 
molecular entities and to extend their possible range of applications. 
 
8.1 Risk Analysis and Technology Assessment 
The research described in this thesis was carried out as part of the drug 
delivery program in the NanoNextNL consortium. In this consortium, researchers, 
companies and medical centres from all over the Netherlands are united to perform 
research aimed at the further development of nanotechnology. Nanotechnology is a 
broad term used for all technologies that deal with entities of nanometer size (10-9 
m). Nanotechnology is a very promising field of research with a strong application 
potential in many different areas. With this increasing popularity, also the public 
concerns about the risks of nanotechnology have been growing. For this reason, 
NanoNextNL stimulates researchers to think about the potential risks and impact of 
their research on society. In this way, more awareness can be generated in the 
general public.  
 A first potential risk that comes to mind when developing a new nanomaterial 
is its toxicity. Although the polyisocyanopeptide bioconjugates described in this thesis 
are still far from a final application, their toxicity was tested before any other research 
was carried out. The first part of this thesis (chapters 2-4) describes potential 
applications of polyisocyanopeptides as a molecular scaffold in the area of 
immunotherapy. The toxicity of this potential new nanomedicine was tested and the 
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results are described in chapter 2 of this thesis. No toxic effect was seen on the cells 
under study. Specifically, no loss in cell viability was observed when treating cells 
with different concentrations of polymer over a period of weeks. Of course, long-term 
effects should be investigated further when moving towards in vivo applications. But 
these first toxicity tests indicate that no severe side effects are to be expected. The 
second part of this thesis (chapters 5 and 6) describes the use of water-soluble 
polyisocyanopeptides for the synthesis of biofunctional hydrogels. The toxic effect of 
these hydrogels on stem cells was also investigated, and the results are described in 
chapter 5. Live-dead assays showed a high viability (>95%) of cells encapsulated in 
these gels. 
Apart from the toxicity of the material in question, it is further important to 
critically evaluate the synthetic processes carried out to fabricate such materials. To 
make a new material suitable for biological applications, the processes should be 
carried out in a sterile environment. Further, they should be easy to perform with a 
minimal number of steps, keeping material consumption low. This is not only an 
important cost factor, but also minimizes the impact of a chemical process on the 
environment. For this reason, a novel protocol for the purification of 
polyisocyanopeptides bioconjugates was developed in chapter 7 of this thesis. The 
new affinity-based method allows for the sterile purification of the final polymer 
bioconjugates with a significantly increased yield. This does not only lead to a clean 
and sterile product, but also minimizes the amount of expensive starting materials. 
The research described in this thesis is only a first step towards the use of water-
soluble polyisocyanopeptides for the mentioned applications. Consequently, it is hard 
to predict their impact on society. More research is still needed before a final product 
can come to the market. Clearly, potential risks and their impact should be 
considered in every step. 
 
8.2 Immunotherapy & Drug Delivery Applications using Polyisocyanopeptide 
Scaffolds 
In chapters 2, 3 and 4 of this thesis the potential of polyisocyanopeptide 
scaffolds for the development of artificial antigen-presenting cells (aAPC) was 
investigated. Considering the natural interaction of natural APCs with T cells, it was 
hypothesized that the ideal aAPC contains multiple effector molecules on a dynamic 
scaffold to allow for the efficient formation of multivalent interactions between both 
cell types. Water-soluble polyisocyanopeptides are interesting polymers that are 
hundreds of nanometres long and possess a helical secondary structure. This helical 
structure is stabilized by hydrogen bonds that form between alanine-containing side 
chains. As a result, polyisocyanopeptides are significantly stiffer than many other 
polymers, which usually lack a helical secondary structure. Considering length and 
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stiffness, this polymer is a unique scaffold, with a very high aspect and surface-to-
volume ratio. This ensures that all effector molecules coupled to this scaffold can 
interact with, their complementary binding partner (e.g. a cell surface) simultaneously 
and in a multivalent fashion. At the same time, the semi-flexible nature of the polymer 
scaffold allows for receptor rearrangements on the cell surface as they occur during 
T cell activation. 
The results described in the first chapters of this thesis indeed support the 
hypothesis that long, semi-flexible molecules are highly powerful multivalent 
scaffolds. Functionalized with T cell-stimulating antibodies, the polyisocyanopeptide 
scaffold outperformed freely soluble antibodies and spherical particles carrying a 
similar number of antibodies in all cases (chapter 2). Polymer length as well as 
effector molecule density are important design parameters that can be easily 
controlled when synthesizing the bioconjugate (chapter 3). Surprisingly, the 
multivalent polyisocyanopeptides conjugate did not only lower the antibody 
concentration needed to obtain a T cell response, but also altered signalling 
pathways involved in T cells activation. This suggests that the polymeric aAPC 
described in this thesis may become a new tool for studying, manipulating and 
regulating the obtained immunoresponse. This potential was partly shown in chapter 
4. Coupling a second, co-stimulatory antibody to the same polymer molecule 
increased the efficacy and specificity of T cell activation, providing evidence that the 
polymer conjugate can be used for shaping the obtained immunoresponse. 
 In this thesis the polyisocyanopeptide scaffold was solely used for the 
activation of T cells in vitro, towards the design of a vaccine that can be used in 
immunotherapy. This new scaffold is clearly also a highly powerful starting point for 
the development of other polymer bioconjugates. Many other biomedical applications 
require multivalent ligands for increasing their binding efficiency, for example drug 
delivery or in vivo imaging. The unique structure of the polymer developed in this 
work will be highly beneficial in these cases. The biofunctionalization of the 
polyisocyanopeptide polymers follows a simple post-modification approach, using 
well-established click chemistry methods. Coupling other biomolecules onto the 
polymer, as required for the previously mentioned applications, can consequently be 
realized in a fast and straightforward manner. 
 An essential next step towards using these polymers in vivo is a detailed 
investigation of their biodistribution in an organism. From the literature it is known 
that filamentous particles circulate much longer in the body compared to spherical 
particles.1 If this were also the case for the polymer conjugates developed here, this 
would greatly strengthen their potential for immunotherapy and drug delivery 
applications. Considering their shape, also other interesting effects may be observed. 
The polymers have a very small diameter (< 2 nm). This may allow them to cross the 
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blood brain barrier, allowing for the delivery of multivalent drugs to the brain. This 
would clearly open up a completely new range of possibilities. 
 
8.3 Polyisocyanopeptide Hydrogels as Multifunctional Materials for Cell Culture 
and Sensing 
In the second part of this thesis (chapters 5 and 6) the focus was moved 
towards hydrogel-forming polyisocyanopeptide bioconjugates. A highly useful 
property of these hydrogels is their thermo-responsive behaviour. At physiological 
temperatures of 37 °C, stable gels are formed that support cells in a 3D environment. 
Cooling down liquefies the mixture so that the encapsulated cells can be retrieved 
easily for further analysis. Apart from this practical advantage, polyisocyanopeptide 
hydrogels possess a non-linear viscoelastic behavior; that is they stiffen upon 
increasing the applied stress. This property is common for biological hydrogels, e.g. 
made from cytoskeletal filaments or extracellular matrix polymer such as collagen. It 
is believed that stress-stiffening is an important functional characteristic of natural 
biological hydrogels and it has been difficult to mimic this property in synthetic 
hydrogels. Water-soluble polyisocyanopeptides are a rare and highly versatile 
example of a synthetic polymer that forms stress-stiffening hydrogels. Considering its 
synthetic nature, an unprecedented level of control is obtained, being able to adjust 
polymer length and ligand density, for example. 
In chapter 5, hydrogels made from polymers of different length were used to 
investigate the effect of stress-stiffening on the differentiation of stem cells. Changing 
the polymer length directly controls the onset of stress-stiffening (critical stress). After 
conjugation of a cell-adhesive peptide, stem cells were cultured in these hydrogels. 
When using hydrogels with low critical stresses (short polymers), stem cells 
differentiated towards fat cells. On the other hand, osteogenic differentiation was 
observed in the hydrogels with higher critical stresses. For the first time, this study of 
the effect of stress-stiffening shows that this mechanical property is an important 
parameter that determines the differentiation of cells. It also establishes 
polyisocyanopeptide hydrogels as a very powerful cell culture platform for performing 
systematic studies aimed at understanding the complex interplay of different 
parameters involved in stem cell differentiation. Synthetic, physically cross-linked 
hydrogels allow for decoupling mechanical and (bio)chemical parameters that are 
often intrinsically linked when using biological hydrogels. Furthermore, their thermo-
responsive behavior makes them an ideal 3D cell culture system that perfectly 
mimics the extracellular environment. In the future, it may find application in many 
areas ranging from fundamental research to tissue engineering. 
To further control the mechanical properties of polyisocyanopeptide hydrogels, 
additional stimuli-responsive cross-links were introduced (chapter 6). The polymer 
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was functionalized with short DNA oligonucleotides that cross-link upon addition of a 
hybridizing complementary sequence. This strategy allowed for the formation of a 
dynamic hydrogel. It was shown that the hydrogel properties could be controlled by 
altering the concentration and the thermal stability of the hybridizing sequence. More 
importantly, the cross-links could be specifically removed using strand displacement. 
In this way, it was possible to alter the hydrogel stiffness and its critical stress in situ. 
Ultimately, this strategy is a starting point for the development of a novel hydrogel 
sensor that stiffens or softens upon binding a bridging analyte like, for example, 
microRNA molecules. Moreover, culturing cells in a DNA-responsive 
polyisocyanopeptide hydrogels may allow for the dynamic regulation of hydrogel 
stiffness and critical stress during cell growth or differentiation. 
 
8.4 Conclusions 
This thesis introduces helical polyisocyanopeptide polymers as a highly 
powerful scaffold for the functionalization with biomolecules and highlights a number 
of potential applications of the resulting bioconjugates. This thesis shows that many 
different kinds of biomolecules such as antibodies, enzymes, DNA oligonucleotides 
or peptides can all be easily coupled to the polymeric scaffold using one and the 
same coupling method. The scaffold is long, semi-flexible and non-toxic, making it a 
highly versatile molecular entity for immunotherapy and drug delivery applications. 
Hydrogels formed by polyisocyanopeptides possess unique non-linear mechanical 
properties that make these materials interesting candidates for a range of biomedical 
applications where these properties are essential, e.g. in cell culture and tissue 
engineering. Many more exciting and currently unexplored applications can be 
imagined with this new class of polymers and this thesis just provides a starting point 
for future research in this field. 
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Summary 
Synthetic polymeric materials have become crucial components of modern day 
health care. They find their use in a wide range of applications such as drug delivery, 
implants, regenerative medicine, biosensors and many more. Water-soluble 
polyisocyanopeptides possess unique properties that make them ideal candidates for 
many of these applications. The work in this thesis describes the synthesis of 
polyisocyanopeptide bioconjugates and explores a number of different biological 
applications of these novel biofunctional molecules. 
Chapter 1 provides a short overview of the history of water-soluble 
polyisocyanopeptides and introduces the biological and medical applications that 
were explored in this thesis. Water-soluble polyisocyanopeptides are long, semi-
flexible and biocompatible polymers that form a hydrogel upon increasing the 
temperature. Depending on the length of the oligo ethylene glycol side chain used in 
the isocyanopeptide monomer, the gelation temperature of polyisocyanopeptide 
hydrogels can be tuned. Tri ethylene glycol substituted polymers (PIAA-OEG3-OMe) 
possess a gelation temperatures of ~20 °C. In contrast, tetra ethylene glycol 
substituted polymers (PIAA-OEG4-OMe) gelate at a temperature of ~42 °C. As a 
direct consequence, PIAA-OEG3-OMe forms a hydrogel at the physiologically 
relevant temperature of 37 °C, whereas PIAA-OEG4-OMe does not. Hydrogels 
consisting of PIAA-OEG3-OMe may find application as wound dressing materials, as 
cell growth matrices or even in tissue engineering. Alternatively, freely soluble PIAA-
OEG4-OMe polymers are ideal fibre-like, multivalent scaffolds for drug delivery or 
other in vivo applications that utilize polymeric scaffolds. 
A first application of PIAA-OEG4-OMe is described in chapter 2. Utilizing the 
length and semi-flexibility of these polymers, the goal of this chapter was to 
synthesize a novel multivalent scaffold that facilitates a more efficient interaction of 
effector molecules with their respective binding partners. Aiming at the development 
of a new vaccine for immunotherapy as a first application, this scaffold was used for 
the activation of T cells. Functional azide handles were introduced into the polymer 
scaffold, which allowed for the further functionalization with T cell stimulating anti-
CD3 antibodies. The resulting non-toxic bioconjugates were able to activate T cells 
more efficiently when compared to soluble antibodies or spherical particles carrying 
the same antibody. Furthermore, the antibody concentration required to obtain a T 
cell response was much lower when the antibody was conjugated to the 
polyisocyanopeptide. 
In this first proof-of-principle study, the polymer length and antibody density 
were kept constant. In chapter 3, these parameters were systematically varied to 
gain more detailed insight into the importance of establishing a multivalent 
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interaction. Increasing either polymer length or antibody density induced stronger 
activation, clearly highlighting the importance of multiple interactions between the 
antibody-functionalized polymer and the T cell. When comparing the longest polymer 
carrying the highest number of antibodies with soluble antibodies, a multivalent 
enhancement factor of 67 was calculated. It was further shown that this highly 
multivalent bioconjugate did not only lower the effective concentration required, but 
also altered T cell signalling. When monitoring signalling T cells over time, it was 
observed that the multivalent scaffold significantly extended the duration of 
activation. 
In a next step towards the development of a vaccine for immunotherapy, the 
polymers were functionalized with a second, co-stimulating anti-CD28 antibody 
(chapter 4). Focussing on the effect of these new bioconjugates on T cell 
differentiation, it was observed that polymers carrying both antibodies induced 
effector (CD8+) and helper (Th1 CD4+) cell populations without inducing regulatory T 
cells. This specific response required co-stimulation with anti-CD28 antibodies. More 
importantly, an optimal response was only obtained when both antibodies were 
coupled to one and the same polymer backbone. This clearly shows that the spatial 
arrangement of both signals is an important parameter for effectively stimulating T 
cells and that such geometry effects need to be taken into consideration when 
designing a T cell stimulating vaccine. 
In chapter 5 the attention was moved towards the biofunctionalization and 
application of PIAA-OEG3-OMe hydrogels. These hydrogels show a non-linear, 
stress-stiffening response. This behaviour is common for biological materials, but it is 
very rare in synthetic hydrogels. Polyisocyanopeptide hydrogels are, therefore, an 
ideal model system for studying the effect of stress-stiffening on cellular 
mechanosensing and transduction processes. For these experiments, the synthetic 
polyisocyanopeptide hydrogel is unique in that it allows for the decoupling of 
mechanical and biochemical parameters, which is difficult to achieve with natural, 
biological hydrogels. One such parameter is the onset for stress-stiffening (critical 
stress). This parameter can be tuned by varying the PIAA-OEG3-OMe length without 
altering the general hydrogel stiffness. In this chapter, the effect of the critical stress 
on stem cell differentiation was investigated. For this purpose, the azide handles in 
the polymer were functionalized with GRGDS integrin-binding peptides to provide cell 
adhesion sites. Stem cells cultured in hydrogels with low critical stress showed 
differentiation into fat cells, whereas stem cells cultured in hydrogels with high critical 
stress showed differentiation into bone cells. This important result highlights the 
potential of these hydrogels as a novel 3D cell culture matrix that can be used for 
investigating fundamental mechanobiological processes. At the same time it may 
provide a new platform for tissue engineering applications. 
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In chapter 6, the PIAA-OEG4-OMe polymer was functionalized with two small 
DNA oligonucleotides that were subsequently hybridized with a third bridging DNA 
sequence. The mechanical properties of this DNA cross-linked hydrogel could be 
dynamically tuned by the concentration of the DNA cross-linker as well as the 
temperature. In this way a multifunctional stimuli-responsive hydrogel was obtained, 
which could serve as a new material for the development of new bio-sensing devices. 
The synthesis of the polyisocyanopeptide bioconjugates requires extensive 
and difficult purification steps. Especially when the biomolecule has a high molecular 
weight (i.e. large size), a high amount of polymer is lost during these purification 
steps. To increase the yield and to reduce the number of steps, an affinity-based 
method was developed (chapter 7). The polyisocyanopeptides were functionalized 
with biotin affinity tags, which were subsequently used to purify the polymer 
conjugate on mono-avidin beads. The suitability of this method was shown with both 
an antibody- and an enzyme-functionalized polymer. Both conjugates were purified in 
yields ranging from 10-25 %, which is a significant improvement over the previously 
used method based on dialysis and ultrafiltration (<1 % yield). Most importantly, the 
conjugates were highly pure. This does not only facilitate a straightforward 
quantitative analysis, but is further expected to improve bioconjugate functionality in 
the intended application. 
The last chapter of this thesis aims at integrating the knowledge obtained 
when synthesizing, purifying and testing the different bioconjugates. It further 
summarizes important aspects to be considered when implementing possible 
applications and highlights possible future directions. Overall, this thesis shows that 
water-soluble polyisocyanopeptides are a highly interesting and versatile class of 
biocompatible polymers with a broad range of possible applications. 
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Samenvatting 
In de moderne gezondheidszorg zijn materialen van synthetische polymeren niet 
meer weg te denken. Ze worden gebruikt in een breed scala aan toepassingen zoals 
in de toediening van medicijnen, regeneratieve geneeskunde, biosensoren en vele 
andere. Water-oplosbare polyisocyanopeptiden bezitten unieke eigenschappen die 
deze klasse van polymeren zeer geschikt maakt voor vele van deze toepassingen. 
Het werk in dit proefschrift beschrijft de synthese van polyisocyanopeptide-
bioconjugaten en verkent verschillende toepassingen van deze nieuwe biofunctionele 
moleculen.  
 Hoofdstuk 1 geeft een kort overzicht van de geschiedenis van water oplosbare 
polyisocyanopeptiden en introduceert de biologische en medische toepassingen die 
zijn onderzocht in dit proefschrift. Water oplosbare polyisocyanopeptiden zijn lange, 
semi-flexibele en biocompatibele polymeren die een hydrogel vormen als de 
temperatuur verhoogd wordt. De temperatuur waarbij de gel gevormd wordt kan 
worden veranderd door de lengte van de oligo-ethyleenglycol zijketen aan te passen. 
Zo vormt een polymeer met een tri-ethyleenglycol zijketen (PIAA-OEG3-OMe) een 
gel bij ~ 20 ºC en een polymeer met een tetra-ethyleenglycol zijketen (PIAA-OEG4-
OMe) bij ~ 42 ºC. Als gevolg hiervan vormt PIAA-OEG3-OMe een hydrogel bij de 
fysiologische temperatuur van 37 ºC en PIAA-OEG4-OMe niet. Hydrogels van PIAA-
OEG3-OMe kunnen goed gebruikt worden als wondbedekkers, celgroei matrices of 
zelfs in weefselkweek. De vrije, oplosbare PIAA-OEG4-OMe polymeren daarentegen 
zijn ideale vezelachtige, multivalente structuren om te gebruiken in de toediening van 
medicijnen of andere in vivo toepassingen. 
 Een eerste toepassing van PIAA-OEG4-OMe is beschreven in hoofdstuk 2.  
Het doel van dit hoofdstuk was om een nieuw multivalent polymeer te ontwikkelen 
dat, door gebruik te maken van zijn lengte en semi-flexibiliteit, effector moleculen een 
efficiëntere interactie geeft met hun bindingspartners. Deze nieuwe structuur is 
gebruikt om T-cellen te activeren, omdat het ontwikkelen van een nieuw vaccin voor 
immuuntherapie de achterliggende toepassing was. In het polymeer werden 
functionele azide handvatten ingebouwd die op hun beurt weer gefunctionaliseerd 
werden met T-cel stimulerende anti-CD3 antilichamen. De resulterende, niet giftige 
bioconjugaten zijn in staat om T-cellen efficiënter te stimuleren dan de vrije 
antilichamen of bolvormige deeltjes waaraan hetzelfde antilichaam vastzit. 
Bovendien is de concentratie van het antilichaam die nodig is om een respons te 
krijgen vele malen lager wanneer het antilichaam geconjugeerd is aan de 
polyisocyanopeptide.  
 In hoofdstuk 2 werden de polymeer lengte en antilichaam dichtheid constant 
gehouden. In hoofdstuk 3 worden deze parameters gevarieerd om meer inzicht te 
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krijgen in het belang van de verkregen multivalente interactie. Het vergroten van de 
polymeer lengte of de antilichaam dichtheid leidt tot een sterkere activatie, wat 
overduidelijk aangeeft dat de multivalente interacties tussen het polymeer 
gefuntionaliseerd met antilichamen en de T-cellen erg belangrijk zijn. Het langste 
polymeer met de hoogste antilichaam dichtheid geeft een multivalente versterkings 
factor van 67 ten opzichte van het vrije antilichaam. Verder laat dit hoofdstuk zien dat 
dit multivalente bioconjugaat niet alleen de effectieve concentratie verlaagd die nodig 
is om een respons te krijgen, maar dat het ook de T-cel signalering verandert. De 
signalerende T-cellen werden voor langere tijd gemonitord en er werd waargenomen 
dat het multivalente polymeer de duur van de activatie significant verlengt.  
 Een volgende stap in de ontwikkeling van een vaccin voor immuuntherapie is 
de functionalisatie van de polymeren met een tweede, co-stimulerend anti-CD28 
antilichaam (hoofdstuk 4).  Het effect van deze nieuwe bioconjugaten op T-cel 
differentiatie werd onderzocht, waarbij er werd aangetoond dat polymeren 
gefunctionaliseerd met beide antilichamen, de effector (CD8+) en helper (Th1 CD4+), 
cel populaties vergroten zonder dat de regulatorische T-cel populatie verhoogd 
wordt. Deze specifieke respons heeft de co-stimulatie van anti-CD28 antilichamen 
nodig. Een optimale respons wordt alleen verkregen wanneer beide antilichamen aan 
hetzelfde polymeer gekoppeld zitten. Dit laat overduidelijk zien dat de ordening van 
beide signalen een belangrijke parameter is in de effectieve stimulatie van T-cellen 
en dat zulke geometrische effecten meegenomen moeten worden in het ontwerpen 
van T-cel stimulerende vaccins.  
 In hoofdstuk 5 wordt de aandacht verlegd naar de biofunctionalisatie en 
toepassingen van PIAA-OEG3-OMe hydrogels. Deze hydrogels worden stijver 
wanneer ze vervormd worden. Deze niet-lineaire mechanische eigenschap is 
normaal in biologische materialen maar erg zeldzaam in synthetische hydrogels. 
Polyisocyanopeptide hydrogels zijn daarom een uitermate geschikt systeem om het 
effect van deze verstijving op cellulaire, mechanogevoelige transductie processen te 
bestuderen. Bovendien kan de synthetische polyisocyanopeptide hydrogel 
mechanische en biochemische parameters ontkoppelen, wat bijna onmogelijk is in 
biologische hydrogels. Een van deze parameters is de stress waarbij de verstijving 
van de hydrogel optreedt, de kritische stress. Door de lengte van de PIAA-OEG3-
OMe polymeren te variëren kan deze parameter verandert worden zonder dat andere 
parameters zoals de algehele hydrogel stijfheid veranderen. In dit hoofdstuk wordt de 
invloed van de kritische stress op stamcel differentiatie onderzocht.  Om dit te 
bewerkstelligen werden de azide handvatten gefunctionaliseerd met GRGDS-
peptiden die binden aan integrines, zodat cellen zich aan de hydrogel kunnen 
hechten. Stamcellen die gekweekt werden in hydrogels met een lage kritische stress 
differentieerden tot vetcellen, terwijl stamcellen die gekweekt werden in hydrogels 
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met een hogere kritische stress zich ontwikkelden tot botcellen. Deze belangrijke 
vinding laat zien dat deze hydrogels een hoog potentieel hebben als 3D celkweek 
matrices om fundamentele mechanobiologische processen te bestuderen. 
Tegelijkertijd biedt het een nieuw platvorm voor weefselkweek toepassingen. 
 In hoofdstuk 6 werd het PIAA-OEG4-OMe polymeer gefunctionaliseerd met 
twee kleine stukjes DNA, die op hun beurt gehybridiseerd kunnen worden met een 
derde overbruggende DNA-sequentie. De mechanische eigenschappen van de 
resulterende DNA gecrosslinkte hydrogel konden dynamisch beïnvloed worden door 
de concentratie van de DNA crosslinker of de temperatuur aan te passen. Op deze 
manier werd een multifunctionele, stimuli gevoelige hydrogel verkregen, die als 
nieuw materiaal voor biosensoren kan dienen.  
 Het synthetiseren van de polyisocyanopeptide bioconjugaten vergt een 
uitgebreide en moeilijke zuivering. Een groot gedeelte van het polymeer gaat 
verloren tijdens deze zuivering, vooral als het gekoppelde biomolecuul een groot 
molecuulgewicht (grote afmeting) heeft. Om de opbrengst te vergroten en het aantal 
stappen te verkleinen werd een op affiniteit gebaseerde zuiveringsmethode 
ontwikkeld (hoofdstuk 7). De polyisocyanopeptiden werden gefunctionaliseerd met 
biotine affiniteits labels, die vervolgens gebruikt worden om het polymeer-
bioconjugaat te zuiveren met agarose gebonden mono-avidine. De toepasbaarheid 
van deze methode werd gedemonstreerd door zowel een antilichaam als een enzym-
polymeer conjugaat te maken en te zuiveren. Beide conjugaten werden gezuiverd 
met een opbrengst tussen de 10-25%, wat een significante verbetering is in 
vergelijking met de oude, op dialyse of ultrafiltratie gebaseerde zuiveringsmethoden 
(<1 % opbrengst). Bovenal, zijn de op deze manier verkregen polymeer conjugaten 
erg zuiver. Dit zorgt er niet alleen voor dat de analyse van de conjugaten 
vergemakkelijkt wordt, maar zal hoogstwaarschijnlijk ook leiden tot een verbetering 
van de functionaliteit in de toepassing waarin ze gebruikt worden.  
 Het laatste hoofdstuk van dit proefschrift vat de kennis samen die verkregen is 
tijdens het synthetiseren, zuiveren en testen van de verschillende bioconjugaten.  
Het beschrijft ook belangrijke aspecten die in acht moeten worden genomen wanneer 
deze toepassingen geïmplementeerd worden in de samenleving. Verder worden 
toekomstige richtingen voor vervolgonderzoek belicht. Alles bij elkaar, laat dit 
proefschrift zien dat water oplosbare polyisocyanopeptiden een zeer interessante en 
veelzijdige klasse van biocompatibele polymeren zijn, met een brede 
toepasbaarheid.    
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